<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Intensive Care Med</journal-id><journal-id journal-id-type="iso-abbrev">Intensive Care Med</journal-id><journal-id journal-id-type="pmc-domain-id">3814</journal-id><journal-id journal-id-type="pmc-domain">phenaturepg</journal-id><journal-title-group><journal-title>Intensive Care Medicine</journal-title></journal-title-group><issn pub-type="ppub">0342-4642</issn><issn pub-type="epub">1432-1238</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer Nature - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7223855</article-id><article-id pub-id-type="pmcid-ver">PMC7223855.1</article-id><article-id pub-id-type="pmcaid">7223855</article-id><article-id pub-id-type="pmcaiid">7223855</article-id><article-id pub-id-type="pmid">32383061</article-id><article-id pub-id-type="doi">10.1007/s00134-020-06050-1</article-id><article-id pub-id-type="publisher-id">6050</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Conference Report and Expert Panel</subject></subj-group></article-categories><title-group><article-title>Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper<sub>#</sub></article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Abdul-Aziz</surname><given-names initials="MH">Mohd H.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alffenaar</surname><given-names initials="JWC">Jan-Willem C.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bassetti</surname><given-names initials="M">Matteo</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bracht</surname><given-names initials="H">Hendrik</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dimopoulos</surname><given-names initials="G">George</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marriott</surname><given-names initials="D">Deborah</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Neely</surname><given-names initials="MN">Michael N.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Paiva</surname><given-names initials="JA">Jose-Artur</given-names></name><xref ref-type="aff" rid="Aff11">11</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pea</surname><given-names initials="F">Federico</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sjovall</surname><given-names initials="F">Fredrik</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Timsit</surname><given-names initials="JF">Jean F.</given-names></name><xref ref-type="aff" rid="Aff15">15</xref><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Udy</surname><given-names initials="AA">Andrew A.</given-names></name><xref ref-type="aff" rid="Aff17">17</xref><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wicha</surname><given-names initials="SG">Sebastian G.</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zeitlinger</surname><given-names initials="M">Markus</given-names></name><xref ref-type="aff" rid="Aff20">20</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>De Waele</surname><given-names initials="JJ">Jan J.</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Roberts</surname><given-names initials="JA">Jason A.</given-names></name><address><email>j.roberts2@uq.edu.au</email></address><xref ref-type="contrib" rid="IA1"/><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff22">22</xref><xref ref-type="aff" rid="Aff23">23</xref><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author" id="IA1"><collab>the Infection Section of European Society of Intensive Care Medicine (ESICM)</collab></contrib><contrib contrib-type="author"><collab>Pharmacokinetic/pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID)</collab></contrib><contrib contrib-type="author"><collab>Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)</collab></contrib><contrib contrib-type="author"><collab>Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC)</collab></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.1003.2</institution-id><institution-id institution-id-type="ISNI">0000 0000 9320 7537</institution-id><institution>University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, </institution><institution>The University of Queensland, </institution></institution-wrap>Brisbane, QLD 4029 Australia </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.1013.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 834X</institution-id><institution>School of Pharmacy, Faculty of Medicine and Health, </institution><institution>University of Sydney, </institution></institution-wrap>Sydney, NSW Australia </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.413252.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0180 6477</institution-id><institution>Westmead Hospital, </institution></institution-wrap>Westmead, NSW Australia </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.1013.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 834X</institution-id><institution>Marie Bashir Institute of Infectious Diseases and Biosecurity, </institution><institution>University of Sydney, </institution></institution-wrap>Sydney, NSW Australia </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.5606.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2151 3065</institution-id><institution>Infectious Diseases Clinic, Department of Health Sciences, </institution><institution>University of Genoa, Genoa and Hospital Policlinico San Martino &#8211; IRCCS, </institution></institution-wrap>Genoa, Italy </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.6582.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9748</institution-id><institution>Department of Anaesthesiology, </institution><institution>University Ulm, </institution></institution-wrap>Ulm, Germany </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.5216.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2155 0800</institution-id><institution>Department of Critical Care, University Hospital Attikon, </institution><institution>National and Kapodistrian University of Athens, </institution></institution-wrap>Athens, Greece </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.437825.f</institution-id><institution-id institution-id-type="ISNI">0000 0000 9119 2677</institution-id><institution>Department of Microbiology and Infectious Diseases, </institution><institution>St. Vincent&#8217;s Hospital, </institution></institution-wrap>Sydney, NSW Australia </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.42505.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 2156 6853</institution-id><institution>Department of Paediatrics, Keck School of Medicine, </institution><institution>University of Southern California, </institution></institution-wrap>Los Angeles, CA USA </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.239546.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2153 6013</institution-id><institution>Division of Infectious Diseases, </institution><institution>Children&#8217;s Hospital Los Angeles, </institution></institution-wrap>Los Angeles, CA USA </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.5808.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 1503 7226</institution-id><institution>Department of Medicine, </institution><institution>Faculty of Medicine of Porto, </institution></institution-wrap>Porto, Portugal </aff><aff id="Aff12"><label>12</label>Department of Emergency and Intensive Care Medicine, Centro Hospitalar Universitario de S&#227;o Jo&#227;o, Porto, Portugal </aff><aff id="Aff13"><label>13</label>Institute of Clinical Pharmacology, SM Misericordia University Hospital, ASUFC, Udine, Italy </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="GRID">grid.411843.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0623 9987</institution-id><institution>Department of Perioperative Medicine, </institution><institution>Sk&#229;ne University Hospital, </institution></institution-wrap>Malm&#246;, Sweden </aff><aff id="Aff15"><label>15</label>Department of Intensive Care Medicine and Infectious Diseases, Bichat-Claude Bernard University Hospital, AP-HP, Paris, France </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="GRID">grid.7452.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2217 0017</institution-id><institution>Infection, Antimicrobials, Modelling, Evolution (IAME), </institution><institution>Paris Diderot University, </institution></institution-wrap>Paris, France </aff><aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="GRID">grid.1002.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7857</institution-id><institution>Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, </institution><institution>Monash University, </institution></institution-wrap>Melbourne, VIC Australia </aff><aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="GRID">grid.1623.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 0432 511X</institution-id><institution>Department of Intensive Care and Hyperbaric Medicine, </institution><institution>The Alfred, </institution></institution-wrap>Melbourne, VIC Australia </aff><aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="GRID">grid.9026.d</institution-id><institution-id institution-id-type="ISNI">0000 0001 2287 2617</institution-id><institution>Department of Clinical Pharmacy, Institute of Pharmacy, </institution><institution>University of Hamburg, </institution></institution-wrap>Hamburg, Germany </aff><aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="GRID">grid.22937.3d</institution-id><institution-id institution-id-type="ISNI">0000 0000 9259 8492</institution-id><institution>Department of Clinical Pharmacology, </institution><institution>Medical University of Vienna, </institution></institution-wrap>Vienna, Austria </aff><aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="GRID">grid.410566.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0626 3303</institution-id><institution>Department of Critical Care Medicine, </institution><institution>Ghent University Hospital, </institution></institution-wrap>Ghent, Belgium </aff><aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="GRID">grid.416100.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 0688 4634</institution-id><institution>Department of Intensive Care Medicine and Pharmacy, </institution><institution>Royal Brisbane and Women&#8217;s Hospital, </institution></institution-wrap>Brisbane, QLD Australia </aff><aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="GRID">grid.1003.2</institution-id><institution-id institution-id-type="ISNI">0000 0000 9320 7537</institution-id><institution>Centre for Translational Anti-infective Pharmacodynamics, School of Pharmacy, </institution><institution>The University of Queensland, </institution></institution-wrap>Brisbane, QLD Australia </aff><aff id="Aff24"><label>24</label><institution-wrap><institution-id institution-id-type="GRID">grid.121334.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2097 0141</institution-id><institution>Division of Anaesthesiology Critical Care Emergency and Pain Medicine, N&#238;mes University Hospital, </institution><institution>University of Montpellier, </institution></institution-wrap>N&#238;mes, France </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="ppub"><year>2020</year></pub-date><volume>46</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">357623</issue-id><fpage>1127</fpage><lpage>1153</lpage><history><date date-type="received"><day>30</day><month>1</month><year>2020</year></date><date date-type="accepted"><day>10</day><month>4</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>14</day><month>05</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>15</day><month>05</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2022-02-15 19:16:47.197"><day>15</day><month>02</month><year>2022</year></date></event></pub-history><permissions><copyright-statement>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2020</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="134_2020_Article_6050.pdf"/><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">This Position Paper aims to review and discuss the available data on therapeutic drug monitoring (TDM) of antibacterials, antifungals and antivirals in critically ill adult patients in the intensive care unit (ICU). This Position Paper also provides a practical guide on how TDM can be applied in routine clinical practice to improve therapeutic outcomes in critically ill adult patients.
</p></sec><sec><title>Methods</title><p id="Par2">Literature review and analysis were performed by Panel Members nominated by the endorsing organisations, European Society of Intensive Care Medicine (ESICM), Pharmacokinetic/Pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID), International Association for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) and International Society of Antimicrobial Chemotherapy (ISAC). Panel members made recommendations for whether TDM should be applied clinically for different antimicrobials/classes.</p></sec><sec><title>Results</title><p id="Par3">TDM-guided dosing has been shown to be clinically beneficial for aminoglycosides, voriconazole and ribavirin. For most common antibiotics and antifungals in the ICU, a clear therapeutic range has been established, and for these agents, routine TDM in critically ill patients appears meritorious. For the antivirals, research is needed to identify therapeutic targets and determine whether antiviral TDM is indeed meritorious in this patient population. The Panel Members recommend routine TDM to be performed for aminoglycosides, beta-lactam antibiotics, linezolid, teicoplanin, vancomycin and voriconazole in critically ill patients.</p></sec><sec><title>Conclusion</title><p id="Par4">Although TDM should be the standard of care for most antimicrobials in every ICU, important barriers need to be addressed before routine TDM can be widely employed worldwide.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1007/s00134-020-06050-1) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Antibacterials</kwd><kwd>Antifungals</kwd><kwd>Antivirals</kwd><kwd>Pharmacokinetics</kwd><kwd>Pharmacodynamics</kwd><kwd>Sepsis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="FPar6"><title>Take-home message:</title><p id="Par222">
<table-wrap id="Taba" position="float" orientation="portrait"><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="2" rowspan="1">The Panel Members recommend routine TDM to be performed for aminoglycosides, beta-lactam antibiotics, linezolid, teicoplanin, vancomycin and voriconazole in critically ill patients.</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec1"><title>Introduction</title><p id="Par5">Despite numerous therapeutic innovations, infection-related mortality in critically ill patients persists as a significant healthcare concern. Given the corresponding high burden of infection, it is unsurprising that the consumption of antimicrobial agents (antibacterials, antifungals and antivirals) in the intensive care unit (ICU) is ten times higher than in other wards [<xref ref-type="bibr" rid="CR1">1</xref>]. It is essential to optimise the use of antimicrobial agents not only to maximise therapeutic success but also to prolong the clinical lifespan of these currently available drugs by limiting the emergence of resistance [<xref ref-type="bibr" rid="CR2">2</xref>]. However, the process of optimising antimicrobial therapy (including both spectrum and therapeutic exposure) is a massive challenge in ICU patients, who often manifest extreme inter- and intra-individual pharmacokinetic (PK) variability [<xref ref-type="bibr" rid="CR3">3</xref>]. It follows that conventional antimicrobial dosing may risk clinical failure in this patient population as most dose-finding studies only included non-ICU populations. Indeed, perhaps more than in any other patient population, non-optimised antimicrobial dosing may more commonly lead to low drug exposure and therapeutic failure and/or antimicrobial resistance [<xref ref-type="bibr" rid="CR4">4</xref>], or high drug exposure, leading to an increased risk of toxicity.</p><p id="Par6">With an expanding knowledge on the relationships between antimicrobial dosing, pharmacokinetic/pharmacodynamic (PK/PD) exposure and patient outcomes, there is now a strong rationale to individualise antimicrobial dosing in critically ill patients with the aid of therapeutic drug monitoring (TDM). Traditionally, TDM was only employed to minimise the likelihood of toxicity in drugs with narrow therapeutic indices (e.g. aminoglycosides and vancomycin) and in drugs with complex pharmacokinetics (e.g. voriconazole) and has been hitherto underused for other antimicrobials. However, the recent surge in multidrug-resistant pathogens causing infections, combined with a declining antimicrobial pipeline, is causing a need to revise this approach. TDM of antimicrobials, even for those with a wide therapeutic index, is becoming more common [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], whilst TDM for the &#8220;traditional&#8221; drugs, such as aminoglycosides and glycopeptides, is continually being studied for further improvement.</p><p id="Par7">Currently, there is significant variation across institutions on how TDM is applied in terms of antimicrobial and patient selection, sampling time points and antimicrobial assays for concentration monitoring, as well as PK/PD targets and the approach to dose modification [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. This Position Paper aims to review and discuss the available data on TDM of antibacterials, antifungals and antivirals in critically ill adult patients. This Paper will also provide a practical guide on how antimicrobial TDM can be applied in everyday clinical practice to improve therapeutic outcomes in critically ill adult patients. Finally, the Panel aims to recommend antimicrobials for which TDM should be routinely performed in critically ill patients.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Position Paper Panel composition</title><p id="Par8">The Position Paper Panel members were nominated by the endorsing organisations including European Society of Intensive Care Medicine (ESICM), Pharmacokinetic/Pharmacodynamic (PK/PD) and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID), International Association for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) and International Society of Antimicrobial Chemotherapy (ISAC).</p></sec><sec id="Sec4"><title>Literature review and analysis</title><p id="Par9">This Position Paper was developed following a review of studies published in English before 1 July 2019. A literature search was performed on PubMed with no date restrictions using the following MeSH terms: (&#8220;anti-bacterial agents&#8221; OR &#8220;antifungal agents&#8221; OR &#8220;antiviral agents&#8221;) AND (&#8220;drug monitoring&#8221; OR &#8220;pharmacokinetics&#8221; OR &#8220;pharmacodynamics&#8221;) AND (&#8220;critical care&#8221; OR &#8220;critical illness&#8221; OR &#8220;intensive care units&#8221;). The search was also performed for each antimicrobial (e.g. meropenem) and antimicrobial class of interest (e.g. carbapenems). For clinical efficacy and toxicity, only studies on critically ill adult patients were reviewed and included in the analysis.</p></sec><sec id="Sec5"><title>Process overview</title><p id="Par10">The Panel members held face-to-face meetings and teleconferences to formulate the structure and content of this Position Paper. Members were divided into groups consisting of a lead author and co-authors for each section. Each group was tasked to review the literature, evaluate the available data and summarise their findings in a draft document addressing whether TDM is indicated for a particular antimicrobial/antimicrobial class in critically ill patients. All members reviewed the full draft document, and discrepancies were discussed and resolved by consensus.</p></sec><sec id="Sec6"><title>Panel consensus for use of TDM</title><p id="Par11">A seven-point Likert scale (1&#8201;=&#8201;strongly disagree, 2&#8201;=&#8201;disagree, 3&#8201;=&#8201;somewhat disagree, 4&#8201;=&#8201;neutral, 5&#8201;=&#8201;somewhat agree, 6&#8201;=&#8201;agree and 7&#8201;=&#8201;strongly agree) was used to score the recommendation of the Panel for performing TDM for each antimicrobial/antimicrobial class in critically ill patients. Consensus was achieved when the sum of 1 and 2 (negative consensus) or 6 and 7 (positive consensus) was&#8201;&#8805;&#8201;75%.</p></sec></sec><sec id="Sec7"><title>Pharmacokinetic and pharmacodynamic issues in critically ill patients</title><sec id="Sec8"><title>Pharmacokinetic changes</title><p id="Par12">Critically ill patients are those patients whose conditions are life-threatening and require specialised care in the ICU. Such patients require intensive monitoring and treatment due to failure of vital organ functions (due to acute and/or chronic disease) or due to the sequelae of surgical or other intensive treatment associated with life-threatening conditions. Critical illness is characterised by marked homoeostatic changes, driven by both the underlying disease process and the interventions required. These features profoundly affect organ function, resulting in a pathophysiological state that is not encountered in an ambulatory setting. Moreover, the presence of chronic comorbidity can further exacerbate the pathophysiological changes commonly encountered during critical illness. All of these factors will significantly influence antimicrobial PK in the critically ill and can be broadly considered in terms of altered volume of distribution (<italic toggle="yes">V</italic><sub>d</sub>) and drug clearance (CL).</p><sec id="Sec9"><title>Altered volume of distribution</title><p id="Par13">Endothelial dysfunction is common in critical illness and is characterised by expansion of the interstitial space through &#8220;capillary leakage&#8221;. This is closely linked to the severity of the underlying disease process and the degree of systemic inflammation. Sepsis and major burn injury are classic examples. This is then further exacerbated by intravenous (IV) fluid loading, a near-ubiquitous intervention in the ICU. For hydrophilic antimicrobials (e.g. acyclovir, aminoglycosides, beta-lactams, daptomycin, fluconazole and glycopeptides), this can result in a significantly expanded <italic toggle="yes">V</italic><sub>d</sub> [<xref ref-type="bibr" rid="CR7">7</xref>]. Changes in protein binding associated with hypoalbuminaemia will also potentially influence antimicrobial PK [<xref ref-type="bibr" rid="CR8">8</xref>]. Indeed, hypoalbuminaemia is commonly encountered (as a negative acute phase reactant), resulting in an increase in the <italic toggle="yes">V</italic><sub>d</sub> for highly protein-bound antimicrobials, such as ceftriaxone, daptomycin, ertapenem, flucloxacillin and teicoplanin [<xref ref-type="bibr" rid="CR8">8</xref>]. In these scenarios, the free (or unbound) fraction is increased, resulting in both greater distribution and potentially CL. Finally, extremes of body size and composition (typically obesity) will also influence <italic toggle="yes">V</italic><sub>d</sub>, although the magnitude of any such change will depend on the physicochemical properties of the antimicrobial (e.g. molecular weight, lipid solubility and degree of ionisation) [<xref ref-type="bibr" rid="CR9">9</xref>].</p></sec><sec id="Sec10"><title>Altered drug clearance</title><p id="Par14">Many commonly prescribed antimicrobials are principally cleared by renal elimination. In this context, critical illness can have a profound impact on renal function and therefore drug CL. Augmented renal clearance (ARC) is being increasingly noted in critically ill sub-populations (incidence of 14&#8211;80%) [<xref ref-type="bibr" rid="CR10">10</xref>]. ARC is defined as an increased creatinine clearance&#8201;&gt;&#8201;130&#160;mL/min/1.73&#160;m<sup>2</sup> measured by 8&#8211;24-h urine collection and refers to the enhanced renal elimination of circulating solute (such as metabolic waste and drugs) [<xref ref-type="bibr" rid="CR11">11</xref>]. The underlying mechanisms are uncertain, although increased solute delivery related to a hyperdynamic high cardiac output state, in combination with tubular and/or neuroendocrine changes, is likely implicated [<xref ref-type="bibr" rid="CR10">10</xref>]. Identifying patients with ARC is challenging as these patients may have elevated renal function despite normal serum creatinine concentrations [<xref ref-type="bibr" rid="CR12">12</xref>], and importantly, commonly used glomerular filtration rate mathematical estimates, such as the Cockcroft&#8211;Gault and Modified Diet in Renal Disease equations, are unlikely to be reliable as compared to urinary creatinine clearance data [<xref ref-type="bibr" rid="CR13">13</xref>]. Younger patients with multiple trauma are at the highest risk [<xref ref-type="bibr" rid="CR12">12</xref>], but ARC has also been described in other patient categories. Moreover, the presence of ARC has been associated with sub-optimal plasma antimicrobial concentrations [<xref ref-type="bibr" rid="CR11">11</xref>], although the implications in terms of clinical outcomes remain unclear [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par15">In contrast, many critically ill patients will develop acute kidney injury, requiring the use of renal replacement therapy (RRT). In the acute setting, continuous veno-venous techniques are most frequently used, with variable fractions of filtration and/or dialysis. Factors such as molecular weight, protein binding, hydrophilicity, mode of RRT, filter porosity, surface area, blood flow rate and total effluent rate will all influence extracorporeal drug handling [<xref ref-type="bibr" rid="CR15">15</xref>]. Given the heterogeneity in clinical practice and pathophysiology, antimicrobial dosing is generally empiric, resulting in substantial intra- and inter-patient variability in drug concentrations [<xref ref-type="bibr" rid="CR16">16</xref>]. The intensity of RRT and any residual native renal function are likely to be the most important variables in determining renal drug CL in this setting [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par16">Other extracorporeal circuits (such as extracorporeal membrane oxygenation) may also contribute to altered drug CL, depending on the degree of adsorption, and any co-existing renal dysfunction [<xref ref-type="bibr" rid="CR18">18</xref>].</p></sec></sec><sec id="Sec11"><title>Pharmacodynamic changes</title><p id="Par17">For antimicrobials, PD links PK exposure with its ability to kill or inhibit the growth of a pathogen. This relationship can be described by relating the PK exposure of an antimicrobial to the minimum inhibitory concentration (MIC) of the offending pathogen. Antimicrobials classically have different PK/PD indices [<xref ref-type="bibr" rid="CR19">19</xref>], and these can be categorised as: (a) the ratio of maximum drug concentration (<italic toggle="yes">C</italic><sub>max</sub>) to MIC (<italic toggle="yes">C</italic><sub>max</sub>/MIC); (b) the duration of time (T) that the free drug concentration remains above the MIC during a dosing interval (fT<sub>&gt;MIC</sub>); and (c) the ratio of the area under the concentration&#8211;time curve during a 24-hour period to MIC (AUC<sub>0&#8211;24</sub>/MIC) [<xref ref-type="bibr" rid="CR20">20</xref>]. However, it is also important to note that individual MICs were rarely measured in most of the earlier studies and parameters such as MIC<sub>50</sub> and MIC<sub>90</sub> were used instead to describe the PK/PD relationships. For antivirals, in particular, measures other than the MIC have been used as the denominator of the PK/PD index such as the in vitro concentration required to obtain 50% of the maximum effect (EC<sub>50</sub>). The denominator in these indices is an important consideration because when it increases, the corresponding PK exposure should also be increased to ensure that the optimal PK/PD index is still achieved. This is mostly relevant in the ICU as at least bacterial pathogens may demonstrate higher MICs, as much as 2&#8211;4 times higher, when compared to the general wards [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par18">Importantly, a recent review by Mouton et al. highlights that the use of an individual MIC to guide antibacterial dosing may not be appropriate due to imprecise and highly variable (varying by 1&#8211;2 dilutions in both directions) measurements associated with MIC determination [<xref ref-type="bibr" rid="CR22">22</xref>]. Therefore, an individual MIC measurement should only be regarded as an estimate and not a &#8220;true&#8221; value of a pathogen&#8217;s susceptibility. MIC may vary according to determination methods (e.g. broth microdilution vs. E-test<sup>&#174;</sup>), and it is therefore important to aim for an appropriate MIC method-specific target, with broth microdilution (BMD) MIC being the preferred method, if they are available. Any potential dosing adjustments with the aid of TDM must consider MIC variation and should be interpreted in the context of assay variation, species identification and wild-type distributions. Measures of MIC distributions such as epidemiologic cut-off (ECOFF) values, which separate bacterial populations into those of a wild-type population and those with either a low- or high-level phenotypically detectable resistance, can be more useful to guide antibacterial dosing. Mouton et al. proposed several practical solutions in their review to optimise antibacterial dosing for patients, and one of the important recommendations included the use of ECOFF values as the PD target for dosing purposes when the measured MIC for the bacterial strain is within the wild-type distribution [<xref ref-type="bibr" rid="CR22">22</xref>]. If the MIC is slightly above the ECOFF, a two-fold dilution of the MIC can be assumed for dosing purposes, whilst MIC-guided therapy should not be an option if the measured MIC is clearly far above the ECOFF and clinical resistance breakpoint.</p></sec></sec><sec id="Sec12"><title>Basic principles of therapeutic drug monitoring</title><p id="Par19">An antimicrobial should fulfil certain criteria for TDM to be of potential benefit and some of these criteria include: (a) a significant intra- and/or inter-individual PK variability; (b) a defined exposure range associated with pharmacological responses (clinical responses and toxicities); (c) defined relevant sampling time points; and (d) accurate and timely bioanalytical assay methods for drug measurement.</p><p id="Par20">Critically ill patients often demonstrate extreme variability in antimicrobial PK, which can be partly explained by patient covariates (e.g. body weight and renal function). Unexplained PK variability can be observed across patients (i.e. inter-individual variability) and also, within a patient (i.e. intra-individual PK variability). TDM-based dosing adjustment is clinically useful for an antimicrobial if the unexplained inter-individual PK variability exceeds the intra-individual variability. Otherwise, solely applying covariate-based dosing strategies would be sufficient, as is the case with Product Information and nomogram-based dosing.</p><p id="Par21">PK sampling for antimicrobial TDM is traditionally performed at the end of each dosing interval to obtain a trough sample (minimum concentration in dosing interval, <italic toggle="yes">C</italic><sub>min</sub>). Whilst <italic toggle="yes">C</italic><sub>min</sub> provides some information on drug CL, determination of <italic toggle="yes">V</italic><sub>d</sub> requires an additional sample earlier in the dosing interval. For the estimation of derived PK parameters, such as the AUC, and PK/PD targets, such as the fT<sub>&gt;MIC</sub>, an optimised PK sampling schedule is suggested for unbiased and precise parameter estimation. A limited sampling strategy (LSS), which uses the most &#8220;informative&#8221; concentration&#8211;time points (commonly 1&#8211;3 sampling time points) to describe a drug&#8217;s PK, is relatively easy to be performed and may provide accurate estimates of full drug exposure [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. The optimal sampling time points for a drug can be identified during &#8220;limited sampling&#8221; studies where these time points will be estimated or calculated using PK models and Monte Carlo simulations. The time points can then be used to predict AUC<sub>0&#8211;24</sub>, and as such, this approach is beneficial for those antimicrobials in which AUC<sub>0&#8211;24</sub>/MIC ratios are the major determinants for efficacy. For example, although 10&#8211;15 time points are conventionally needed to calculate 80% of the total AUC, Alsultan et al. demonstrated that these can be reduced to only 2 time points (sampling at 4 and 6&#160;h post-dose) with LSS to estimate levofloxacin AUC [<xref ref-type="bibr" rid="CR25">25</xref>]. For antibacterials that are administered via continuous infusion, a sample at any given time during administration can be used.</p><p id="Par22">Ideally, measuring antimicrobial concentration at the site of infection (e.g. epithelial lining fluid in pneumonia and cerebrospinal fluid in meningitis) is preferred as most antimicrobial&#8211;pathogen interactions are thought to occur here. However, due to practical limitations, most centres have been using plasma concentrations as a surrogate for concentrations at the actual site of infection. Importantly, some antimicrobials are unevenly distributed and plasma concentration does not always reflect concentrations at the infected tissues.</p><p id="Par23">Bioanalytical assays for measuring antimicrobial concentrations should be precise, accurate, highly selective for a particular drug and, importantly, available in a timely manner (e.g. turnaround times of&#8201;&lt;&#8201;8&#160;h, preferably shorter or within the same day of sampling). Regular quality control exercises through proficiency testing programs are recommended to ensure that the assays have sufficient accuracy, precision and specificity for routine TDM and patient management [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Ideally, free drug concentrations should be measured at physiologically relevant conditions [<xref ref-type="bibr" rid="CR28">28</xref>] and reported, but due to practical limitations, most laboratories report only total concentrations. Further to this, exposure targets for some drugs have only been defined in terms of total exposure (e.g. vancomycin).</p><p id="Par24">TDM-based dosing adjustments can be performed in several different ways. Whilst it is still popular to compare and evaluate a single drug concentration (e.g. <italic toggle="yes">C</italic><sub>min</sub>) against a therapeutic target range, and this method is the easiest, it is the least accurate method for dosing adjustment. Dosing nomograms, on the other hand, can integrate PK/PD data with measures of organ function (e.g. renal function described using creatinine clearance) and have demonstrated to be superior to conventional antimicrobial dosing [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. However, separating the sources of PK variability and incorporating&#8201;&gt;&#8201;1 covariate for dosing adjustments (e.g. creatinine clearance and weight) are not possible with a single dosing nomogram. Additionally, the dose prediction from such nomograms would be inaccurate if the pre-defined PK sampling/dosing schedule is not strictly adhered to. The use of dosing software overcomes these limitations [<xref ref-type="bibr" rid="CR2">2</xref>], and these methods have been shown to be superior over conventional antimicrobial dosing for vancomycin [<xref ref-type="bibr" rid="CR31">31</xref>], particularly in the context of:<list list-type="alpha-lower"><list-item><p id="Par25">the first dose can initially be individualised for patients by using Monte Carlo simulations;</p></list-item><list-item><p id="Par26">the sources of PK variability can be separated into intra- and inter-individual variability;</p></list-item><list-item><p id="Par27">PK sampling before reaching steady state is possible; and</p></list-item><list-item><p id="Par28">through Bayesian estimation, the entire antimicrobial PK profile can be estimated from a single PK sample. Bayesian estimation is most accurate when an optimal sampling time is chosen to provide the most information about the drug&#8217;s PK behaviour in the patient and a suitable population PK model matching the target population to serve as the Bayesian prior model [<xref ref-type="bibr" rid="CR32">32</xref>]. After initial TDM, it is recommended to repeat TDM (within 1&#8211;2&#160;days for most drugs) to confirm therapeutic exposures have been achieved and again thereafter if there are concerns of significant changes to PK (e.g. enteral absorption, renal function).</p></list-item></list></p><p id="Par29">The following sections describe the specific TDM data relating to various antimicrobial classes. Tables&#160;<xref rid="Tab1" ref-type="table">1</xref>, <xref rid="Tab2" ref-type="table">2</xref> and <xref rid="Tab3" ref-type="table">3</xref> describe optimal PK/PD indices and magnitudes associated with clinical efficacy and toxicity of antibacterials, antifungals and antivirals, respectively. TDM recommendations for each antimicrobial are summarised in Table&#160;<xref rid="Tab4" ref-type="table">4</xref>. Table&#160;<xref rid="Tab5" ref-type="table">5</xref> highlights relevant studies/data that demonstrate clinical outcome benefits of antimicrobial TDM. The primary data that support each recommendation and the suggested empirical dosing of these antimicrobials in critically ill patients are included in Supplementary Tables. We highly recommend readers to use the information presented in the following sections in conjunction with the data presented in Tables&#160;<xref rid="Tab1" ref-type="table">1</xref>, <xref rid="Tab2" ref-type="table">2</xref>, <xref rid="Tab3" ref-type="table">3</xref>, <xref rid="Tab4" ref-type="table">4</xref> and <xref rid="Tab5" ref-type="table">5</xref>, as well as those presented in Supplementary Tables&#160;1&#8211;5, for specific suggestions on how TDM can be performed for a particular antimicrobial/antimicrobial class in critically ill patients.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Pharmacokinetic/pharmacodynamic (PK/PD) indices and the magnitudes associated with antibacterial clinical efficacy and toxicity</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Antibacterial class</th><th align="left" colspan="1" rowspan="1">PK/PD index</th><th align="left" colspan="1" rowspan="1">Pre-clinical PK/PD target for efficacy</th><th align="left" colspan="1" rowspan="1">Clinical PK/PD target for efficacy</th><th align="left" colspan="1" rowspan="1">Clinical PK/PD threshold for toxicity</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Aminoglycosides</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Amikacin</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC: 80&#8211;100</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>max</sub>/MIC&#8201;&#8805;&#8201;8&#8211;10</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>min</sub>&#8201;&gt;&#8201;5&#160;mg/L<sup>a</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Gentamicin/tobramycin</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC: 80&#8211;100</td><td align="left" colspan="1" rowspan="1"><p>AUC<sub>0&#8211;24</sub>/MIC&#8201;&#8805;&#8201;110</p><p><italic toggle="yes">C</italic><sub>max</sub>/MIC&#8201;&#8805;&#8201;8&#8211;10</p></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>min</sub>&#8201;&gt;&#8201;1&#160;mg/L<sup>a</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Beta-lactams</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Carbapenems</td><td align="left" colspan="1" rowspan="1">% fT<sub>&gt;MIC</sub></td><td align="left" colspan="1" rowspan="1">40% fT<sub>&gt;MIC</sub></td><td align="left" colspan="1" rowspan="1">50&#8211;100% fT<sub>&gt;MIC</sub></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>min</sub>&#8201;&gt;&#8201;44.5&#160;mg/L<sup>b</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Cephalosporins</td><td align="left" colspan="1" rowspan="1">% fT<sub>&gt;MIC</sub></td><td align="left" colspan="1" rowspan="1">60&#8211;70% fT<sub>&gt;MIC</sub></td><td align="left" colspan="1" rowspan="1">45&#8211;100% fT<sub>&gt;MIC</sub></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>min</sub>&#8201;&gt;&#8201;20&#160;mg/L<sup>c</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Penicillins</td><td align="left" colspan="1" rowspan="1">% fT<sub>&gt;MIC</sub></td><td align="left" colspan="1" rowspan="1">50% fT<sub>&gt;MIC</sub></td><td align="left" colspan="1" rowspan="1">50&#8211;100% fT<sub>&gt;MIC</sub></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>min</sub>&#8201;&gt;&#8201;361&#160;mg/L<sup>d</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Co-trimoxazole</td><td align="left" colspan="1" rowspan="1">Unclear</td><td align="left" colspan="1" rowspan="1">Unclear</td><td align="left" colspan="1" rowspan="1">Unclear</td><td align="left" colspan="1" rowspan="1">Unclear</td></tr><tr><td align="left" colspan="1" rowspan="1">Daptomycin</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC&#8201;&#8805;&#8201;517</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC&#8201;&#8805;&#8201;666&#160;mg/L</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>min</sub>&#8201;&gt;&#8201;24&#160;mg/L<sup>e</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Fluoroquinolones</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC</td><td align="left" colspan="1" rowspan="1"><p>AUC<sub>0&#8211;24</sub>/MIC&#8201;&#8805;&#8201;100</p><p><italic toggle="yes">C</italic><sub>max</sub>/MIC&#8201;&#8805;&#8201;8</p></td><td align="left" colspan="1" rowspan="1"><p>AUC<sub>0&#8211;24</sub>/MIC&#8201;&#8805;&#8201;125&#8211;250</p><p><italic toggle="yes">C</italic><sub>max</sub>/MIC&#8201;&#8805;&#8201;12</p></td><td align="left" colspan="1" rowspan="1">Unclear</td></tr><tr><td align="left" colspan="1" rowspan="1">Glycopeptides</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Teicoplanin</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC&#8201;&#8805;&#8201;610</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>min</sub>&#8201;&#8805;&#8201;10&#160;mg/L</td><td align="left" colspan="1" rowspan="1">Unclear</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Vancomycin</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC: 86&#8211;460</td><td align="left" colspan="1" rowspan="1"><p>AUC<sub>0&#8211;24</sub>/MIC&#8201;&#8805;&#8201;400</p><p><italic toggle="yes">C</italic><sub>min</sub>&#8201;&gt;&#8201;10&#8211;20&#160;mg/L</p></td><td align="left" colspan="1" rowspan="1"><p>AUC<sub>0&#8211;24</sub>&#8201;&gt;&#8201;700&#160;mg&#160;h/L<sup>f</sup></p><p><italic toggle="yes">C</italic><sub>min</sub>&#8201;&gt;&#8201;20&#160;mg/L<sup>f</sup></p></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Linezolid</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC&#8201;&#8805;&#8201;100</td><td align="left" colspan="1" rowspan="1"><p>AUC<sub>0&#8211;24</sub>/MIC: 80&#8211;120</p><p>&#8805;85% T<sub>&gt;MIC</sub></p></td><td align="left" colspan="1" rowspan="1"><p>AUC<sub>0&#8211;24</sub>&#8201;&gt;&#8201;300<sup>g</sup></p><p><italic toggle="yes">C</italic><sub>min</sub>&#8201;&gt;&#8201;7<sup>g</sup></p></td></tr><tr><td align="left" colspan="1" rowspan="1">Polymyxins</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Colistin</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC</td><td align="left" colspan="1" rowspan="1"><p>fAUC<sub>0&#8211;24</sub>/MIC: 6.6&#8211;13.7<sup>h</sup></p><p>fAUC<sub>0&#8211;24</sub>/MIC: 3.5&#8211;17.6<sup>i</sup></p></td><td align="left" colspan="1" rowspan="1">No data</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>min</sub>&#8201;&gt;&#8201;2.4&#160;mg/L<sup>f</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Polymyxin B</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC</td><td align="left" colspan="1" rowspan="1">fAUC<sub>0&#8211;24</sub>/MIC: 3.7&#8211;28.0</td><td align="left" colspan="1" rowspan="1">No data</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>&#8201;&gt;&#8201;100<sup>f</sup></td></tr></tbody></table><table-wrap-foot><p>AUC<sub>0&#8211;24</sub>/MIC&#8201;=&#8201;the ratio of the area under the concentration&#8211;time curve during a 24-hour period to minimum inhibitory concentration; <italic toggle="yes">C</italic><sub>max</sub>/MIC&#8201;=&#8201;the ratio of maximum drug concentration to minimum inhibitory concentration; <italic toggle="yes">C</italic><sub>min</sub>&#8201;=&#8201;trough drug concentration; fAUC<sub>0&#8211;24</sub>/MIC&#8201;=&#8201;the free (unbound drug concentration) ratio of the area under the concentration&#8211;time curve during a 24-h period to minimum inhibitory concentration; fT<sub>&gt;MIC</sub>&#8201;=&#8201;the duration of time that the free drug concentration remains above the MIC during a dosing interval; PK/PD&#8201;=&#8201;pharmacokinetic/pharmacodynamic</p><p><sup>a</sup>Nephrotoxicity or ototoxicity</p><p><sup>b</sup>Data only available for meropenem and related to nephrotoxicity or neurotoxicity</p><p><sup>c</sup>Data only available for cefepime and related to neurotoxicity</p><p><sup>d</sup>Data mostly on piperacillin and related to nephrotoxicity and neurotoxicity</p><p><sup>e</sup>Myopathy indicated by creatine phosphokinase elevation</p><p><sup>f</sup>Related to nephrotoxicity</p><p><sup>g</sup>Related to haematological toxicity</p><p><sup>h</sup>Exposure against <italic toggle="yes">Pseudomonas aeruginosa</italic></p><p><sup>i</sup>Exposure against <italic toggle="yes">Acinetobacter baumannii</italic></p></table-wrap-foot></table-wrap><table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Pharmacokinetic/pharmacodynamic (PK/PD) indices and the magnitudes associated with antifungal clinical efficacy and toxicity</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Antifungal class</th><th align="left" colspan="1" rowspan="1">PK/PD index</th><th align="left" colspan="1" rowspan="1">Pre-clinical PK/PD target for efficacy</th><th align="left" colspan="1" rowspan="1">Clinical PK/PD target for efficacy</th><th align="left" colspan="1" rowspan="1">Clinical PK/PD threshold for toxicity</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Echinocandins</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC</td><td align="left" colspan="1" rowspan="1">fAUC<sub>0&#8211;24</sub>/MIC: 10&#8211;20</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC&#8201;&gt;&#8201;3000<sup>a</sup></td><td align="left" colspan="1" rowspan="1">No data</td></tr><tr><td align="left" colspan="1" rowspan="1">Fluconazole</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC: 25&#8211;44</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC&#8201;&#8805;&#8201;55&#8211;100</td><td align="left" colspan="1" rowspan="1">Unclear</td></tr><tr><td align="left" colspan="1" rowspan="1">Flucytosine</td><td align="left" colspan="1" rowspan="1">fT<sub>&gt;MIC</sub></td><td align="left" colspan="1" rowspan="1">&#8805;&#8201;20&#8211;45% fT<sub>&gt;MIC</sub></td><td align="left" colspan="1" rowspan="1">No data</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>max</sub>&#8201;&gt;&#8201;100&#160;mg/L<sup>b</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Isavuconazole</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC</td><td align="left" colspan="1" rowspan="1">fAUC<sub>0&#8211;24</sub>/MIC: 25&#8211;50</td><td align="left" colspan="1" rowspan="1">No data</td><td align="left" colspan="1" rowspan="1">No data</td></tr><tr><td align="left" colspan="1" rowspan="1">Itraconazole</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>max</sub>&#8201;&gt;&#8201;6&#160;mg/L<sup>c</sup></td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">C</italic><sub>min</sub>&#8201;&#8805;&#8201;0.25&#8211;0.5&#160;mg/L (Prop)</p><p><italic toggle="yes">C</italic><sub>min</sub>&#8201;&#8805;&#8201;1&#160;mg/L (Tx)</p></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>ave</sub>&#8201;&#8805;&#8201;17.1&#160;mg/L<sup>d</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Posaconazole</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC</td><td align="left" colspan="1" rowspan="1">fAUC<sub>0&#8211;24</sub>/MIC: 25&#8211;50</td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">C</italic><sub>min</sub>&#8201;&gt;&#8201;0.5 (Prop)</p><p><italic toggle="yes">C</italic><sub>min</sub>&#8201;&gt;&#8201;1&#160;mg/L (Tx)</p></td><td align="left" colspan="1" rowspan="1">No data</td></tr><tr><td align="left" colspan="1" rowspan="1">Voriconazole</td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC</td><td align="left" colspan="1" rowspan="1">fAUC<sub>0&#8211;24</sub>/MIC: 25&#8211;50</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>min</sub>&#8201;&#8805;&#8201;1&#8211;2&#160;mg/L</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>min</sub>&#8201;&#8805;&#8201;4.5&#8211;6&#160;mg/L<sup>e</sup></td></tr></tbody></table><table-wrap-foot><p>AUC<sub>0&#8211;24</sub>/MIC&#8201;=&#8201;the ratio of the area under the concentration&#8211;time curve during a 24-h period to minimum inhibitory concentration; <italic toggle="yes">C</italic><sub>ave</sub>&#8201;=&#8201;average drug concentration; <italic toggle="yes">C</italic><sub>min</sub>&#8201;=&#8201;trough drug concentration; fAUC<sub>0&#8211;24</sub>/MIC&#8201;=&#8201;the free (unbound drug concentration) ratio of the area under the concentration&#8211;time curve during a 24-hour period to minimum inhibitory concentration; fT<sub>&gt;MIC</sub>&#8201;=&#8201;the duration of time that the free drug concentration remains above the MIC during a dosing interval; PK/PD&#8201;=&#8201;pharmacokinetic/pharmacodynamic; Prop&#8201;=&#8201;prophylaxis; Tx&#8201;=&#8201;treatment</p><p><sup>a</sup>In patients receiving micafungin for invasive candidiasis/candidemia</p><p><sup>b</sup>Related to haematological toxicity and hepatotoxicity</p><p><sup>c</sup>Concentration determined by bioassay</p><p><sup>d</sup>Mostly related to gastrointestinal toxicity</p><p><sup>e</sup>Mostly related to hepatotoxicity and neurotoxicity</p></table-wrap-foot></table-wrap><table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>Pharmacokinetic/pharmacodynamic (PK/PD) indices and the magnitudes associated with antiviral clinical efficacy and toxicity</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Antivirals</th><th align="left" colspan="1" rowspan="1">PK/PD index</th><th align="left" colspan="1" rowspan="1">Pre-clinical PK/PD target for efficacy<sup>a</sup></th><th align="left" colspan="1" rowspan="1">Clinical PK/PD target for efficacy</th><th align="left" colspan="1" rowspan="1">Clinical PK/PD threshold for toxicity</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Aciclovir/valaciclovir</td><td align="left" colspan="1" rowspan="1">Unclear</td><td align="left" colspan="1" rowspan="1">Unclear</td><td align="left" colspan="1" rowspan="1">Unclear</td><td align="left" colspan="1" rowspan="1">Unclear</td></tr><tr><td align="left" colspan="1" rowspan="1">Foscarnet</td><td align="left" colspan="1" rowspan="1">Unclear</td><td align="left" colspan="1" rowspan="1">Unclear</td><td align="left" colspan="1" rowspan="1">Unclear</td><td align="left" colspan="1" rowspan="1">No data</td></tr><tr><td align="left" colspan="1" rowspan="1">Ganciclovir/valganciclovir</td><td align="left" colspan="1" rowspan="1">AUC</td><td align="left" colspan="1" rowspan="1">Unclear</td><td align="left" colspan="1" rowspan="1">AUC: 40&#8211;60&#160;mg&#160;h/L (Prop)</td><td align="left" colspan="1" rowspan="1">Unclear</td></tr><tr><td align="left" colspan="1" rowspan="1">Oseltamivir/oseltamivir carboxylate</td><td align="left" colspan="1" rowspan="1">Unclear</td><td align="left" colspan="1" rowspan="1">Unclear</td><td align="left" colspan="1" rowspan="1">Unclear</td><td align="left" colspan="1" rowspan="1">Unclear</td></tr><tr><td align="left" colspan="1" rowspan="1">Ribavirin</td><td align="left" colspan="1" rowspan="1">AUC</td><td align="left" colspan="1" rowspan="1">Unclear</td><td align="left" colspan="1" rowspan="1"><p>AUC<sub>0&#8211;4</sub>&#8201;&gt;&#8201;1755&#160;mg&#160;h/L</p><p>AUC<sub>0&#8211;12</sub>&#8201;&gt;&#8201;3014&#160;mg&#160;h/L</p><p><italic toggle="yes">C</italic><sub>min</sub>&#8201;&#8805;&#8201;2&#160;mg/L</p></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>min</sub>&#8201;&gt;&#8201;2.3&#160;mg/L<sup>b</sup></td></tr></tbody></table><table-wrap-foot><p>AUC&#8201;=&#8201;area under the concentration&#8211;time curve; AUC<sub>0&#8211;4</sub>&#8201;=&#8201;the ratio of the area under the concentration&#8211;time curve during a 4-h period; AUC<sub>0&#8211;12</sub>&#8201;=&#8201;the ratio of the area under the concentration&#8211;time curve during a 12-h period; <italic toggle="yes">C</italic><sub>min</sub>&#8201;=&#8201;trough drug concentration; PK/PD&#8201;=&#8201;pharmacokinetic/pharmacodynamic; Prop&#8201;=&#8201;prophylaxis</p><p><sup>a</sup>Whilst in vitro concentrations at which viral replication is inhibited by 50% (i.e. EC<sub>50</sub> representing antiviral activity) have been widely determined, there are no/limited data which correlate these values with in vivo pharmacokinetic parameters (e.g. AUC) to describe magnitudes required for pre-clinical efficacy</p><p><sup>b</sup>Mostly related to anaemia</p></table-wrap-foot></table-wrap><table-wrap id="Tab4" position="float" orientation="portrait"><label>Table&#160;4</label><caption><p>Recommendations for therapeutic drug monitoring (TDM) for antibiotics, antifungals and antivirals in critically ill patients<sup>a</sup></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Antibacterials</th><th align="left" colspan="2" rowspan="1">TDM recommendation, suggested TDM sampling and targets in critically ill patients</th></tr><tr><th align="left" colspan="1" rowspan="1">Recommendation and suggested sampling scheme/strategy</th><th align="left" colspan="1" rowspan="1">Target</th></tr></thead><tbody><tr><td align="left" rowspan="4" colspan="1">Aminoglycosides</td><td align="left" colspan="1" rowspan="1">TDM recommendation by Panel: &#8220;YES&#8221;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><p>AUC-based monitoring</p><p>&#160;Two samples<sup>b</sup></p><p>&#160;One taken 30&#160;min after the end of infusion and the other one taken between 6 and 22&#160;h post-infusion</p></td><td align="left" colspan="1" rowspan="1">AUC: 80&#8211;120&#160;mg&#160;h/L</td></tr><tr><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">C</italic><sub>max</sub>/MIC monitoring</p><p>&#160;One sample</p><p>&#160;30&#160;min after the end of infusion</p></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>max</sub>/MIC&#8201;&#8805;&#8201;8&#8211;10</td></tr><tr><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">C</italic><sub>min</sub> monitoring<sup>c</sup></p><p>&#160;One sample</p><p>&#160;30&#160;min or just before the next dosing</p></td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">C</italic><sub>min</sub></p><p>&#160;Amikacin&#8201;&lt;&#8201;2.5&#160;mg/L</p><p>&#160;Gentamicin/tobramycin&#8201;&lt;&#8201;0.5&#160;mg/L</p></td></tr><tr><td align="left" rowspan="3" colspan="1">Beta-lactams</td><td align="left" colspan="1" rowspan="1">TDM recommendation by Panel: &#8220;YES&#8221;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">C</italic><sub>min</sub> monitoring</p><p>&#160;One sample</p><p>&#160;30&#160;min or just before the next dosing</p><p>&#160;Sampling should occur 24&#8211;48&#160;h post-initiation of therapy</p></td><td align="left" colspan="1" rowspan="1">100% fT<sub>&gt;MIC</sub></td></tr><tr><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">C</italic><sub>ss</sub> monitoring for continuous infusion</p><p>&#160;One sample at any time point during the infusion</p></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>ss</sub>&#8201;&gt;&#8201;MIC</td></tr><tr><td align="left" colspan="1" rowspan="1">Co-trimoxazole</td><td align="left" colspan="1" rowspan="1">TDM recommendation by Panel: &#8220;NEITHER RECOMMEND NOR DISCOURAGE&#8221;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">Daptomycin</td><td align="left" colspan="1" rowspan="1">TDM recommendation by Panel: &#8220;NEITHER RECOMMEND NOR DISCOURAGE&#8221;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><p>AUC/MIC-based monitoring</p><p>&#160;Two samples</p><p>&#160;One taken between 1.5 and 3&#160;h post-dosing and the other one taken within 1&#160;h of the next infusion</p></td><td align="left" colspan="1" rowspan="1">AUC/MIC&#8201;&gt;&#8201;666</td></tr><tr><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">C</italic><sub>min</sub> monitoring</p><p>&#160;One sample</p><p>&#160;Within 1&#160;h of the next infusion</p><p>&#160;Sampling should occur 72&#160;h post-initiation of therapy</p></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>min</sub>&#8201;&lt;&#8201;24&#160;mg/L</td></tr><tr><td align="left" rowspan="3" colspan="1">Fluoroquinolones</td><td align="left" colspan="1" rowspan="1">TDM recommendation by Panel: &#8220;NEITHER RECOMMEND NOR DISCOURAGE&#8221;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><p>AUC/MIC-based monitoring</p><p>&#160;Two samples<sup>b</sup></p><p>&#160;One taken 2&#160;h post-dosing and the other one taken 6&#160;h post-dosing</p></td><td align="left" colspan="1" rowspan="1">fAUC<sub>0&#8211;24</sub>/MIC&#8201;&#8805;&#8201;80</td></tr><tr><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">C</italic><sub>max</sub>/MIC monitoring</p><p>&#160;One sample</p><p>&#160;30&#160;min after the end of infusion</p></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>max</sub>/MIC&#8201;&#8805;&#8201;8&#8211;12</td></tr><tr><td align="left" colspan="1" rowspan="1">Glycopeptides</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">&#160;Teicoplanin</td><td align="left" colspan="1" rowspan="1">TDM recommendation by Panel: &#8220;YES&#8221;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">C</italic><sub>min</sub> monitoring</p><p>&#160;One sample</p><p>&#160;30&#160;min or just before the next dosing</p></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>min</sub>&#8201;&#8805;&#8201;15&#8211;30&#160;mg/L</td></tr><tr><td align="left" rowspan="4" colspan="1">&#160;Vancomycin</td><td align="left" colspan="1" rowspan="1">TDM recommendation by Panel: &#8220;YES&#8221;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><p>AUC/MIC-based monitoring</p><p>&#160;Two samples<sup>b</sup></p><p>&#160;One taken 1&#160;h after the end of infusion and the other one taken within 1&#8211;2&#160;h of the next infusion</p></td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>/MIC&#8201;&#8805;&#8201;400</td></tr><tr><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">C</italic><sub>min</sub> monitoring for intermittent infusion</p><p>&#160;One sample</p><p>&#160;30&#160;min or just before the next dosing</p></td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">C</italic><sub>min</sub>&#8201;&gt;&#8201;10&#160;mg/L</p><p><italic toggle="yes">C</italic><sub>min</sub>&#8201;&#8805;&#8201;15&#8211;20&#160;mg/L (severe infections)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">C</italic><sub>ss</sub> monitoring for continuous infusion</p><p>&#160;One sample at any time point during the infusion</p></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>ss</sub>: 20&#8211;25&#160;mg/L</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Linezolid</td><td align="left" colspan="1" rowspan="1">TDM recommendation by Panel: &#8220;YES&#8221;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">C</italic><sub>min</sub> monitoring</p><p>&#160;One sample</p><p>&#160;30&#160;min or just before the next dosing</p><p>&#160;Sampling should occur 48&#160;h post-initiation of therapy</p></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>min</sub>: 2&#8211;7&#160;mg/L</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymyxins</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">&#160;Colistin</td><td align="left" colspan="1" rowspan="1">TDM recommendation by Panel: &#8220;NEITHER RECOMMEND NOR DISCOURAGE&#8221;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">C</italic><sub>min</sub> monitoring</p><p>&#160;One sample</p><p>&#160;Just before the next infusion</p><p>&#160;Sampling should occur 48&#8211;72&#160;h post-initiation of therapy</p></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>min</sub>: 2&#160;mg/L</td></tr><tr><td align="left" rowspan="2" colspan="1">&#160;Polymyxin B</td><td align="left" colspan="1" rowspan="1">TDM recommendation: &#8220;NEITHER RECOMMEND NOR DISCOURAGE&#8221;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><p>AUC-based monitoring</p><p>&#160;At least one sample</p><p>&#160;Sampling should occur 12&#8211;24&#160;h post-initiation of therapy</p></td><td align="left" colspan="1" rowspan="1">AUC<sub>0&#8211;24</sub>: 50&#8211;100&#160;mg&#160;h/L</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Antifungals</th><th align="left" colspan="1" rowspan="1">Suggested sampling scheme/strategy</th><th align="left" colspan="1" rowspan="1">Target</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Echinocandins</td><td align="left" colspan="1" rowspan="1">TDM recommendation by Panel: &#8220;NEITHER RECOMMEND NOR DISCOURAGE&#8221;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Fluconazole</td><td align="left" colspan="1" rowspan="1">TDM recommendation by Panel: &#8220;NEITHER RECOMMEND NOR DISCOURAGE&#8221;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">Flucytosine</td><td align="left" colspan="1" rowspan="1">TDM recommendation by Panel: &#8220;NEITHER RECOMMEND NOR DISCOURAGE&#8221;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">C</italic><sub>max</sub> monitoring</p><p>&#160;One sample</p><p>&#160;2&#160;h post-dose</p><p>&#160;Sampling should occur 48&#160;h post-initiation of therapy</p></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>max</sub>&#8201;&lt;&#8201;100&#160;mg/L</td></tr><tr><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">C</italic><sub>min</sub> monitoring</p><p>&#160;One sample</p><p>&#160;30&#160;min or just before the next dosing</p><p>&#160;Sampling should occur 72&#160;h post-initiation of therapy</p></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>min</sub>&#8201;&#8805;&#8201;25&#160;mg/L<sup>d</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Isavuconazole</td><td align="left" colspan="1" rowspan="1">TDM recommendation by Panel: &#8220;NEITHER RECOMMEND NOR DISCOURAGE&#8221;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Itraconazole</td><td align="left" colspan="1" rowspan="1"><p>TDM recommendation by Panel: &#8220;NEITHER RECOMMEND NOR DISCOURAGE&#8221;</p><p><italic toggle="yes">C</italic><sub>min</sub> monitoring</p><p>&#160;One sample</p><p>&#160;30&#160;min or just before the next dosing</p><p>&#160;Sampling should occur within 5&#8211;7&#160;days post-initiation of therapy</p></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>min</sub>&#8201;&gt;&#8201;0.5&#8211;1&#160;mg/L</td></tr><tr><td align="left" rowspan="2" colspan="1">Posaconazole</td><td align="left" colspan="1" rowspan="1">TDM recommendation by Panel: &#8220;NEITHER RECOMMEND NOR DISCOURAGE&#8221;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">C</italic><sub>min</sub> monitoring</p><p>&#160;One sample</p><p>&#160;30&#160;min or just before the next dosing</p><p>&#160;Sampling should occur after 7&#160;days of initiation of therapy</p></td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">C</italic><sub>min</sub>&#8201;&gt;&#8201;0.5&#8211;0.7&#160;mg/L (prophylaxis)</p><p><italic toggle="yes">C</italic><sub>min</sub>&#8201;&gt;&#8201;1&#160;mg/L (treatment)</p></td></tr><tr><td align="left" rowspan="2" colspan="1">Voriconazole</td><td align="left" colspan="1" rowspan="1">TDM recommendation by Panel: &#8220;YES&#8221;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">C</italic><sub>min</sub> monitoring</p><p>&#160;One sample</p><p>&#160;30&#160;min or just before the next dosing</p><p>&#160;Sampling should occur between 2 and 5&#160;days of initiation of therapy</p></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>min</sub>: 2&#8211;6&#160;mg/L (prophylaxis or treatment)</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Antivirals</th><th align="left" colspan="1" rowspan="1">Suggested sampling scheme/strategy</th><th align="left" colspan="1" rowspan="1">Target</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Aciclovir/valaciclovir</td><td align="left" colspan="1" rowspan="1">TDM recommendation by Panel: &#8220;NEITHER RECOMMEND NOR DISCOURAGE&#8221;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Foscarnet</td><td align="left" colspan="1" rowspan="1">TDM recommendation by Panel: &#8220;NEITHER RECOMMEND NOR DISCOURAGE&#8221;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Ganciclovir/valganciclovir</td><td align="left" colspan="1" rowspan="1">TDM recommendation by Panel: &#8220;NEITHER RECOMMEND NOR DISCOURAGE&#8221;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Oseltamivir</td><td align="left" colspan="1" rowspan="1">TDM recommendation by Panel: &#8220;NEITHER RECOMMEND NOR DISCOURAGE&#8221;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Ribavirin</td><td align="left" colspan="1" rowspan="1">TDM recommendation by Panel: &#8220;NEITHER RECOMMEND NOR DISCOURAGE&#8221;</td><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>AUC&#8201;=&#8201;area under the concentration&#8211;time curve; AUC<sub>0&#8211;24</sub>/MIC&#8201;=&#8201;the ratio of the area under the concentration&#8211;time curve during a 24-hour period to minimum inhibitory concentration; CI&#8201;=&#8201;continuous infusion; <italic toggle="yes">C</italic><sub>max</sub>/MIC&#8201;=&#8201;the ratio of maximum drug concentration to minimum inhibitory concentration; <italic toggle="yes">C</italic><sub>min</sub>&#8201;=&#8201;trough drug concentration; <italic toggle="yes">C</italic><sub>ss</sub>&#8201;=&#8201;average steady-state drug concentration; fT<sub>&gt;MIC</sub>&#8201;=&#8201;the duration of time that the free drug concentration remains above the MIC during a dosing interval; II&#8201;=&#8201;intermittent infusion</p><p><sup>a</sup>Although consensus may not have been achieved for some of these antimicrobials/antimicrobial classes, suggested sampling strategies and targets for TDM are presented for those antimicrobials/antimicrobial classes where TDM data/experience have been reported</p><p><sup>b</sup>Only one sample is needed with Bayesian dose adaptation/adaptive feedback control</p><p><sup>c</sup>Only for treatment of more than 3&#160;days</p><p><sup>d</sup>Concentrations preventing resistance development based on in vitro pharmacokinetic model</p></table-wrap-foot></table-wrap><table-wrap id="Tab5" position="float" orientation="portrait"><label>Table&#160;5</label><caption><p>Comparative studies highlighting clinical benefits of performing therapeutic drug monitoring for gentamicin, voriconazole and ribavirin</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Study/country/population</th><th align="left" colspan="1" rowspan="1">Patients</th><th align="left" colspan="1" rowspan="1">Study design</th><th align="left" colspan="1" rowspan="1">Clinical outcomes<sup>a</sup></th><th align="left" colspan="1" rowspan="1">TDM</th><th align="left" colspan="1" rowspan="1">Non-TDM</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Van Lent-Evers (1999)</td><td align="left" colspan="1" rowspan="1">Total: 232</td><td align="left" colspan="1" rowspan="1">Multi-centre, non-randomised, before-and-after trial</td><td align="left" colspan="1" rowspan="1">Dose changes (%)*</td><td align="left" colspan="1" rowspan="1">48.6</td><td align="left" colspan="1" rowspan="1">80.4</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Netherlands</td><td align="left" colspan="1" rowspan="1">TDM: 105</td><td align="left" colspan="1" rowspan="1">TDM: Bayesian-guided dosing</td><td align="left" colspan="1" rowspan="1">Duration of therapy (days)*</td><td align="left" colspan="1" rowspan="1">5.9&#8201;&#177;&#8201;2.9</td><td align="left" colspan="1" rowspan="1">8.0&#8201;&#177;&#8201;4.9</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Gentamicin</td><td align="left" colspan="1" rowspan="1">Non-TDM: 127</td><td align="left" colspan="1" rowspan="1">Non-TDM: standard or nomogram</td><td align="left" colspan="1" rowspan="1">Length of stay (days)*</td><td align="left" colspan="1" rowspan="1">20.0&#8201;&#177;&#8201;13.7</td><td align="left" colspan="1" rowspan="1">26.3&#8201;&#177;&#8201;31.5</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Gram-negative sepsis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><p>Mortality (%)</p><p>Nephrotoxicity (%)*</p><p>Total costs (in DFL)*</p></td><td align="left" colspan="1" rowspan="1"><p>9 (8.6%)</p><p>3 (2.8)</p><p>13,125&#8201;&#177;&#8201;9,267</p></td><td align="left" colspan="1" rowspan="1"><p>18 (14.2)</p><p>17 (13.4)</p><p>16,862&#8201;&#177;&#8201;17,721</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Park (2012)</td><td align="left" colspan="1" rowspan="1">Total: 110</td><td align="left" colspan="1" rowspan="1">Single-centre, assessor-blinded, randomised controlled trial</td><td align="left" colspan="1" rowspan="1">Adverse events (%)</td><td align="left" colspan="1" rowspan="1">23 (42)</td><td align="left" colspan="1" rowspan="1">22 (42)<sup>b</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;South Korea</td><td align="left" colspan="1" rowspan="1">TDM: 55</td><td align="left" colspan="1" rowspan="1">TDM: concentration-controlled<sup>c</sup></td><td align="left" colspan="1" rowspan="1">Drug discontinuation (%)*</td><td align="left" colspan="1" rowspan="1">2 (4)</td><td align="left" colspan="1" rowspan="1">9 (17)<sup>b</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Voriconazole</td><td align="left" colspan="1" rowspan="1">Non-TDM: 55</td><td align="left" colspan="1" rowspan="1">Non-TDM: standard therapy</td><td align="left" colspan="1" rowspan="1">Treatment response (%)*<sup>,d</sup></td><td align="left" colspan="1" rowspan="1">30 (81)<sup>e</sup></td><td align="left" colspan="1" rowspan="1">20 (59)<sup>f</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Invasive fungal infections</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Stickel (2013)<sup>g</sup></td><td align="left" colspan="1" rowspan="1">Total: 16</td><td align="left" colspan="1" rowspan="1">Multi-centre, open-labelled, randomised controlled trial</td><td align="left" colspan="1" rowspan="1">Sustained virological response (%)<sup>h</sup></td><td align="left" colspan="1" rowspan="1">10 (62.5)</td><td align="left" colspan="1" rowspan="1">6 (37.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Switzerland</td><td align="left" colspan="1" rowspan="1">TDM: 16</td><td align="left" colspan="1" rowspan="1">TDM: concentration-controlled<sup>i</sup></td><td align="left" colspan="1" rowspan="1">Mean haemoglobin (g/L)*</td><td align="left" colspan="1" rowspan="1">99.6</td><td align="left" colspan="1" rowspan="1">106.3</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Ribavirin</td><td align="left" colspan="1" rowspan="1">Non-TDM: 16</td><td align="left" colspan="1" rowspan="1">Non-TDM: weight-based dosing</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Chronic hepatitis C</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>DFL&#8201;=&#8201;Dutch florin, i.e. the currency of Netherlands up to 2002; TDM&#8201;=&#8201;therapeutic drug monitoring</p><p><sup>a</sup>An asterisk indicates a significant difference between TDM and non-TDM groups</p><p><sup>b</sup>Only 53 patients were included</p><p><sup>c</sup>Target trough concentration of 1.0&#8211;5.5&#160;mg/L</p><p><sup>d</sup>Included either complete or partial response</p><p><sup>e</sup>Only 37 patients were included</p><p><sup>f</sup>Only 34 patients were included</p><p><sup>g</sup>Reported in a research letter</p><p><sup>h</sup>Cumulative ribavirin exposure above 224.3&#160;mg/L was significantly associated with sustained virological response</p><p><sup>i</sup>Target concentration of 3.7&#160;mg/L</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Antibacterials</title><sec id="Sec14"><title>Aminoglycosides</title><sec id="Sec15"><title>Pharmacokinetics</title><p id="Par30">Aminoglycosides are hydrophilic with a low <italic toggle="yes">V</italic><sub>d</sub> and CL that is proportional to glomerular filtration rate. Significant <italic toggle="yes">V</italic><sub>d</sub> and CL alterations have been widely described in critically ill patients.</p></sec><sec id="Sec16"><title>Pharmacodynamics</title><p id="Par31">Aminoglycosides demonstrate &#8220;concentration-dependent&#8221; bactericidal activity, which is optimal when the <italic toggle="yes">C</italic><sub>max</sub> is&#8201;&#8805;&#8201;8&#8211;10&#8201;&#215;&#8201;MIC [<xref ref-type="bibr" rid="CR33">33</xref>&#8211;<xref ref-type="bibr" rid="CR35">35</xref>]. Recent data, however, have suggested that the AUC<sub>0&#8211;24</sub>/MIC ratio might be a better predictor of activity and is better suited to judge target attainment in extended-interval dosing of aminoglycosides. High <italic toggle="yes">C</italic><sub>min</sub> and AUC exposures over days have been associated with oto- and nephrotoxicity.</p></sec><sec id="Sec17"><title>Dosing in critically ill patients</title><p id="Par32">High, single-dose, extended-interval dosing should be used in patients with Gram-negative infections. Recent data suggest that higher-than-standard aminoglycoside dosing regimen may be required for critically ill patients [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>].</p></sec><sec id="Sec18"><title>TDM in critically ill patients</title><p id="Par33">The Panel recommends that TDM be routinely performed when aminoglycosides are used in critically ill patients.</p><p id="Par34">AUC-based monitoring with at least two time points collected combined with Bayesian dose adaptation best predicts aminoglycoside dosing requirements [<xref ref-type="bibr" rid="CR38">38</xref>&#8211;<xref ref-type="bibr" rid="CR40">40</xref>]. TDM-guided dosing with Bayesian dose adaptation has led to a shorter length of hospital stay and a reduced incidence of nephrotoxicity in patients receiving gentamicin for Gram-negative infections [<xref ref-type="bibr" rid="CR39">39</xref>].</p></sec><sec id="Sec19"><title>Bioanalytical assay</title><p id="Par35">Commercial immunoassays are available for amikacin, gentamicin and tobramycin TDM. For other aminoglycosides (e.g. kanamycin and plazomicin), modified immunoassays or chromatographic assays need to be established.</p></sec></sec><sec id="Sec20"><title>Beta-lactam antibacterials</title><sec id="Sec21"><title>Pharmacokinetics</title><p id="Par36">Beta-lactam antibacterials are generally hydrophilic, demonstrate low <italic toggle="yes">V</italic><sub>d</sub> and are predominantly cleared via renal elimination. Most beta-lactams have a moderate (30&#8211;70%) to low (&lt;&#8201;30%) degrees of protein binding. Significant <italic toggle="yes">V</italic><sub>d</sub> and CL alterations are common, and these PK alterations may lead to inadequate beta-lactam concentrations particularly in the earlier phase of critical illness. Hypoalbuminemia has been associated with an increase in the free fraction (non-protein bound) of highly protein-bound beta-lactams (e.g. ceftriaxone, ertapenem and semisynthetic penicillins such as flucloxacillin, oxacillin and temocillin) and low unbound concentrations towards the end of the dosing interval [<xref ref-type="bibr" rid="CR8">8</xref>].</p></sec><sec id="Sec22"><title>Pharmacodynamics</title><p id="Par37">The PK/PD index associated with optimal beta-lactam activity is the &#160;% fT<sub>&gt;MIC</sub> (40&#8211;70%). Critically ill patients data suggest that patients may benefit from longer (e.g. 100% fT<sub>&gt;MIC</sub>) [<xref ref-type="bibr" rid="CR41">41</xref>&#8211;<xref ref-type="bibr" rid="CR43">43</xref>] and higher (e.g. 2&#8211;5&#8201;&#215;&#8201;MIC) [<xref ref-type="bibr" rid="CR42">42</xref>&#8211;<xref ref-type="bibr" rid="CR44">44</xref>] beta-lactam exposures than those previously described. Although the beta-lactams generally have a wide therapeutic index, high exposures have been associated with neurotoxicity. Although myelosuppression is well-known toxicity for the beta-lactams [<xref ref-type="bibr" rid="CR45">45</xref>], no toxicity thresholds have been well established to date.</p></sec><sec id="Sec23"><title>Dosing in critically ill patients</title><p id="Par38">An initial loading dose (LD) followed by prolonged beta-lactam infusion (continuous or extended infusion) maximises PK/PD target attainment and is likely to improve clinical outcomes in critically ill patients [<xref ref-type="bibr" rid="CR46">46</xref>].</p></sec><sec id="Sec24"><title>TDM in critically ill patients</title><p id="Par39">The Panel recommends that TDM be routinely performed when beta-lactam antibiotics are used in critically ill patients.</p><p id="Par40">The collateral damage of more aggressive beta-lactam dosing to account for altered drug PK, i.e. excessive drug exposure, has been increasingly reported over the last 10&#160;years, although it is probably still under-reported. TDM of beta-lactam antibiotics in critically ill patients is, therefore, becoming more common to optimise dosing whilst minimising the likelihood of toxicity [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. <italic toggle="yes">C</italic><sub>min</sub> samples at steady state are widely used, although the use of dosing software could enable even earlier sampling and dose optimisation [<xref ref-type="bibr" rid="CR48">48</xref>].</p></sec><sec id="Sec25"><title>Bioanalytical assay</title><p id="Par41">Several high-performance liquid chromatography with ultraviolet detection (HPLC&#8211;UV) and liquid chromatography&#8211;tandem mass spectrometry (LC&#8211;MS/MS) assays have been applied to beta-lactam TDM.</p></sec></sec><sec id="Sec26"><title>Co-trimoxazole</title><sec id="Sec27"><title>Pharmacokinetics</title><p id="Par42">Co-trimoxazole consists of a combination of sulfamethoxazole and trimethoprim in a 5:1 ratio. Both drugs are predominantly cleared by renal elimination and are moderately bound to plasma proteins. Although the impact of critical illness on its PK has been scarcely reported, significant PK variability has been observed with weight-based dosing of co-trimoxazole in older studies [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>].</p></sec><sec id="Sec28"><title>Pharmacodynamics</title><p id="Par43"><italic toggle="yes">C</italic><sub>max</sub> and fAUC<sub>0&#8211;24</sub>/MIC ratios have been linked with optimal sulfamethoxazole/trimethoprim activity. Higher doses and exposures may likely increase the likelihood of adverse events such as hyperkalemia and metabolic acidosis.</p></sec><sec id="Sec29"><title>Dosing in critically ill patients</title><p id="Par44">There are insufficient clinical data to support altering co-trimoxazole dosing for maximal outcomes in critically ill patients. Weight-based dosing depending on the pathogen is appropriate.</p></sec><sec id="Sec30"><title>TDM in critically ill patients</title><p id="Par45">The Panel neither recommends, nor discourages routine sulfamethoxazole (as the representative drug in co-trimoxazole) TDM in critically ill patients.</p></sec><sec id="Sec31"><title>Bioanalytical assay</title><p id="Par46">No commercial assays are currently available, and a chromatographic assay is required to facilitate TDM.</p></sec></sec><sec id="Sec32"><title>Daptomycin</title><sec id="Sec33"><title>Pharmacokinetics</title><p id="Par47">Daptomycin demonstrates a low <italic toggle="yes">V</italic><sub>d</sub> and is predominantly cleared via renal elimination. <italic toggle="yes">V</italic><sub>d</sub> and CL alterations are common, leading to variable and low drug exposure. It is a highly protein-bound drug (92&#8211;94%) and the free fraction increases in critically ill patients.</p></sec><sec id="Sec34"><title>Pharmacodynamics</title><p id="Par48">AUC<sub>0&#8211;24</sub>/MIC ratios of&#8201;&#8805;&#8201;666&#160;mg/L have been described for daptomycin efficacy in critically ill patients [<xref ref-type="bibr" rid="CR51">51</xref>]. More recently, a <italic toggle="yes">C</italic><sub>min</sub> of&#8201;&lt;&#8201;3.2&#160;mg/L has been linked to poor clinical outcomes in hospitalised patients with various Gram-positive infections [<xref ref-type="bibr" rid="CR52">52</xref>]. A <italic toggle="yes">C</italic><sub>min</sub> of &#8201;&#8805;&#8201;24.3&#160;mg/L is associated with an increased likelihood of creatine phosphokinase (CPK) elevation by&#8201;&gt;&#8201;30-fold [<xref ref-type="bibr" rid="CR53">53</xref>].</p></sec><sec id="Sec35"><title>Dosing in critically ill patients</title><p id="Par49">Current data suggest that optimal AUC<sub>0&#8211;24</sub>/MIC ratios can easily be achieved with a Product Information dose of 6&#160;mg/kg but only for pathogens with an MIC of 0.1&#160;mg/L. With increasing MICs, higher doses (10&#8211;12&#160;mg/kg/day) are probably required to achieve these targets [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>].</p></sec><sec id="Sec36"><title>TDM in critically ill patients</title><p id="Par50">The Panel neither recommends, nor discourages routine daptomycin TDM in critically ill patients.</p><p id="Par51">As daptomycin presents highly variable and unpredictable PK, several centres have performed TDM and have reported their clinical experience [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. Previous work has aimed for <italic toggle="yes">C</italic><sub>min</sub>&#8201;&lt;&#8201;24&#160;mg/L at steady-state [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. AUC-based monitoring, via LSS, can also be applied to guide daptomycin dosing to achieve AUC<sub>0&#8211;24</sub>/MIC ratios of&#8201;&#8805;&#8201;666 [<xref ref-type="bibr" rid="CR58">58</xref>].</p></sec><sec id="Sec37"><title>Bioanalytical assay</title><p id="Par52">HPLC&#8211;UV and LC&#8211;MS/MS assays have been published for daptomycin TDM.</p></sec></sec><sec id="Sec38"><title>Fluoroquinolones</title><sec id="Sec39"><title>Pharmacokinetics</title><p id="Par53">Fluoroquinolones are moderately lipophilic with <italic toggle="yes">V</italic><sub>d</sub> generally unaffected by critical illness, with the exception of levofloxacin. Most fluoroquinolones have a moderate to low degree of protein binding, and some are cleared, at least to some degree, by renal elimination.</p></sec><sec id="Sec40"><title>Pharmacodynamics</title><p id="Par54">Fluoroquinolones exhibit &#8220;concentration-dependent&#8221; bactericidal activity, and the AUC<sub>0&#8211;24</sub>/MIC ratio best predicts clinical efficacy. Higher <italic toggle="yes">C</italic><sub>max</sub>/MIC ratios (&gt;&#8201;8&#8211;20) may also be required for optimal bactericidal activity [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. AUC<sub>0&#8211;24</sub>/MIC ratios of 25&#8211;30 may suffice against the Gram-positive organisms, but higher values (&#8805;&#8201;125) are needed against the Gram-negative organisms [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Several studies have also suggested that a ratio of&#8201;&gt;&#8201;100&#8211;200 may suppress the emergence of resistance against Gram-negative organisms. Although increasing reports of fluoroquinolones-associated seizures have emerged [<xref ref-type="bibr" rid="CR63">63</xref>&#8211;<xref ref-type="bibr" rid="CR65">65</xref>], no toxicity thresholds have been established and causality is debated [<xref ref-type="bibr" rid="CR66">66</xref>].</p></sec><sec id="Sec41"><title>Dosing in critically ill patients</title><p id="Par55">A quinolone dosing regimen that maximises the AUC<sub>0&#8211;24</sub>/MIC (e.g. LD with higher maintenance doses) should be considered in critically ill patients.</p></sec><sec id="Sec42"><title>TDM in critically ill patients</title><p id="Par56">The Panel neither recommends, nor discourages routine fluoroquinolone TDM in critically ill patients.</p><p id="Par57">Given the inter-individual PK variability reported in critically ill patients and the high propensity for emergence of resistance against quinolones, TDM may be useful, particularly where pathogens have MICs close to the susceptibility breakpoint.</p></sec><sec id="Sec43"><title>Bioanalytical assay</title><p id="Par58">HPLC and LC&#8211;MS/MS assays have been published for fluoroquinolones TDM.</p></sec></sec><sec id="Sec44"><title>Glycopeptides</title></sec><sec id="Sec45"><title>Teicoplanin</title><sec id="Sec46"><title>Pharmacokinetics</title><p id="Par59">Teicoplanin is hydrophilic, with a <italic toggle="yes">V</italic><sub>d</sub> of 0.7&#8211;1.4&#160;L/kg, and is predominantly cleared via renal elimination. It has a long elimination half-life (<italic toggle="yes">t</italic><sub>&#189;</sub>) due to its high plasma protein binding (&#8805;&#8201;90%). Variability of teicoplanin exposure is significant in critically ill patients [<xref ref-type="bibr" rid="CR67">67</xref>&#8211;<xref ref-type="bibr" rid="CR69">69</xref>].</p></sec><sec id="Sec47"><title>Pharmacodynamics</title><p id="Par60">A <italic toggle="yes">C</italic><sub>min</sub> of&#8201;&#8805;&#8201;10&#8211;20&#160;mg/L has been associated with favourable clinical response in uncomplicated infection [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>], but higher concentrations (&#8805;&#8201;20&#8211;30&#160;mg/L) are advocated for severe <italic toggle="yes">Staphylococcal</italic> infections including endocarditis and osteomyelitis. However, the clinical data supporting these higher concentrations are sparse. More recent data suggested that the AUC<sub>0&#8211;24</sub>/MIC ratio (&#8805;&#8201;750) may better predict teicoplanin activity in serious methicillin-resistant <italic toggle="yes">S. aureus</italic> (MRSA) infections [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. Unpublished studies reported that a <italic toggle="yes">C</italic><sub>min</sub> of&#8201;&gt;&#8201;60&#160;mg/L increased the likelihood of nephrotoxicity.</p></sec><sec id="Sec48"><title>Dosing in critically ill patients</title><p id="Par61">Teicoplanin has a long <italic toggle="yes">t</italic><sub>&#189;</sub> (150&#160;h) with the use of LD essential to reduce the time to reach therapeutic exposures.</p></sec><sec id="Sec49"><title>TDM in critically ill patients</title><p id="Par62">The Panel recommends that TDM be routinely performed when teicoplanin is used in critically ill patients.</p></sec><sec id="Sec50"><title>Bioanalytical assay</title><p id="Par63">HPLC&#8211;UV, LC&#8211;MS/MS and immunoassays have been published for teicoplanin TDM.</p></sec></sec><sec id="Sec51"><title>Vancomycin</title><sec id="Sec52"><title>Pharmacokinetics</title><p id="Par64">Vancomycin is hydrophilic, demonstrates a low <italic toggle="yes">V</italic><sub>d</sub> and is predominantly cleared via renal elimination. Critical illness alters the <italic toggle="yes">V</italic><sub>d</sub> and CL of vancomycin leading to variable and low drug exposure.</p></sec><sec id="Sec53"><title>Pharmacodynamics</title><p id="Par65">AUC<sub>0&#8211;24</sub>/MIC ratios of&#8201;&#8805;&#8201;400 are recommended against <italic toggle="yes">Staphylococcus aureus</italic> infection, whereas higher exposures are advocated when treating critically ill patients with septic shock [<xref ref-type="bibr" rid="CR74">74</xref>&#8211;<xref ref-type="bibr" rid="CR76">76</xref>]. Prolonged (&#8805;&#8201;7&#160;days) and high vancomycin exposures are associated with nephrotoxicity.</p></sec><sec id="Sec54"><title>Dosing in critically ill patients</title><p id="Par66">Safely attaining optimal AUC<sub>0&#8211;24</sub>/MIC ratios when treating pathogens with MICs of&#8201;&gt;&#8201;1&#160;mg/L is highly challenging with vancomycin [<xref ref-type="bibr" rid="CR77">77</xref>]. LD of 25&#8211;30&#160;mg/kg, followed by 15&#8211;20&#160;mg/kg every 8&#8211;12&#160;h should be considered in critically ill patients without renal impairment. Continuous vancomycin infusion has been associated with a lower nephrotoxicity risk [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>], but clinical superiority has yet to be demonstrated over intermittent dosing. For practical reasons and ease of TDM, however, continuous vancomycin infusion is sometimes preferred and has been increasingly used in some centres.</p></sec><sec id="Sec55"><title>TDM in critically ill patients</title><p id="Par67">The Panel recommends that TDM be routinely performed when vancomycin is used in critically ill patients.</p><p id="Par68">Monitoring <italic toggle="yes">C</italic><sub>min</sub> (15&#8211;20&#160;mg/L for intermittent infusion) or average steady-state concentration (<italic toggle="yes">C</italic><sub>ss</sub>, 20&#8211;25&#160;mg/L for continuous infusion) for pathogens with MIC&#8201;&#8804;&#8201;1&#160;mg/L has been widely used as a surrogate for the AUC<sub>0&#8211;24</sub>/MIC target. However, current data have demonstrated that <italic toggle="yes">C</italic><sub>min</sub> is a poor surrogate for AUC<sub>0&#8211;24</sub> and may tend to underestimate the actual vancomycin exposure [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR80">80</xref>&#8211;<xref ref-type="bibr" rid="CR83">83</xref>]. AUC-based monitoring with Bayesian dose adaptation may likely be a better tool to guide vancomycin treatment in critically ill patients. Although the contemporary AUC<sub>0&#8211;24</sub>/MIC target has always been approximated as&#8201;&#8805;&#8201;400 for vancomycin, this index was derived from BMD MIC, and the E-test equivalence to this might only be 226 [<xref ref-type="bibr" rid="CR84">84</xref>].</p></sec><sec id="Sec56"><title>Bioanalytical assay</title><p id="Par69">Immunoassays are commercially available for vancomycin TDM.</p></sec></sec><sec id="Sec57"><title>Linezolid</title><sec id="Sec58"><title>Pharmacokinetics</title><p id="Par70">Linezolid is moderately lipophilic, demonstrates a <italic toggle="yes">V</italic><sub>d</sub> that approximates the total volume of total body water, is predominantly cleared via non-renal elimination and demonstrates significant intra- and inter-patient PK variability leading to variable linezolid exposure.</p></sec><sec id="Sec59"><title>Pharmacodynamics</title><p id="Par71">Maximum efficacy is demonstrated at % <italic toggle="yes">T</italic><sub>&gt;MIC</sub> of&#8201;&#8805;&#8201;85% and AUC<sub>0&#8211;24</sub>/MIC ratio of 80&#8211;120 [<xref ref-type="bibr" rid="CR85">85</xref>]. Linezolid-induced thrombocytopenia has been reported at <italic toggle="yes">C</italic><sub>min</sub> and AUC<sub>0&#8211;24</sub> of&#8201;&gt;&#8201;7&#8211;10 and&#8201;&gt;&#8201;300&#8211;350, respectively.</p></sec><sec id="Sec60"><title>Dosing in critically ill patients</title><p id="Par72">Critically ill patients may benefit from higher linezolid doses and/or altered dosing approaches (e.g. front-loaded dosing regimen and continuous infusion) although these approaches should be supported with TDM if available. Subgroups of patients who may likely require higher-than-standard linezolid doses include those who are obese, those with acute respiratory distress syndrome and ARC, as well as those who are infected with pathogens with MIC&#8201;&#8805;&#8201;2&#160;mg/L [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR86">86</xref>].</p></sec><sec id="Sec61"><title>TDM in critically ill patients</title><p id="Par73">The Panel recommends that TDM be routinely performed when linezolid is used in critically ill patients.</p><p id="Par74">Using an epidemiological MIC distribution, a <italic toggle="yes">C</italic><sub>min</sub> target of&#8201;&gt;&#8201;2&#160;mg/L is well correlated with an AUC<sub>0&#8211;24</sub>/MIC ratio of&#8201;&#8805;&#8201;80 [<xref ref-type="bibr" rid="CR87">87</xref>]. Therefore, maintaining linezolid <italic toggle="yes">C</italic><sub>min</sub> between 2 and 7&#160;mg/L is recommended for optimal drug exposure whilst minimising haematological toxicity [<xref ref-type="bibr" rid="CR88">88</xref>]. Alternatively, TDM via LSS can be used [<xref ref-type="bibr" rid="CR89">89</xref>].</p></sec><sec id="Sec62"><title>Bioanalytical assay</title><p id="Par75">HPLC&#8211;UV, LC&#8211;MS/MS and immunoassays have been published, but these assays are currently sparsely implemented for routine TDM.</p></sec></sec><sec id="Sec63"><title>Colistin</title><sec id="Sec64"><title>Pharmacokinetics</title><p id="Par76">Colistin is administered parenterally as the prodrug colistin methanesulfonate (CMS). CMS and colistin demonstrate a low <italic toggle="yes">V</italic><sub>d</sub> and have mixed elimination routes. The <italic toggle="yes">V</italic><sub>d</sub> and CL of colistin may be altered in critically ill patients, potentially affecting colistin exposure. Colistin protein binding in critically ill patients was reported as 59&#8211;74% and was concentration dependent [<xref ref-type="bibr" rid="CR90">90</xref>].</p></sec><sec id="Sec65"><title>Pharmacodynamics</title><p id="Par77">Colistin demonstrates &#8220;concentration-dependent&#8221; bactericidal activity, and both in vitro and in vivo data have suggested that the free AUC<sub>0&#8211;24</sub>/MIC (fAUC<sub>0&#8211;24</sub>/MIC) ratio best predicts its activity. fAUC<sub>0&#8211;24</sub>/MIC ratios of 10.9&#8211;13.7 and 3.5&#8211;9.0 have been described for optimal killing against <italic toggle="yes">Pseudomonas aeruginosa</italic> and <italic toggle="yes">Acinetobacter baumannii</italic>, respectively [<xref ref-type="bibr" rid="CR91">91</xref>]. Prolonged high exposures are associated with neuro- and nephrotoxicity [<xref ref-type="bibr" rid="CR92">92</xref>&#8211;<xref ref-type="bibr" rid="CR95">95</xref>]. A <italic toggle="yes">C</italic><sub>min</sub> of&#8201;&gt;&#8201;2.4&#160;mg/L increases the likelihood of colistin-induced nephrotoxicity [<xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>].</p></sec><sec id="Sec66"><title>Dosing in critically ill patients</title><p id="Par78">A LD is recommended to compensate for the enlarged <italic toggle="yes">V</italic><sub>d</sub> in critically ill patients with the CMS dosing regimen also adapted to renal function. The variability in conversion from prodrug to active compound, particularly in patients with ARC, makes dosing highly challenging in this patient group, and as such, leading studies on colistin dosing define a singular dose for all creatinine clearance values&#8201;&gt;&#8201;90&#160;mL/min [<xref ref-type="bibr" rid="CR98">98</xref>].</p></sec><sec id="Sec67"><title>TDM in critically ill patients</title><p id="Par79">The Panel neither recommends, nor discourages routine colistin TDM in critically ill patients.</p><p id="Par80">The therapeutic index for colistin is exceptionally narrow&#8212;if TDM is performed, due to the ongoing conversion of CMS to colistin, it is recommended to collect <italic toggle="yes">C</italic><sub>min</sub> samples when CMS concentrations and conversion are at the lowest (i.e. samples to be drawn just before the next dose or <italic toggle="yes">C</italic><sub>min</sub> monitoring), and these samples should be processed immediately. It has been suggested that an average steady-state concentration (<italic toggle="yes">C</italic><sub>ss</sub>) of 2&#160;mg/L predicts colistin efficacy whilst limiting the likelihood of nephrotoxicity [<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR99">99</xref>]. This target concentration should achieve an fAUC<sub>0&#8211;24</sub>/MIC ratio of&#8201;~&#8201;12 for pathogens with an MIC of&#8201;&#8804;&#8201;2&#160;mg/L, which corresponds to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint for susceptibility. As colistin concentrations are relatively constant with little fluctuations at steady state, this target concentration can also be applied for <italic toggle="yes">C</italic><sub>min</sub> monitoring. However, this target concentration has not been correlated with clinical outcomes.</p></sec><sec id="Sec68"><title>Bioanalytical assay</title><p id="Par81">High-performance liquid chromatography with fluorescence detection (HPLC-FL) and LC&#8211;MS/MS assays have been published for colistin TDM.</p></sec></sec><sec id="Sec69"><title>Polymyxin B</title><sec id="Sec70"><title>Pharmacokinetics</title><p id="Par82">Polymyxin B demonstrates a low <italic toggle="yes">V</italic><sub>d</sub> and is predominantly cleared via non-renal elimination. Protein binding was high and hugely variable in critically ill patients and was reported as 58&#8211;98.4%. Although the PK of polymyxin B is relatively favourable when compared to colistin, current Product Information dosing recommendations may likely lead to sub-optimal drug exposure in critically ill patients.</p></sec><sec id="Sec71"><title>Pharmacodynamics</title><p id="Par83">Polymyxin B demonstrates &#8220;concentration-dependent&#8221; kill characteristics, and both in vitro and in vivo data have suggested that the fAUC<sub>0&#8211;24</sub>/MIC ratio best predicts its activity. fAUC<sub>0&#8211;24</sub>/MIC ratios of 3.7&#8211;28.0 correlated best with <italic toggle="yes">Klebsiella pneumoniae</italic> killing [<xref ref-type="bibr" rid="CR100">100</xref>], and these indices are in line with those reported for colistin against <italic toggle="yes">P. aeruginosa</italic> and <italic toggle="yes">A. baumannii</italic> (3.5&#8211;13.9) [<xref ref-type="bibr" rid="CR91">91</xref>]. A steady-state AUC<sub>0&#8211;24</sub> of 100&#160;mg&#160;h/L has been proposed as the nephrotoxicity threshold [<xref ref-type="bibr" rid="CR101">101</xref>].</p></sec><sec id="Sec72"><title>Dosing in critically ill patients</title><p id="Par84">Current data suggest that LD of 2.5&#160;mg/kg followed by 1.5&#8211;2.5&#160;mg/kg/day (in two divided doses) may be appropriate for pathogens with an MIC of&#8201;&#8804;&#8201;1&#160;mg/L [<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>]. Higher daily doses (up to 3&#160;mg/kg/day), preceded by LD, should be considered for pathogens with an MIC of&#8201;&gt;&#8201;1&#8211;2&#160;mg/L. Although it has been generally accepted that IV polymyxin B is best dosed by total body weight, emerging data have since disputed this approach [<xref ref-type="bibr" rid="CR104">104</xref>].</p></sec><sec id="Sec73"><title>TDM in critically ill patients</title><p id="Par85">The Panel neither recommends, nor discourages routine polymyxin B TDM in critically ill patients.</p><p id="Par86">The therapeutic index for polymyxin B is exceptionally narrow&#8212;if performed, AUC-based TDM (50&#8211;100&#160;mg&#160;h/L) with at least one sample collected (concentrations at 12&#8211;24&#160;h post-initiation of therapy) combined with Bayesian dose adaptation has been suggested to optimise polymyxin B dosing in critically ill patients [<xref ref-type="bibr" rid="CR101">101</xref>, <xref ref-type="bibr" rid="CR102">102</xref>].</p></sec><sec id="Sec74"><title>Bioanalytical assay</title><p id="Par87">LC&#8211;MS/MS assays have been published for polymyxin B TDM.</p></sec></sec></sec><sec id="Sec76"><title>Antifungals</title><sec id="Sec77"><title>Echinocandins</title><sec id="Sec78"><title>Pharmacokinetics</title><p id="Par88">The echinocandin antifungals include anidulafungin, caspofungin and micafungin, which are only available for parenteral use. The echinocandins have high plasma protein binding (&#8805;&#8201;97&#8211;99%). Exposure in critically ill patients is generally lower and more variable compared to healthy volunteers, but the clinical implication of this is unclear due to the heterogeneous case mix and small sample sizes in these studies.</p></sec><sec id="Sec79"><title>Pharmacodynamics</title><p id="Par89">Echinocandin exposures relating to optimal clinical outcomes and toxicity occurrence have not been identified thus far. However, optimal mycological response for micafungin against <italic toggle="yes">Candida</italic> spp. has been observed in patients with AUC<sub>0&#8211;24</sub>/MIC ratios of&#8201;&gt;&#8201;3000 [<xref ref-type="bibr" rid="CR105">105</xref>].</p></sec><sec id="Sec80"><title>Dosing in critically ill patients</title><p id="Par90">Although echinocandins are presumed to be clinically comparable with each other, subtle dosing differences exist, e.g. the need for a loading dose, metabolic route and drug&#8211;drug interactions. Higher body weight may require higher dosing [<xref ref-type="bibr" rid="CR106">106</xref>&#8211;<xref ref-type="bibr" rid="CR108">108</xref>]. Echinocandin exposure can be influenced in patients with severe hepatic impairment, particularly for caspofungin. Lower exposure, as well as higher exposure, has been observed in these patients [<xref ref-type="bibr" rid="CR109">109</xref>&#8211;<xref ref-type="bibr" rid="CR111">111</xref>].</p></sec><sec id="Sec81"><title>TDM in critically ill patients</title><p id="Par91">The Panel neither recommends, nor discourages routine echinocandin TDM in critically ill patients.</p></sec><sec id="Sec82"><title>Bioanalytical assay</title><p id="Par92">LC&#8211;MS/MS assays have been published but are sparsely implemented for routine TDM.</p></sec></sec><sec id="Sec83"><title>Fluconazole</title><sec id="Sec84"><title>Pharmacokinetics</title><p id="Par93">Fluconazole is available for parenteral and oral administration, is well absorbed from the gastrointestinal tract and displays linear PK. It is moderately lipophilic, demonstrates a <italic toggle="yes">V</italic><sub>d</sub> of around 1 L/kg and is predominantly cleared via renal elimination. Significant inter-individual PK variability has been observed in critically ill patients.</p></sec><sec id="Sec85"><title>Pharmacodynamics</title><p id="Par94">Maximal clinical efficacy in patients with candidemia has been described with AUC<sub>0&#8211;24</sub>/MIC ratios of&#8201;&#8805;&#8201;55.2&#8211;100 [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR113">113</xref>]. As the dose can be used as a surrogate for fluconazole AUC [<xref ref-type="bibr" rid="CR114">114</xref>], the ratio of dose to MIC (dose/MIC) has also been used to describe clinical outcomes [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR113">113</xref>, <xref ref-type="bibr" rid="CR115">115</xref>]. Higher dosing may likely lead to hepatotoxicity and seizures [<xref ref-type="bibr" rid="CR116">116</xref>].</p></sec><sec id="Sec86"><title>Dosing in critically ill patients</title><p id="Par95">LD of 12&#160;mg/kg IV followed by a maintenance dose (MD) of 6 or 12&#160;mg/kg/day IV is advocated to achieve either the low (AUC<sub>0&#8211;24</sub>/MIC ratio of 25) or high (AUC<sub>0&#8211;24</sub>/MIC ratio of 100) PK/PD target, respectively, in critically ill patients with normal renal function [<xref ref-type="bibr" rid="CR117">117</xref>].</p></sec><sec id="Sec87"><title>TDM in critically ill patients</title><p id="Par96">The Panel neither recommends, nor discourages routine fluconazole TDM in critically ill patients.</p></sec><sec id="Sec88"><title>Bioanalytical assay</title><p id="Par97">Several chromatographic assays have been published for fluconazole TDM.</p></sec></sec><sec id="Sec89"><title>Flucytosine</title><sec id="Sec90"><title>Pharmacokinetics</title><p id="Par98">Flucytosine&#8217;s <italic toggle="yes">V</italic><sub>d</sub> ranges from 0.6 to 0.9 L/kg and is predominantly cleared via renal elimination. Significant inter-patient PK variability has been observed, leading to variable flucytosine concentrations.</p></sec><sec id="Sec91"><title>Pharmacodynamics</title><p id="Par99">A <italic toggle="yes">C</italic><sub>max</sub> of&#8201;&gt;&#8201;100&#160;mg/L has been associated with hepatotoxicity and myelosuppression in several clinical studies [<xref ref-type="bibr" rid="CR118">118</xref>&#8211;<xref ref-type="bibr" rid="CR121">121</xref>]. Concentrations of&#8201;&lt;&#8201;25&#160;mg/L may selectively amplify resistant <italic toggle="yes">C. albicans</italic> mutants [<xref ref-type="bibr" rid="CR122">122</xref>].</p></sec><sec id="Sec92"><title>Dosing in critically ill patients</title><p id="Par100">There are insufficient clinical data to support altering flucytosine dosing for maximal outcomes in critically ill patients. Standard, weight-based dosing, adapted to renal function, is appropriate.</p></sec><sec id="Sec93"><title>TDM in critically ill patients</title><p id="Par101">The Panel neither recommends, nor discourages routine flucytosine TDM in critically ill patients.</p><p id="Par102">TDM-guided dosing to optimise flucytosine efficacy remains poorly described as opposed to prevention of toxicity. If TDM is performed, a <italic toggle="yes">C</italic><sub>max</sub> of&#8201;&lt;&#8201;100&#160;mg/L and <italic toggle="yes">C</italic><sub>min</sub> of&#8201;&#8805;&#8201;25&#160;mg/L can be used to prevent flucytosine toxicity and resistance, respectively.</p></sec><sec id="Sec94"><title>Bioanalytical assay</title><p id="Par103">Several chromatographic assays have been published for flucytosine TDM.</p></sec></sec><sec id="Sec95"><title>Isavuconazole</title><sec id="Sec96"><title>Pharmacokinetics</title><p id="Par104">Isavuconazole is available in oral (capsule) and IV formulations, and switching between these formulations is acceptable. It has a large <italic toggle="yes">V</italic><sub>d</sub>, and its CL is highly dependent on hepatic metabolism. Plasma protein binding is high (&gt;&#8201;99%). It displays linear and favourable PK compared to the other triazoles. Exposures in real-world clinical settings are very similar to those described in clinical trials with&#8201;&gt;&#8201;90% of patients receiving standard isavuconazole dosing expected to achieve a proposed therapeutic concentration of 1&#160;mg/L [<xref ref-type="bibr" rid="CR123">123</xref>, <xref ref-type="bibr" rid="CR124">124</xref>].</p></sec><sec id="Sec97"><title>Pharmacodynamics</title><p id="Par105">Current data do not identify any significant relationship between isavuconazole exposure with clinical efficacy and safety end points.</p></sec><sec id="Sec98"><title>Dosing in critically ill patients</title><p id="Par106">LD of 200&#160;mg IV 8 hourly for six doses (or 48&#160;h) followed by MD of 200&#160;mg IV once daily is recommended to achieve an effective <italic toggle="yes">C</italic><sub>ss</sub> by day 3 of treatment.</p></sec><sec id="Sec99"><title>TDM in critically ill patients</title><p id="Par107">The Panel neither recommends, nor discourages routine isavuconazole TDM in critically ill patients.</p></sec><sec id="Sec100"><title>Bioanalytical assay</title><p id="Par108">HPLC&#8211;UV and LC/MS&#8211;MS assays have been published for isavuconazole monitoring.</p></sec></sec><sec id="Sec101"><title>Itraconazole</title><sec id="Sec102"><title>Pharmacokinetics</title><p id="Par109">Itraconazole is available in oral (capsule/tablet and oral solution) and IV formulations. It has 30% higher bioavailability as an oral solution and is more preferred to capsule/tablet formulations. It is lipophilic, demonstrates a large <italic toggle="yes">V</italic><sub>d</sub> and is predominantly cleared via hepatic metabolism. Plasma protein binding is high (&gt;&#8201;99%). Itraconazole displays variable and nonlinear PK. There are few data available concerning the use of itraconazole in critically ill patients, although continuous haemodiafiltration results in increased itraconazole elimination [<xref ref-type="bibr" rid="CR125">125</xref>].</p></sec><sec id="Sec103"><title>Pharmacodynamics</title><p id="Par110">Higher itraconazole <italic toggle="yes">C</italic><sub>min</sub> has been associated with clinical outcome benefits in <italic toggle="yes">Aspergillus</italic> spp. [<xref ref-type="bibr" rid="CR126">126</xref>], <italic toggle="yes">Cryptococcus neoformans</italic> [<xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR128">128</xref>] and <italic toggle="yes">Histoplasma capsulatum</italic> infections [<xref ref-type="bibr" rid="CR129">129</xref>]. During itraconazole prophylaxis, breakthrough infections and mortality are more likely in neutropenic patients with a <italic toggle="yes">C</italic><sub>min</sub> of&#8201;&lt;&#8201;0.25&#8211;0.5&#160;mg/L [<xref ref-type="bibr" rid="CR130">130</xref>&#8211;<xref ref-type="bibr" rid="CR132">132</xref>]. Oropharyngeal and oesophageal candidiasis patients demonstrated better clinical responses when itraconazole concentrations are&#8201;&gt;&#8201;0.6&#8211;1&#160;mg/L [<xref ref-type="bibr" rid="CR133">133</xref>, <xref ref-type="bibr" rid="CR134">134</xref>]. An average concentration of&#8201;&#8805;&#8201;17.1&#160;mg/L has been linked with itraconazole toxicity [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>].</p></sec><sec id="Sec104"><title>Dosing in critically ill patients</title><p id="Par111">LD of 200&#160;mg IV 8 hourly for nine doses (or 72&#160;h) followed by MD of 200&#160;mg IV once or twice daily is recommended to achieve target concentrations within the first few days of therapy.</p></sec><sec id="Sec105"><title>TDM in critically ill patients</title><p id="Par112">The Panel neither recommends, nor discourages routine itraconazole TDM in critically ill patients.</p><p id="Par113">Apart from demonstrating nonlinear PK [<xref ref-type="bibr" rid="CR137">137</xref>], its high variability in bioavailability and hepatic metabolism together with a less favourable safety profile when compared to other azoles traditionally support itraconazole TDM. A <italic toggle="yes">C</italic><sub>min</sub> target between 0.5 and 1&#160;mg/L is used to guide both prophylaxis and treatment of invasive fungal infections.</p></sec><sec id="Sec106"><title>Bioanalytical assay</title><p id="Par114">Several LC&#8211;MS/MS assays have been published for itraconazole TDM.</p></sec></sec><sec id="Sec107"><title>Posaconazole</title><sec id="Sec108"><title>Pharmacokinetics</title><p id="Par115">Posaconazole is available as an oral suspension, tablet and IV formulations. It is lipophilic, demonstrates a large <italic toggle="yes">V</italic><sub>d</sub> and is predominantly cleared via hepatic glucuronidation. Plasma protein binding is high (&gt;&#8201;98%). Extreme inter- and intra-individual PK variability and, consequently, sub-optimal exposures are typically seen with the oral suspension [<xref ref-type="bibr" rid="CR138">138</xref>&#8211;<xref ref-type="bibr" rid="CR142">142</xref>].</p></sec><sec id="Sec109"><title>Pharmacodynamics</title><p id="Par116">Higher <italic toggle="yes">C</italic><sub>min</sub> (&gt;&#8201;0.5&#8211;0.7&#160;mg/L) has been associated with reduced breakthrough infections in patients receiving posaconazole prophylaxis [<xref ref-type="bibr" rid="CR143">143</xref>&#8211;<xref ref-type="bibr" rid="CR150">150</xref>]. Patients with invasive aspergillosis demonstrated improved clinical response with an average posaconazole concentration of&#8201;&gt;&#8201;1&#160;mg/L [<xref ref-type="bibr" rid="CR151">151</xref>, <xref ref-type="bibr" rid="CR152">152</xref>]. Exposure-related toxicity has not been described for posaconazole although the European Medicines Agency (EMA), and most clinical studies have suggested a putative <italic toggle="yes">C</italic><sub>min</sub> threshold of&#8201;&gt;&#8201;3.75&#8211;4&#160;mg/L [<xref ref-type="bibr" rid="CR153">153</xref>], which has yet to be validated clinically.</p></sec><sec id="Sec110"><title>Dosing in critically ill patients</title><p id="Par117">LD of 300&#160;mg IV every 12 hourly on day 1 followed by MD of 300&#160;mg IV once daily is recommended for invasive fungal infections.</p></sec><sec id="Sec111"><title>TDM in critically ill patients</title><p id="Par118">The Panel neither recommends, nor discourages routine posaconazole TDM in critically ill patients.</p><p id="Par119">Although extensive PK variability has been previously described, the newer delayed-release oral tablets and IV formulations increase the likelihood therapeutic targets will be achieved [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR154">154</xref>&#8211;<xref ref-type="bibr" rid="CR156">156</xref>]. However, recent data still report highly variable PK in critically ill patients, even with IV posaconazole [<xref ref-type="bibr" rid="CR157">157</xref>], and therefore TDM may still be useful in this population. Because of the long half-life of the drug (16&#8211;35&#160;h) [<xref ref-type="bibr" rid="CR158">158</xref>], a concentration obtained at a random time with respect to the previous dose, including a <italic toggle="yes">C</italic><sub>min</sub>, is approximately representative of the average daily concentration (<italic toggle="yes">C</italic><sub>ave</sub>) and is accepted as a surrogate for AUC. If TDM is performed, a steady-state <italic toggle="yes">C</italic><sub>ave</sub> target of&#8201;&gt;&#8201;0.5&#8211;0.7&#160;mg/L and&#8201;&gt;&#8201;1&#160;mg/L can be used to guide posaconazole prophylaxis and treatment of invasive fungal infections, respectively, particularly when oral suspension is used.</p></sec><sec id="Sec112"><title>Bioanalytical assay</title><p id="Par120">Several chromatographic assays have been published for posaconazole TDM.</p></sec></sec><sec id="Sec113"><title>Voriconazole</title><sec id="Sec114"><title>Pharmacokinetics</title><p id="Par121">Voriconazole is lipophilic, demonstrates a large <italic toggle="yes">V</italic><sub>d</sub> and is predominantly cleared via hepatic metabolism. Plasma protein binding is 58%. Voriconazole displays nonlinear PK in adults and exhibits extensive inter-individual PK variability in all patient populations.</p></sec><sec id="Sec115"><title>Pharmacodynamics</title><p id="Par122">A <italic toggle="yes">C</italic><sub>min</sub> of&#8201;&#8805;&#8201;1 [<xref ref-type="bibr" rid="CR159">159</xref>&#8211;<xref ref-type="bibr" rid="CR165">165</xref>] or&#8201;&#8805;&#8201;2&#160;mg/L [<xref ref-type="bibr" rid="CR166">166</xref>&#8211;<xref ref-type="bibr" rid="CR168">168</xref>], as well as a <italic toggle="yes">C</italic><sub>min</sub> to MIC (<italic toggle="yes">C</italic><sub>min</sub>/MIC) ratio of 2&#8211;5 [<xref ref-type="bibr" rid="CR169">169</xref>], has been associated with improved clinical outcomes in the treatment of invasive fungal infections. Although no clear exposure&#8211;response relationship has been established for voriconazole prophylaxis, breakthrough fungal infections are reported to be more likely with a <italic toggle="yes">C</italic><sub>min</sub> of&#8201;&#8804;&#8201;1.5&#8211;2&#160;mg/L [<xref ref-type="bibr" rid="CR170">170</xref>, <xref ref-type="bibr" rid="CR171">171</xref>]. <italic toggle="yes">C</italic><sub>min</sub> of&#8201;&#8805;&#8201;4.5&#8211;6&#160;mg/L has been linked with voriconazole-associated hepatotoxicity and neurotoxicity [<xref ref-type="bibr" rid="CR161">161</xref>, <xref ref-type="bibr" rid="CR165">165</xref>, <xref ref-type="bibr" rid="CR167">167</xref>, <xref ref-type="bibr" rid="CR172">172</xref>&#8211;<xref ref-type="bibr" rid="CR175">175</xref>].</p></sec><sec id="Sec116"><title>Dosing in critically ill patients</title><p id="Par123">LD of 6&#160;mg/kg IV every 12 hourly for two doses followed by 3&#8211;4&#160;mg/kg IV 12-hourly is recommended for invasive fungal infections.</p></sec><sec id="Sec117"><title>TDM in critically ill patients</title><p id="Par124">The Panel recommends that TDM be routinely performed when voriconazole is used in critically ill patients.</p><p id="Par125">TDM-guided voriconazole dosing in the treatment of invasive fungal infections has been shown to improve clinical response and reduce voriconazole discontinuation due to adverse events [<xref ref-type="bibr" rid="CR163">163</xref>]. Limited data are available in critically ill patients, but sub-optimal exposures and negative clinical outcomes have been observed in these patients with standard voriconazole dosing [<xref ref-type="bibr" rid="CR160">160</xref>]. Also, recent publications reported the significant role of the inflammatory response in the unpredictable PK of voriconazole with a 0.015&#160;mg/L rise in the <italic toggle="yes">C</italic><sub>min</sub> for every 1&#160;mg/L increase in C-reactive protein (CRP) [<xref ref-type="bibr" rid="CR176">176</xref>&#8211;<xref ref-type="bibr" rid="CR178">178</xref>]. As inflammation is common in critically ill patients, this could have a significant impact on the incidence of voriconazole toxicities. A <italic toggle="yes">C</italic><sub>min</sub> target between 2 and 6&#160;mg/L is recommended to guide voriconazole dosing.</p></sec><sec id="Sec118"><title>Bioanalytical assay</title><p id="Par126">Several chromatographic assays have been published for voriconazole TDM.</p></sec></sec></sec><sec id="Sec119"><title>Antivirals</title><sec id="Sec120"><title>Aciclovir/valaciclovir</title><sec id="Sec121"><title>Pharmacokinetics</title><p id="Par127">Valaciclovir is the orally administered prodrug of aciclovir, which is moderately lipophilic, demonstrates a large <italic toggle="yes">V</italic><sub>d</sub> and is predominantly cleared via renal elimination.</p></sec><sec id="Sec122"><title>Pharmacodynamics</title><p id="Par128">Limited data exist linking aciclovir exposures with clinical efficacy and toxicity. Although the efficacy of aciclovir/valaciclovir in the treatment of herpes simplex virus (HSV) infection has been associated with AUC and the time that the drug remains above the 50% inhibitory concentration (EC<sub>50</sub>; <italic toggle="yes">T</italic>&#8201;&gt;&#8201;EC<sub>50</sub>) [<xref ref-type="bibr" rid="CR179">179</xref>&#8211;<xref ref-type="bibr" rid="CR183">183</xref>], these indices require further investigations. Higher concentrations, particularly in patients with renal impairment, have been linked with the likelihood of gastrointestinal and neurological adverse events [<xref ref-type="bibr" rid="CR184">184</xref>&#8211;<xref ref-type="bibr" rid="CR187">187</xref>].</p></sec><sec id="Sec123"><title>Dosing in critically ill patients</title><p id="Par129">A standard dose of 10&#8211;15&#160;mg/kg IV 8 hourly is recommended for severe viral infections in immunocompetent patients.</p></sec><sec id="Sec124"><title>TDM in critically ill patients</title><p id="Par130">The Panel neither recommends, nor discourages routine aciclovir TDM in critically ill patients.</p><p id="Par131">Few reports are available on aciclovir TDM, and most of them included patients with encephalitis [<xref ref-type="bibr" rid="CR188">188</xref>, <xref ref-type="bibr" rid="CR189">189</xref>]. A <italic toggle="yes">C</italic><sub>min</sub> of 2&#8211;4&#160;mg/L can be recommended if TDM is performed.</p></sec><sec id="Sec125"><title>Bioanalytical assay</title><p id="Par132">Several HPLC&#8211;UV and LCMS-MS assays have been published for aciclovir TDM.</p></sec></sec><sec id="Sec126"><title>Foscarnet</title><sec id="Sec127"><title>Pharmacokinetics</title><p id="Par133">Significant inter- and intra-individual PK variability has been reported, and it may be challenging to estimate foscarnet concentrations over time in an individual patient accurately.</p></sec><sec id="Sec128"><title>Pharmacodynamics</title><p id="Par134">No clear relationship has been established so far between its concentration and clinical efficacy. Most investigators have suggested maintaining plasma concentrations between an arbitrary range of 300&#8211;500&#160;&#181;mol/L to ensure that effective antiviral activity is achieved and sustained. Although several small-scale clinical studies have reported that clinical response (e.g. progression of CMV retinitis in HIV patients) and nephrotoxicity can be predicted by the AUC [<xref ref-type="bibr" rid="CR190">190</xref>&#8211;<xref ref-type="bibr" rid="CR194">194</xref>], the therapeutic exposure range of foscarnet remains undefined.</p></sec><sec id="Sec129"><title>Dosing in critically ill patients</title><p id="Par135">There are insufficient clinical data to support altering foscarnet dosing for maximal outcomes in critically ill patients. Standard, weight-based dosing, adapted to renal function, depending on the indication is appropriate.</p></sec><sec id="Sec130"><title>TDM in critically ill patients</title><p id="Par136">The Panel neither recommends, nor discourages routine foscarnet TDM in critically ill patients.</p></sec><sec id="Sec131"><title>Bioanalytical assay</title><p id="Par137">Several HPLC&#8211;UV methods have been published to determine foscarnet concentration in biological fluids.</p></sec></sec><sec id="Sec132"><title>Ganciclovir/valganciclovir</title><sec id="Sec133"><title>Pharmacokinetics</title><p id="Par138">Valganciclovir is the prodrug of ganciclovir, which is hydrophilic, demonstrates a low <italic toggle="yes">V</italic><sub>d</sub> (0.7 L/kg) and is predominantly cleared via renal elimination. The PK of ganciclovir/valganciclovir appears to be predictable with minimal unexplained inter-patient variability in solid organ transplant recipients. There is concern that plasma PK exposures may not be an accurate surrogate marker for intracellular concentrations to predict clinical response and toxicity [<xref ref-type="bibr" rid="CR195">195</xref>, <xref ref-type="bibr" rid="CR196">196</xref>].</p></sec><sec id="Sec134"><title>Pharmacodynamics</title><p id="Par139">No clear relationship has been established between ganciclovir exposures with clinical efficacy and toxicity. AUC<sub>0&#8211;24</sub> has been associated with ganciclovir antiviral activity with values of&#8201;&#8805;&#8201;40&#8211;60&#160;mg&#160;h/L advocated for CMV prophylaxis [<xref ref-type="bibr" rid="CR197">197</xref>&#8211;<xref ref-type="bibr" rid="CR201">201</xref>]. <italic toggle="yes">C</italic><sub>min</sub> has also been used to predict ganciclovir activity, but the optimal cut-off value remains poorly defined [<xref ref-type="bibr" rid="CR202">202</xref>&#8211;<xref ref-type="bibr" rid="CR207">207</xref>]. No clearly defined toxicity thresholds have been described for ganciclovir, but higher <italic toggle="yes">C</italic><sub>min</sub> and AUC<sub>0&#8211;24</sub> values are likely to increase the risk of haematological and neurological toxicity [<xref ref-type="bibr" rid="CR199">199</xref>, <xref ref-type="bibr" rid="CR208">208</xref>].</p></sec><sec id="Sec135"><title>Dosing in critically ill patients</title><p id="Par140">In the treatment of CMV infections in immunocompromised patients, the usual dose of ganciclovir for induction therapy is 5&#160;mg/kg IV every 12 hourly which is then followed by 5&#160;mg/kg as a single daily infusion for maintenance therapy.</p></sec><sec id="Sec136"><title>TDM in critically ill patients</title><p id="Par141">The Panel neither recommends, nor discourages routine ganciclovir/valganciclovir TDM in critically ill patients.</p><p id="Par142">Several centres have reported their experience with ganciclovir/valganciclovir TDM [<xref ref-type="bibr" rid="CR208">208</xref>, <xref ref-type="bibr" rid="CR209">209</xref>], even though changes in immunological markers have been reported to predict clinical outcomes reliably [<xref ref-type="bibr" rid="CR210">210</xref>, <xref ref-type="bibr" rid="CR211">211</xref>]. A <italic toggle="yes">C</italic><sub>min</sub> of&#8201;&gt;&#8201;2&#160;mg/L or AUC<sub>0&#8211;24</sub> of&#8201;&gt;&#8201;40&#160;mg&#160;h/L can be applied if TDM is performed. A clinically applicable LSS to estimate ganciclovir/valganciclovir AUC<sub>0&#8211;24</sub> has been described [<xref ref-type="bibr" rid="CR24">24</xref>] and combined with Bayesian dose adaptation; this approach demonstrated superior PK/PD outcomes and trends towards patient benefits when compared to standard dosing recommendations [<xref ref-type="bibr" rid="CR208">208</xref>].</p></sec><sec id="Sec137"><title>Bioanalytical assay</title><p id="Par143">Several HPLC&#8211;UV and LC/MS&#8211;MS assays have been published for ganciclovir/valganciclovir TDM.</p></sec></sec><sec id="Sec138"><title>Oseltamivir</title><sec id="Sec139"><title>Pharmacokinetics</title><p id="Par144">Oseltamivir is hydrophilic, demonstrates a large <italic toggle="yes">V</italic><sub>d</sub> and is predominantly cleared via renal elimination. Its active metabolite, oseltamivir carboxylate (OC), displays minimal inter- and intra-individual PK.</p></sec><sec id="Sec140"><title>Pharmacodynamics</title><p id="Par145">No clear relationship has been established between oseltamivir and OC exposures with either clinical efficacy or toxicity. Although the efficacy of oseltamivir in animal models of influenza appears to be dose dependent, no formal exposure&#8211;response relationships have been established [<xref ref-type="bibr" rid="CR212">212</xref>&#8211;<xref ref-type="bibr" rid="CR214">214</xref>]. It has been suggested that the AUC<sub>0&#8211;24</sub> or AUC<sub>0&#8211;24</sub>/EC<sub>50</sub> might be suitable indices to guide therapy, but further studies are warranted to validate the clinical relevance of these findings [<xref ref-type="bibr" rid="CR215">215</xref>, <xref ref-type="bibr" rid="CR216">216</xref>]. Higher AUC<sub>0&#8211;12</sub> OC exposures have been associated with mild-to-moderate adverse events [<xref ref-type="bibr" rid="CR217">217</xref>]. The PK of OC appears to be predictable, although this has been mostly determined in healthy volunteers where PK variability is known to be low [<xref ref-type="bibr" rid="CR217">217</xref>, <xref ref-type="bibr" rid="CR218">218</xref>].</p></sec><sec id="Sec141"><title>Dosing in critically ill patients</title><p id="Par146">A dose of 75&#160;mg PO once or twice daily is currently recommended for prophylaxis and treatment of influenza in critically ill patients.</p></sec><sec id="Sec142"><title>TDM in critically ill patients</title><p id="Par147">The Panel neither recommends, nor discourages routine oseltamivir TDM in critically ill patients.</p><p id="Par148">Although there are limited clinical data to support oseltamivir TDM, French investigators have recently described the utility of paracetamol absorption test to predict OC absorption and likely plasma concentrations in critically ill patients [<xref ref-type="bibr" rid="CR219">219</xref>].</p></sec><sec id="Sec143"><title>Bioanalytical assay</title><p id="Par149">Several HPLC&#8211;UV and LC/MS&#8211;MS assays have been published for oseltamivir TDM.</p></sec></sec><sec id="Sec144"><title>Ribavirin</title><sec id="Sec145"><title>Pharmacokinetics</title><p id="Par150">Ribavirin demonstrates a large <italic toggle="yes">V</italic><sub>d</sub> (&#8805;&#8201;18 L/kg) and is predominantly cleared via renal elimination. Wide inter-individual PK variability, including bioavailability, has been reported with this drug.</p></sec><sec id="Sec146"><title>Pharmacodynamics</title><p id="Par151">Inconsistent data have been reported on the relationship between ribavirin exposure and efficacy, as well as toxicity occurrence. Although higher <italic toggle="yes">C</italic><sub>min</sub> [<xref ref-type="bibr" rid="CR220">220</xref>&#8211;<xref ref-type="bibr" rid="CR226">226</xref>] and AUC [<xref ref-type="bibr" rid="CR225">225</xref>, <xref ref-type="bibr" rid="CR227">227</xref>, <xref ref-type="bibr" rid="CR228">228</xref>] values have been associated with eradication of hepatitis C virus (HCV) or sustained virological response in some studies, it is important to note that numerous studies have also shown no association between these parameters and sustained virological response. It has been suggested that the AUC<sub>0&#8211;4</sub> (1.76&#160;mg&#160;h/L) and AUC<sub>0&#8211;12</sub> (3.01&#160;mg&#160;h/L) after the first dose may be a better sustained virological response predictor when compared to <italic toggle="yes">C</italic><sub>min</sub> or any single time point [<xref ref-type="bibr" rid="CR228">228</xref>]. Although haemolytic anaemia has been linked with a <italic toggle="yes">C</italic><sub>min</sub> of&#8201;&gt;&#8201;2.3&#8211;3.5 [<xref ref-type="bibr" rid="CR224">224</xref>, <xref ref-type="bibr" rid="CR229">229</xref>, <xref ref-type="bibr" rid="CR230">230</xref>], some studies have found no significant correlation. Additionally, other studies indicated that other factors (e.g. pegIFN-alpha-2a levels) may have a greater impact on the outcome than ribavirin concentrations [<xref ref-type="bibr" rid="CR231">231</xref>].</p></sec><sec id="Sec147"><title>TDM in critically ill patients</title><p id="Par152">The Panel neither recommends, nor discourages routine ribavirin TDM in critically ill patients.</p><p id="Par153">Ribavirin TDM has been controversially discussed for at least a decade since hepatitis C is no longer treated as a pathogenic entity but rather according to different genotypes, and old combination partners are no longer state of the art. Furthermore, there is currently conflicting data regarding the relationship between ribavirin exposures with therapeutic or toxic effects. However, it is important to note that as opposed to weight-based dosing, TDM-guided ribavirin dosing has been shown to significantly improve sustained virological response in patients with chronic hepatitis C genotype 1 [<xref ref-type="bibr" rid="CR227">227</xref>]. Although anaemia was more severe in the TDM group, it was well managed with erythropoietin beta. More recently, TDM has been suggested as a useful tool to guide ribavirin treatment in lung transplant recipients with paramyxovirus infection [<xref ref-type="bibr" rid="CR232">232</xref>].</p></sec><sec id="Sec148"><title>Bioanalytical assay</title><p id="Par154">Several HPLC&#8211;UV and LC/MS&#8211;MS assays have been published for ribavirin TDM.</p></sec></sec></sec><sec id="Sec149"><title>Main areas for future investigations</title><sec id="Sec150"><title>Optimal antimicrobial exposures and PK/PD targets in the treatment of sepsis and septic shock in ICU</title><p id="Par155">Optimal intravenous antimicrobial therapy needs to be administered as soon as possible, preferably within the first hour of sepsis and septic shock recognition [<xref ref-type="bibr" rid="CR233">233</xref>]. Empirical antimicrobial therapy should attempt to provide coverage against all likely pathogens (bacterial, fungal and/or viral) and effective exposures are needed in the interstitial fluid of tissues presumed to be the source of infection. As extreme pathophysiological changes are likely to affect antimicrobial exposures, factors associated with PK/PD alterations need to be determined and considered in critically ill patients with sepsis and septic shock. Optimal antimicrobial exposures and PK/PD targets for patient benefits need to be further elucidated before appropriate dosing regimens and strategies can be improved in this population. The role of biomarkers as a surrogate for an antimicrobial response should be investigated as an earlier therapeutic intervention can be made rather than relying on clinical signs and symptoms [<xref ref-type="bibr" rid="CR234">234</xref>, <xref ref-type="bibr" rid="CR235">235</xref>]. More data on plasma and target-site tissue PK of antimicrobials, particularly in the first 24&#160;h of therapy, are needed to evaluate the appropriateness of the current dosing regimen in this patient population.</p></sec><sec id="Sec151"><title>Optimal antimicrobial exposures for reducing resistance development in ICU</title><p id="Par156">Most of the Panel&#8217;s treatment goals have been focused on maximising clinical and microbiological outcomes and not including resistance suppression. However, for most antimicrobials, clinical data are urgently needed to define thresholds that can minimise resistance emergence and whether they are safe for patients.</p></sec><sec id="Sec152"><title>Impact of TDM in personalised antimicrobial dosing in critically ill patients</title><p id="Par157">Only a few studies have attempted to compare the clinical outcomes of TDM-guided antimicrobial dosing versus outcomes without this intervention [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR227">227</xref>]. Currently, most data were obtained from small-scale and uncontrolled studies, which are not of itself, sufficient to support a global practice shift towards routine antimicrobial TDM in ICU. Therefore, well-designed and controlled studies focusing on patient-centred outcomes should be performed in this population to evaluate the real benefits of incorporating TDM into daily ICU practice.</p></sec><sec id="Sec153"><title>The tools and essentials for TDM</title><p id="Par158">Routine antimicrobial TDM in critically ill patients is currently hampered by slow turnaround times, and even in expert centres, antimicrobial concentrations may only be available after 6&#8211;8&#160;h of blood collection, potentially leading to delayed dosing improvements. Furthermore, in most ICUs, TDM is probably not available for all important antimicrobials and certainly, not for 24&#160;h and 7&#160;days a week [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. An easy-to-use chromatography-based method that enables rapid and reliable simultaneous determination of antimicrobial concentrations in plasma and tissues can be developed, and some are now being used routinely in clinical settings. Although concentration measurements are usually performed in blood matrices (e.g. plasma or serum), several alternative sampling strategies (e.g. dried blood spots and volumetric absorptive microsamples), which are minimally or non-invasive approaches, need to be further investigated and validated for routine TDM in critically ill patients. Importantly, these &#8220;patient-friendly&#8221; strategies may play an important role in the establishment of TDM centres in remote and resource-limited settings.</p></sec></sec><sec id="Sec154"><title>Conclusion</title><p id="Par159">Although alternative dosing strategies can improve antimicrobial exposure in critically ill patients, the extreme PK variability in this patient population means that some may still receive sub-optimal antibiotic exposure leading to unpredictable clinical outcomes. TDM-guided dosing is the only safe and effective way to ensure that all critically ill patients achieve therapeutic antimicrobial exposures. TDM-guided dosing has been shown to be clinically beneficial for aminoglycosides, voriconazole and ribavirin. For most common antibiotics and antifungals in the ICU, a clear therapeutic range has been established and for these agents, routine TDM in critically ill patients may be useful. Specifically, we recommend routine TDM when one of these antibiotics or antifungals is used in critically ill patients: aminoglycosides, beta-lactam antibiotics, linezolid, teicoplanin, vancomycin and voriconazole. For the antivirals, urgent research is needed to identify therapeutic targets for patient benefits and to also ascertain whether antiviral TDM is indeed meritorious in this patient population. Although we believe that TDM should be the standard of care for most antimicrobials in every ICU, important barriers, such as the availability of bioanalytical experts and TDM equipments in an institution, need to be addressed before routine TDM can be widely employed worldwide.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec155"><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="134_2020_6050_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary material 1 (DOCX 234&#160;kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="134_2020_6050_MOESM2_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary material 2 (DOCX 125&#160;kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="134_2020_6050_MOESM3_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary material 3 (DOCX 104&#160;kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="134_2020_6050_MOESM4_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary material 4 (DOCX 134&#160;kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM5" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="134_2020_6050_MOESM5_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary material 5 (DOCX 383&#160;kb)</p></caption></media></supplementary-material></p></sec></sec></body><back><fn-group><fn><p><sub>#</sub>Societies: European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) and International Society of Antimicrobial Chemotherapy (ISAC)</p></fn><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We wish to acknowledge the individual societies for their endorsement of this Position Paper. We also wish to acknowledge the members of the public who provided public feedback that was addressed by the Panel as part of the ESCMID endorsement process.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>The idea and design of the Position Paper was conceptualised by Jan J. De Waele and Jason A. Roberts. Literature review and data analysis were performed by all authors. The first draft of the Position Paper was written by Mohd H. Abdul&#8211;Aziz, and all authors critically revised and commented on subsequent versions of the manuscript. All authors read and approved the final version of the Position Paper.</p></notes><notes notes-type="ethics"><title>Compliance with ethical standards</title><notes id="FPar1" notes-type="COI-statement"><title>Conflicts of interest</title><p id="Par160">Mohd H. Abdul-Aziz, Jan-Willem C. Alffenaar, Matteo Bassetti, Hendrik Bracht, George Dimopoulos, Deborah Marriott, Michael Neely, Jose-Artur Paiva, Fredrik Sjovall, Sebastian G. Wicha and Markus Zeitlinger declare no conflict of interest. Federico Pea participated in speaker bureau for Angelini, Basilea Pharmaceutica, Gilead, Hikma, Merck Sharp &amp; Dohme, Nordic Pharma, Pfizer and Sanofi Aventis and in advisory board for Angelini, Basilea Pharmaceutica, Correvio, Gilead, Merck Sharp &amp; Dohme, Nordic Pharma, Novartis, Pfizer and Thermo-Fisher. Jean F. Timsit has contributed to Medical Advisory Boards for Gilead Sciences, Inc., Merck Sharp &amp; Dohme, MedImmune, Paratek Pharmaceuticals, Pfizer Inc. and Venatorx Pharmaceuticals, Inc. Jean F. Timsit has received research grants and/or lecture fees from Biomerieux, Gilead Sciences, Inc., Merck Sharp &amp; Dohme and Pfizer Inc. Andrew A. Udy has contributed to Medical Advisory Boards for Baxter Healthcare Pty Ltd, Merck Sharp &amp; Dohme (Australia) Pty Ltd, in addition to previously receiving honorarium and travel support from Pfizer Australia Pty Ltd. Jan J. De Waele has received consultation fees for Accelerate Diagnostics, Inc., Bayer Healthcare, Cubist Pharmaceuticals, Grifols, Merck Sharp &amp; Dohme and Pfizer Inc. Jan J. De Waele is supported by a grant from the Research Foundation Flanders (Senior Clinical Investigator Grant FWO, Ref. 1881020&#160;N). Jason A. Roberts receives funding from the Australian National Health and Medical Research Council for a Centre of Research Excellence (APP1099452) and a Practitioner Fellowship (APP1117065).</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dulhunty</surname><given-names>JM</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>D</given-names></name><name name-style="western"><surname>Webb</surname><given-names>SA</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name></person-group><article-title>Antimicrobial utilisation in 37 Australian and New Zealand intensive care units</article-title><source>Anaesth Intensive Care</source><year>2011</year><volume>39</volume><fpage>231</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1177/0310057X1103900212</pub-id><pub-id pub-id-type="pmid">21485671</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name><name name-style="western"><surname>Abdul-Aziz</surname><given-names>MH</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name><name name-style="western"><surname>Mouton</surname><given-names>JW</given-names></name><name name-style="western"><surname>Vinks</surname><given-names>AA</given-names></name><name name-style="western"><surname>Felton</surname><given-names>TW</given-names></name><name name-style="western"><surname>Hope</surname><given-names>WW</given-names></name><name name-style="western"><surname>Farkas</surname><given-names>A</given-names></name><name name-style="western"><surname>Neely</surname><given-names>MN</given-names></name><name name-style="western"><surname>Schentag</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Drusano</surname><given-names>G</given-names></name><name name-style="western"><surname>Frey</surname><given-names>OR</given-names></name><name name-style="western"><surname>Theuretzbacher</surname><given-names>U</given-names></name><name name-style="western"><surname>Kuti</surname><given-names>JL</given-names></name><collab>International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases</collab></person-group><article-title>Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions</article-title><source>Lancet Infect Dis</source><year>2014</year><volume>14</volume><fpage>498</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(14)70036-2</pub-id><pub-id pub-id-type="pmid">24768475</pub-id><pub-id pub-id-type="pmcid">PMC4181663</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name><name name-style="western"><surname>Paul</surname><given-names>SK</given-names></name><name name-style="western"><surname>Akova</surname><given-names>M</given-names></name><name name-style="western"><surname>Bassetti</surname><given-names>M</given-names></name><name name-style="western"><surname>De Waele</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Dimopoulos</surname><given-names>G</given-names></name><name name-style="western"><surname>Kaukonen</surname><given-names>KM</given-names></name><name name-style="western"><surname>Koulenti</surname><given-names>D</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C</given-names></name><name name-style="western"><surname>Montravers</surname><given-names>P</given-names></name><name name-style="western"><surname>Rello</surname><given-names>J</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>A</given-names></name><name name-style="western"><surname>Starr</surname><given-names>T</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>SC</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name><collab>DALI Study</collab></person-group><article-title>DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients?</article-title><source>Clin Infect Dis</source><year>2014</year><volume>58</volume><fpage>1072</fpage><lpage>1083</lpage><pub-id pub-id-type="doi">10.1093/cid/ciu027</pub-id><pub-id pub-id-type="pmid">24429437</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sumi</surname><given-names>CD</given-names></name><name name-style="western"><surname>Heffernan</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name><name name-style="western"><surname>Sime</surname><given-names>FB</given-names></name></person-group><article-title>What antibiotic exposures are required to suppress the emergence of resistance for gram-negative bacteria? A systematic review</article-title><source>Clin Pharmacokinet</source><year>2019</year><volume>58</volume><fpage>1407</fpage><lpage>1443</lpage><pub-id pub-id-type="doi">10.1007/s40262-019-00791-z</pub-id><pub-id pub-id-type="pmid">31325141</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabah</surname><given-names>A</given-names></name><name name-style="western"><surname>De Waele</surname><given-names>J</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name><name name-style="western"><surname>Zahar</surname><given-names>JR</given-names></name><name name-style="western"><surname>Cotta</surname><given-names>MO</given-names></name><name name-style="western"><surname>Barton</surname><given-names>G</given-names></name><name name-style="western"><surname>Timsit</surname><given-names>JF</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name></person-group><article-title>The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs</article-title><source>J Antimicrob Chemother</source><year>2015</year><volume>70</volume><fpage>2671</fpage><lpage>2677</lpage><pub-id pub-id-type="doi">10.1093/jac/dkv165</pub-id><pub-id pub-id-type="pmid">26169558</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>G</given-names></name><name name-style="western"><surname>Brinkman</surname><given-names>A</given-names></name><name name-style="western"><surname>Benefield</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Carlier</surname><given-names>M</given-names></name><name name-style="western"><surname>De Waele</surname><given-names>JJ</given-names></name><name name-style="western"><surname>El Helali</surname><given-names>N</given-names></name><name name-style="western"><surname>Frey</surname><given-names>O</given-names></name><name name-style="western"><surname>Harbarth</surname><given-names>S</given-names></name><name name-style="western"><surname>Huttner</surname><given-names>A</given-names></name><name name-style="western"><surname>McWhinney</surname><given-names>B</given-names></name><name name-style="western"><surname>Misset</surname><given-names>B</given-names></name><name name-style="western"><surname>Pea</surname><given-names>F</given-names></name><name name-style="western"><surname>Preisenberger</surname><given-names>J</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>MS</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>TA</given-names></name><name name-style="western"><surname>Roehr</surname><given-names>A</given-names></name><name name-style="western"><surname>Sime</surname><given-names>FB</given-names></name><name name-style="western"><surname>Taccone</surname><given-names>FS</given-names></name><name name-style="western"><surname>Ungerer</surname><given-names>JP</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name></person-group><article-title>An international, multicentre survey of beta-lactam antibiotic therapeutic drug monitoring practice in intensive care units</article-title><source>J Antimicrob Chemother</source><year>2014</year><volume>69</volume><fpage>1416</fpage><lpage>1423</lpage><pub-id pub-id-type="doi">10.1093/jac/dkt523</pub-id><pub-id pub-id-type="pmid">24443514</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goncalves-Pereira</surname><given-names>J</given-names></name><name name-style="western"><surname>Povoa</surname><given-names>P</given-names></name></person-group><article-title>Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams</article-title><source>Crit Care</source><year>2011</year><volume>15</volume><fpage>R206</fpage><pub-id pub-id-type="doi">10.1186/cc10441</pub-id><pub-id pub-id-type="pmid">21914174</pub-id><pub-id pub-id-type="pmcid">PMC3334750</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name><name name-style="western"><surname>Pea</surname><given-names>F</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name></person-group><article-title>The clinical relevance of plasma protein binding changes</article-title><source>Clin Pharmacokinet</source><year>2013</year><volume>52</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s40262-012-0018-5</pub-id><pub-id pub-id-type="pmid">23150213</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alobaid</surname><given-names>AS</given-names></name><name name-style="western"><surname>Hites</surname><given-names>M</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name><name name-style="western"><surname>Taccone</surname><given-names>FS</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name></person-group><article-title>Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: a structured review</article-title><source>Int J Antimicrob Agents</source><year>2016</year><volume>47</volume><fpage>259</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2016.01.009</pub-id><pub-id pub-id-type="pmid">26988339</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahmoud</surname><given-names>SH</given-names></name><name name-style="western"><surname>Shen</surname><given-names>C</given-names></name></person-group><article-title>Augmented renal clearance in critical illness: an important consideration in drug dosing</article-title><source>Pharmaceutics</source><year>2017</year><volume>9</volume><issue>3</issue><fpage>36</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics9030036</pub-id><pub-id pub-id-type="pmcid">PMC5620577</pub-id><pub-id pub-id-type="pmid">28926966</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Udy</surname><given-names>AA</given-names></name><name name-style="western"><surname>Varghese</surname><given-names>JM</given-names></name><name name-style="western"><surname>Altukroni</surname><given-names>M</given-names></name><name name-style="western"><surname>Briscoe</surname><given-names>S</given-names></name><name name-style="western"><surname>McWhinney</surname><given-names>BC</given-names></name><name name-style="western"><surname>Ungerer</surname><given-names>JP</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name></person-group><article-title>Subtherapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations</article-title><source>Chest</source><year>2012</year><volume>142</volume><fpage>30</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1378/chest.11-1671</pub-id><pub-id pub-id-type="pmid">22194591</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Udy</surname><given-names>AA</given-names></name><name name-style="western"><surname>Baptista</surname><given-names>JP</given-names></name><name name-style="western"><surname>Lim</surname><given-names>NL</given-names></name><name name-style="western"><surname>Joynt</surname><given-names>GM</given-names></name><name name-style="western"><surname>Jarrett</surname><given-names>P</given-names></name><name name-style="western"><surname>Wockner</surname><given-names>L</given-names></name><name name-style="western"><surname>Boots</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name></person-group><article-title>Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations</article-title><source>Crit Care Med</source><year>2014</year><volume>42</volume><fpage>520</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1097/CCM.0000000000000029</pub-id><pub-id pub-id-type="pmid">24201175</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baptista</surname><given-names>JP</given-names></name><name name-style="western"><surname>Udy</surname><given-names>AA</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>E</given-names></name><name name-style="western"><surname>Pimentel</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name></person-group><article-title>A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance</article-title><source>Crit Care</source><year>2011</year><volume>15</volume><fpage>R139</fpage><pub-id pub-id-type="doi">10.1186/cc10262</pub-id><pub-id pub-id-type="pmid">21651804</pub-id><pub-id pub-id-type="pmcid">PMC3219011</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Udy</surname><given-names>AA</given-names></name><name name-style="western"><surname>Dulhunty</surname><given-names>JM</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name><name name-style="western"><surname>Davis</surname><given-names>JS</given-names></name><name name-style="western"><surname>Webb</surname><given-names>SAR</given-names></name><name name-style="western"><surname>Bellomo</surname><given-names>R</given-names></name><name name-style="western"><surname>Gomersall</surname><given-names>C</given-names></name><name name-style="western"><surname>Shirwadkar</surname><given-names>C</given-names></name><name name-style="western"><surname>Eastwood</surname><given-names>GM</given-names></name><name name-style="western"><surname>Myburgh</surname><given-names>J</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>DL</given-names></name><name name-style="western"><surname>Starr</surname><given-names>T</given-names></name><name name-style="western"><surname>Paul</surname><given-names>SK</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name><collab>BLING-II Investigators</collab><collab>ANZICS Clinical Trials Group</collab></person-group><article-title>Association between augmented renal clearance and clinical outcomes in patients receiving beta-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial</article-title><source>Int J Antimicrob Agents</source><year>2017</year><volume>49</volume><fpage>624</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2016.12.022</pub-id><pub-id pub-id-type="pmid">28286115</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>G</given-names></name><name name-style="western"><surname>Gomersall</surname><given-names>CD</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Q</given-names></name><name name-style="western"><surname>Joynt</surname><given-names>GM</given-names></name><name name-style="western"><surname>Freebairn</surname><given-names>R</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name></person-group><article-title>Principles of antibacterial dosing in continuous renal replacement therapy</article-title><source>Crit Care Med</source><year>2009</year><volume>37</volume><fpage>2268</fpage><lpage>2282</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3181aab3d0</pub-id><pub-id pub-id-type="pmid">19487930</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>DM</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>MS</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Nair</surname><given-names>P</given-names></name><name name-style="western"><surname>Cole</surname><given-names>L</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name><name name-style="western"><surname>Bellomo</surname><given-names>R</given-names></name><name name-style="western"><surname>Investigators</surname><given-names>RRTS</given-names></name></person-group><article-title>Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study</article-title><source>Crit Care Med</source><year>2012</year><volume>40</volume><fpage>1523</fpage><lpage>1528</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e318241e553</pub-id><pub-id pub-id-type="pmid">22511133</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Roberts JA, Joynt G, Lee A, Choi G, Bellomo R, Kanji S, Mudaliar MY, Peake SL, Stephens D, Taccone FS, Ulldemolins M, Valkonen MM, Agbeve J, Baptista JP, Bekos V, Boidin C, Brinkmann A, Buizen L, Castro P, Cole CL, Creteur J, De Waele JJ, Deans R, Eastwood GM, Escobar L, Gomersall C, Gresham R, Jamal JA, Kluge S, Konig C, Koulouras VP, Lassig-Smith M, Laterre PF, Lei K, Leung P, Lefrant JY, Llaurado-Serra M, Martin-Loeches I, Mat Nor MB, Ostermann M, Parker SL, Rello J, Roberts DM, Roberts MS, Richards B, Rodriguez A, Roehr AC, Roger C, Seoane L, Sinnollareddy M, Sousa E, Soy D, Spring A, Starr T, Thomas J, Turnidge J, Wallis SC, Williams T, Wittebole X, Zikou XT, Paul S, Lipman J (2020) The effect of renal replacement therapy and antibiotic dose on antibiotic concentrations in critically ill patients: data from the multinational SMARRT Study. Clin Infect Dis</mixed-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>V</given-names></name><name name-style="western"><surname>Abdul-Aziz</surname><given-names>MH</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name><name name-style="western"><surname>Shekar</surname><given-names>K</given-names></name></person-group><article-title>Optimising drug dosing in patients receiving extracorporeal membrane oxygenation</article-title><source>J Thorac Dis</source><year>2018</year><volume>10</volume><fpage>S629</fpage><lpage>s641</lpage><pub-id pub-id-type="doi">10.21037/jtd.2017.09.154</pub-id><pub-id pub-id-type="pmid">29732181</pub-id><pub-id pub-id-type="pmcid">PMC5911560</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Craig</surname><given-names>WA</given-names></name></person-group><article-title>Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men</article-title><source>Clin Infect Dis</source><year>1998</year><volume>26</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1086/516284</pub-id><pub-id pub-id-type="pmid">9455502</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mouton</surname><given-names>JW</given-names></name><name name-style="western"><surname>Dudley</surname><given-names>MN</given-names></name><name name-style="western"><surname>Cars</surname><given-names>O</given-names></name><name name-style="western"><surname>Derendorf</surname><given-names>H</given-names></name><name name-style="western"><surname>Drusano</surname><given-names>GL</given-names></name></person-group><article-title>Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update</article-title><source>J Antimicrob Chemother</source><year>2005</year><volume>55</volume><fpage>601</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1093/jac/dki079</pub-id><pub-id pub-id-type="pmid">15772142</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sievert</surname><given-names>DM</given-names></name><name name-style="western"><surname>Ricks</surname><given-names>P</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>JR</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>A</given-names></name><name name-style="western"><surname>Patel</surname><given-names>J</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>A</given-names></name><name name-style="western"><surname>Kallen</surname><given-names>A</given-names></name><name name-style="western"><surname>Limbago</surname><given-names>B</given-names></name><name name-style="western"><surname>Fridkin</surname><given-names>S</given-names></name><collab>National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities</collab></person-group><article-title>Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010</article-title><source>Infect Control Hosp Epidemiol</source><year>2013</year><volume>34</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1086/668770</pub-id><pub-id pub-id-type="pmid">23221186</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mouton</surname><given-names>JW</given-names></name><name name-style="western"><surname>Muller</surname><given-names>AE</given-names></name><name name-style="western"><surname>Canton</surname><given-names>R</given-names></name><name name-style="western"><surname>Giske</surname><given-names>CG</given-names></name><name name-style="western"><surname>Kahlmeter</surname><given-names>G</given-names></name><name name-style="western"><surname>Turnidge</surname><given-names>J</given-names></name></person-group><article-title>MIC-based dose adjustment: facts and fables</article-title><source>J Antimicrob Chemother</source><year>2018</year><volume>73</volume><fpage>564</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1093/jac/dkx427</pub-id><pub-id pub-id-type="pmid">29216348</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Oh</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K</given-names></name><name name-style="western"><surname>Yu</surname><given-names>KS</given-names></name><name name-style="western"><surname>Chung</surname><given-names>JY</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>JH</given-names></name><name name-style="western"><surname>Nam</surname><given-names>EY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M</given-names></name><name name-style="western"><surname>Park</surname><given-names>JS</given-names></name><name name-style="western"><surname>Song</surname><given-names>KH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>ES</given-names></name><name name-style="western"><surname>Song</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HB</given-names></name></person-group><article-title>Pharmacokinetic characteristics and limited sampling strategies for therapeutic drug monitoring of colistin in patients with multidrug-resistant gram-negative bacterial infections</article-title><source>Ther Drug Monit</source><year>2019</year><volume>41</volume><fpage>102</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1097/FTD.0000000000000572</pub-id><pub-id pub-id-type="pmid">30299430</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Padulles Caldes</surname><given-names>A</given-names></name><name name-style="western"><surname>Colom</surname><given-names>H</given-names></name><name name-style="western"><surname>Caldes</surname><given-names>A</given-names></name><name name-style="western"><surname>Cerezo</surname><given-names>G</given-names></name><name name-style="western"><surname>Torras</surname><given-names>J</given-names></name><name name-style="western"><surname>Grinyo</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lloberas</surname><given-names>N</given-names></name></person-group><article-title>Optimal sparse sampling for estimating ganciclovir/valganciclovir AUC in solid organ transplant patients using NONMEM</article-title><source>Ther Drug Monit</source><year>2014</year><volume>36</volume><fpage>371</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1097/FTD.0000000000000007</pub-id><pub-id pub-id-type="pmid">24305626</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alsultan</surname><given-names>A</given-names></name><name name-style="western"><surname>An</surname><given-names>G</given-names></name><name name-style="western"><surname>Peloquin</surname><given-names>CA</given-names></name></person-group><article-title>Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis</article-title><source>Antimicrob Agents Chemother</source><year>2015</year><volume>59</volume><fpage>3800</fpage><lpage>3807</lpage><pub-id pub-id-type="doi">10.1128/AAC.00341-15</pub-id><pub-id pub-id-type="pmid">25870068</pub-id><pub-id pub-id-type="pmcid">PMC4468713</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlier</surname><given-names>M</given-names></name><name name-style="western"><surname>Athanasopoulos</surname><given-names>A</given-names></name><name name-style="western"><surname>Borrey</surname><given-names>D</given-names></name><name name-style="western"><surname>Colin</surname><given-names>P</given-names></name><name name-style="western"><surname>Cotton</surname><given-names>F</given-names></name><name name-style="western"><surname>Denooz</surname><given-names>R</given-names></name><name name-style="western"><surname>Neels</surname><given-names>H</given-names></name><name name-style="western"><surname>Spriet</surname><given-names>I</given-names></name><name name-style="western"><surname>Ghys</surname><given-names>T</given-names></name><name name-style="western"><surname>Verstraete</surname><given-names>AG</given-names></name><name name-style="western"><surname>Stove</surname><given-names>V</given-names></name></person-group><article-title>Proficiency testing for meropenem and piperacillin therapeutic drug monitoring: preliminary results from the Belgian society on infectiology and clinical microbiology pharmacokinetic-pharmacodynamic working group</article-title><source>Ther Drug Monit</source><year>2018</year><volume>40</volume><fpage>156</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">29140892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FTD.0000000000000467</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lempers</surname><given-names>VJ</given-names></name><name name-style="western"><surname>Alffenaar</surname><given-names>JW</given-names></name><name name-style="western"><surname>Touw</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Burger</surname><given-names>DM</given-names></name><name name-style="western"><surname>Uges</surname><given-names>DR</given-names></name><name name-style="western"><surname>Aarnoutse</surname><given-names>RE</given-names></name><name name-style="western"><surname>Bruggemann</surname><given-names>RJ</given-names></name></person-group><article-title>Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations</article-title><source>J Antimicrob Chemother</source><year>2014</year><volume>69</volume><fpage>2988</fpage><lpage>2994</lpage><pub-id pub-id-type="doi">10.1093/jac/dku242</pub-id><pub-id pub-id-type="pmid">25006236</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorn</surname><given-names>C</given-names></name><name name-style="western"><surname>Kratzer</surname><given-names>A</given-names></name><name name-style="western"><surname>Liebchen</surname><given-names>U</given-names></name><name name-style="western"><surname>Schleibinger</surname><given-names>M</given-names></name><name name-style="western"><surname>Murschhauser</surname><given-names>A</given-names></name><name name-style="western"><surname>Schlossmann</surname><given-names>J</given-names></name><name name-style="western"><surname>Kees</surname><given-names>F</given-names></name><name name-style="western"><surname>Simon</surname><given-names>P</given-names></name><name name-style="western"><surname>Kees</surname><given-names>MG</given-names></name></person-group><article-title>Impact of experimental variables on the protein binding of tigecycline in human plasma as determined by ultrafiltration</article-title><source>J Pharm Sci</source><year>2018</year><volume>107</volume><fpage>739</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2017.09.006</pub-id><pub-id pub-id-type="pmid">28927988</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cristallini</surname><given-names>S</given-names></name><name name-style="western"><surname>Hites</surname><given-names>M</given-names></name><name name-style="western"><surname>Kabtouri</surname><given-names>H</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name><name name-style="western"><surname>Beumier</surname><given-names>M</given-names></name><name name-style="western"><surname>Cotton</surname><given-names>F</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>F</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>JL</given-names></name><name name-style="western"><surname>Creteur</surname><given-names>J</given-names></name><name name-style="western"><surname>Taccone</surname><given-names>FS</given-names></name></person-group><article-title>New regimen for continuous infusion of vancomycin in critically Ill patients</article-title><source>Antimicrob Agents Chemother</source><year>2016</year><volume>60</volume><fpage>4750</fpage><lpage>4756</lpage><pub-id pub-id-type="doi">10.1128/AAC.00330-16</pub-id><pub-id pub-id-type="pmid">27216073</pub-id><pub-id pub-id-type="pmcid">PMC4958221</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pea</surname><given-names>F</given-names></name><name name-style="western"><surname>Viale</surname><given-names>P</given-names></name><name name-style="western"><surname>Cojutti</surname><given-names>P</given-names></name><name name-style="western"><surname>Furlanut</surname><given-names>M</given-names></name></person-group><article-title>Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach</article-title><source>Antimicrob Agents Chemother</source><year>2012</year><volume>56</volume><fpage>6343</fpage><lpage>6348</lpage><pub-id pub-id-type="doi">10.1128/AAC.01291-12</pub-id><pub-id pub-id-type="pmid">23045356</pub-id><pub-id pub-id-type="pmcid">PMC3497191</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neely</surname><given-names>MN</given-names></name><name name-style="western"><surname>Kato</surname><given-names>L</given-names></name><name name-style="western"><surname>Youn</surname><given-names>G</given-names></name><name name-style="western"><surname>Kraler</surname><given-names>L</given-names></name><name name-style="western"><surname>Bayard</surname><given-names>D</given-names></name><name name-style="western"><surname>van Guilder</surname><given-names>M</given-names></name><name name-style="western"><surname>Schumitzky</surname><given-names>A</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>W</given-names></name><name name-style="western"><surname>Jones</surname><given-names>B</given-names></name><name name-style="western"><surname>Minejima</surname><given-names>E</given-names></name></person-group><article-title>Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing</article-title><source>Antimicrob Agents Chemother</source><year>2018</year><volume>62</volume><fpage>e02042-17</fpage><pub-id pub-id-type="doi">10.1128/AAC.02042-17</pub-id><pub-id pub-id-type="pmid">29203493</pub-id><pub-id pub-id-type="pmcid">PMC5786789</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Broeker A, Nardecchia M, Klinker KP, Derendorf H, Day RO, Marriott DJ, Carland JE, Stocker SL, Wicha SG (2019) Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting. Clin Microbiol Infect 25:1286 e1281&#8211;e1286 e1287<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmi.2019.02.029</pub-id><pub-id pub-id-type="pmid">30872102</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruiz</surname><given-names>J</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>P</given-names></name><name name-style="western"><surname>Company</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>M</given-names></name><name name-style="western"><surname>Villarreal</surname><given-names>E</given-names></name><name name-style="western"><surname>Concha</surname><given-names>P</given-names></name><name name-style="western"><surname>Aroca</surname><given-names>M</given-names></name><name name-style="western"><surname>Frasquet</surname><given-names>J</given-names></name><name name-style="western"><surname>Remedios-Marques</surname><given-names>M</given-names></name><name name-style="western"><surname>Castellanos-Ortega</surname><given-names>A</given-names></name></person-group><article-title>Impact of amikacin pharmacokinetic/pharmacodynamic index on treatment response in critically ill patients</article-title><source>J Glob Antimicrob Resist</source><year>2018</year><volume>12</volume><fpage>90</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.jgar.2017.09.019</pub-id><pub-id pub-id-type="pmid">29017888</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duszynska</surname><given-names>W</given-names></name><name name-style="western"><surname>Taccone</surname><given-names>FS</given-names></name><name name-style="western"><surname>Hurkacz</surname><given-names>M</given-names></name><name name-style="western"><surname>Kowalska-Krochmal</surname><given-names>B</given-names></name><name name-style="western"><surname>Wiela-Hojenska</surname><given-names>A</given-names></name><name name-style="western"><surname>Kubler</surname><given-names>A</given-names></name></person-group><article-title>Therapeutic drug monitoring of amikacin in septic patients</article-title><source>Crit Care</source><year>2013</year><volume>17</volume><fpage>R165</fpage><pub-id pub-id-type="doi">10.1186/cc12844</pub-id><pub-id pub-id-type="pmid">23886243</pub-id><pub-id pub-id-type="pmcid">PMC4057344</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>RD</given-names></name><name name-style="western"><surname>Lietman</surname><given-names>PS</given-names></name><name name-style="western"><surname>Smith</surname><given-names>CR</given-names></name></person-group><article-title>Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration</article-title><source>J Infect Dis</source><year>1987</year><volume>155</volume><fpage>93</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1093/infdis/155.1.93</pub-id><pub-id pub-id-type="pmid">3540140</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Winter</surname><given-names>S</given-names></name><name name-style="western"><surname>Wauters</surname><given-names>J</given-names></name><name name-style="western"><surname>Meersseman</surname><given-names>W</given-names></name><name name-style="western"><surname>Verhaegen</surname><given-names>J</given-names></name><name name-style="western"><surname>Van Wijngaerden</surname><given-names>E</given-names></name><name name-style="western"><surname>Peetermans</surname><given-names>W</given-names></name><name name-style="western"><surname>Annaert</surname><given-names>P</given-names></name><name name-style="western"><surname>Verelst</surname><given-names>S</given-names></name><name name-style="western"><surname>Spriet</surname><given-names>I</given-names></name></person-group><article-title>Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial</article-title><source>Int J Antimicrob Agents</source><year>2018</year><volume>51</volume><fpage>562</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2017.11.009</pub-id><pub-id pub-id-type="pmid">29180278</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Montmollin</surname><given-names>E</given-names></name><name name-style="western"><surname>Bouadma</surname><given-names>L</given-names></name><name name-style="western"><surname>Gault</surname><given-names>N</given-names></name><name name-style="western"><surname>Mourvillier</surname><given-names>B</given-names></name><name name-style="western"><surname>Mariotte</surname><given-names>E</given-names></name><name name-style="western"><surname>Chemam</surname><given-names>S</given-names></name><name name-style="western"><surname>Massias</surname><given-names>L</given-names></name><name name-style="western"><surname>Papy</surname><given-names>E</given-names></name><name name-style="western"><surname>Tubach</surname><given-names>F</given-names></name><name name-style="western"><surname>Wolff</surname><given-names>M</given-names></name><name name-style="western"><surname>Sonneville</surname><given-names>R</given-names></name></person-group><article-title>Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25&#160;mg/kg total body weight regimen</article-title><source>Intensive Care Med</source><year>2014</year><volume>40</volume><fpage>998</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1007/s00134-014-3276-x</pub-id><pub-id pub-id-type="pmid">24687298</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delattre</surname><given-names>IK</given-names></name><name name-style="western"><surname>Musuamba</surname><given-names>FT</given-names></name><name name-style="western"><surname>Nyberg</surname><given-names>J</given-names></name><name name-style="western"><surname>Taccone</surname><given-names>FS</given-names></name><name name-style="western"><surname>Laterre</surname><given-names>PF</given-names></name><name name-style="western"><surname>Verbeeck</surname><given-names>RK</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>F</given-names></name><name name-style="western"><surname>Wallemacq</surname><given-names>PE</given-names></name></person-group><article-title>Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients</article-title><source>Ther Drug Monit</source><year>2010</year><volume>32</volume><fpage>749</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1097/FTD.0b013e3181f675c2</pub-id><pub-id pub-id-type="pmid">20962708</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Lent-Evers</surname><given-names>NA</given-names></name><name name-style="western"><surname>Mathot</surname><given-names>RA</given-names></name><name name-style="western"><surname>Geus</surname><given-names>WP</given-names></name><name name-style="western"><surname>van Hout</surname><given-names>BA</given-names></name><name name-style="western"><surname>Vinks</surname><given-names>AA</given-names></name></person-group><article-title>Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis</article-title><source>Ther Drug Monit</source><year>1999</year><volume>21</volume><fpage>63</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1097/00007691-199902000-00010</pub-id><pub-id pub-id-type="pmid">10051056</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Begg</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Barclay</surname><given-names>ML</given-names></name><name name-style="western"><surname>Duffull</surname><given-names>SB</given-names></name></person-group><article-title>A suggested approach to once-daily aminoglycoside dosing</article-title><source>Br J Clin Pharmacol</source><year>1995</year><volume>39</volume><fpage>605</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1995.tb05719.x</pub-id><pub-id pub-id-type="pmid">7654477</pub-id><pub-id pub-id-type="pmcid">PMC1365071</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKinnon</surname><given-names>PS</given-names></name><name name-style="western"><surname>Paladino</surname><given-names>JA</given-names></name><name name-style="western"><surname>Schentag</surname><given-names>JJ</given-names></name></person-group><article-title>Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T&#8201;&gt;&#8201;MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections</article-title><source>Int J Antimicrob Agents</source><year>2008</year><volume>31</volume><fpage>345</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2007.12.009</pub-id><pub-id pub-id-type="pmid">18313273</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Du</surname><given-names>X</given-names></name><name name-style="western"><surname>Kuti</surname><given-names>JL</given-names></name><name name-style="western"><surname>Nicolau</surname><given-names>DP</given-names></name></person-group><article-title>Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections</article-title><source>Antimicrob Agents Chemother</source><year>2007</year><volume>51</volume><fpage>1725</fpage><lpage>1730</lpage><pub-id pub-id-type="doi">10.1128/AAC.00294-06</pub-id><pub-id pub-id-type="pmid">17307978</pub-id><pub-id pub-id-type="pmcid">PMC1855547</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tam</surname><given-names>VH</given-names></name><name name-style="western"><surname>McKinnon</surname><given-names>PS</given-names></name><name name-style="western"><surname>Akins</surname><given-names>RL</given-names></name><name name-style="western"><surname>Rybak</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Drusano</surname><given-names>GL</given-names></name></person-group><article-title>Pharmacodynamics of cefepime in patients with Gram-negative infections</article-title><source>J Antimicrob Chemother</source><year>2002</year><volume>50</volume><fpage>425</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1093/jac/dkf130</pub-id><pub-id pub-id-type="pmid">12205070</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aitken</surname><given-names>SL</given-names></name><name name-style="western"><surname>Altshuler</surname><given-names>J</given-names></name><name name-style="western"><surname>Guervil</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>EB</given-names></name><name name-style="western"><surname>Ostrosky-Zeichner</surname><given-names>LL</given-names></name><name name-style="western"><surname>Ericsson</surname><given-names>CD</given-names></name><name name-style="western"><surname>Tam</surname><given-names>VH</given-names></name></person-group><article-title>Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia</article-title><source>Int J Antimicrob Agents</source><year>2015</year><volume>45</volume><fpage>541</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2014.12.018</pub-id><pub-id pub-id-type="pmid">25665726</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vial</surname><given-names>T</given-names></name><name name-style="western"><surname>Bailly</surname><given-names>H</given-names></name><name name-style="western"><surname>Perault-Pochat</surname><given-names>MC</given-names></name><name name-style="western"><surname>Default</surname><given-names>A</given-names></name><name name-style="western"><surname>Boulay</surname><given-names>C</given-names></name><name name-style="western"><surname>Chouchana</surname><given-names>L</given-names></name><name name-style="western"><surname>Kassai</surname><given-names>B</given-names></name><collab>French Network of Pharmacovigilance Centres</collab></person-group><article-title>Beta-lactam-induced severe neutropaenia: a descriptive study</article-title><source>Fundam Clin Pharmacol</source><year>2019</year><volume>33</volume><fpage>225</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1111/fcp.12419</pub-id><pub-id pub-id-type="pmid">30289173</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vardakas</surname><given-names>KZ</given-names></name><name name-style="western"><surname>Voulgaris</surname><given-names>GL</given-names></name><name name-style="western"><surname>Maliaros</surname><given-names>A</given-names></name><name name-style="western"><surname>Samonis</surname><given-names>G</given-names></name><name name-style="western"><surname>Falagas</surname><given-names>ME</given-names></name></person-group><article-title>Prolonged versus short-term intravenous infusion of antipseudomonal beta-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials</article-title><source>Lancet Infect Dis</source><year>2018</year><volume>18</volume><fpage>108</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(17)30615-1</pub-id><pub-id pub-id-type="pmid">29102324</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>G</given-names></name><name name-style="western"><surname>Briscoe</surname><given-names>S</given-names></name><name name-style="western"><surname>McWhinney</surname><given-names>B</given-names></name><name name-style="western"><surname>Ally</surname><given-names>M</given-names></name><name name-style="western"><surname>Ungerer</surname><given-names>J</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name></person-group><article-title>Therapeutic drug monitoring of beta-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures</article-title><source>J Antimicrob Chemother</source><year>2018</year><volume>73</volume><fpage>3087</fpage><lpage>3094</lpage><pub-id pub-id-type="doi">10.1093/jac/dky314</pub-id><pub-id pub-id-type="pmid">30137377</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heil</surname><given-names>EL</given-names></name><name name-style="western"><surname>Nicolau</surname><given-names>DP</given-names></name><name name-style="western"><surname>Farkas</surname><given-names>A</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name><name name-style="western"><surname>Thom</surname><given-names>KA</given-names></name></person-group><article-title>Pharmacodynamic target attainment for cefepime, meropenem, and piperacillin-tazobactam using a pharmacokinetic/pharmacodynamic-based dosing calculator in critically ill patients</article-title><source>Antimicrob Agents Chemother</source><year>2018</year><volume>62</volume><fpage>e01008-18</fpage><pub-id pub-id-type="doi">10.1128/AAC.01008-18</pub-id><pub-id pub-id-type="pmid">29967022</pub-id><pub-id pub-id-type="pmcid">PMC6125501</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blaser</surname><given-names>J</given-names></name><name name-style="western"><surname>Joos</surname><given-names>B</given-names></name><name name-style="western"><surname>Opravil</surname><given-names>M</given-names></name><name name-style="western"><surname>Luthy</surname><given-names>R</given-names></name></person-group><article-title>Variability of serum concentrations of trimethoprim and sulfamethoxazole during high dose therapy</article-title><source>Infection</source><year>1993</year><volume>21</volume><fpage>206</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1007/BF01728888</pub-id><pub-id pub-id-type="pmid">8225622</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hess</surname><given-names>MM</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>BA</given-names></name><name name-style="western"><surname>Laizure</surname><given-names>SC</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>RC</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>PL</given-names></name><name name-style="western"><surname>Janning</surname><given-names>SW</given-names></name><name name-style="western"><surname>Croce</surname><given-names>MA</given-names></name><name name-style="western"><surname>Fabian</surname><given-names>TC</given-names></name></person-group><article-title>Trimethoprim-sulfamethoxazole pharmacokinetics in trauma patients</article-title><source>Pharmacotherapy</source><year>1993</year><volume>13</volume><fpage>602</fpage><lpage>606</lpage><pub-id pub-id-type="pmid">8302685</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falcone</surname><given-names>M</given-names></name><name name-style="western"><surname>Russo</surname><given-names>A</given-names></name><name name-style="western"><surname>Cassetta</surname><given-names>MI</given-names></name><name name-style="western"><surname>Lappa</surname><given-names>A</given-names></name><name name-style="western"><surname>Tritapepe</surname><given-names>L</given-names></name><name name-style="western"><surname>d&#8217;Ettorre</surname><given-names>G</given-names></name><name name-style="western"><surname>Fallani</surname><given-names>S</given-names></name><name name-style="western"><surname>Novelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Venditti</surname><given-names>M</given-names></name></person-group><article-title>Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?</article-title><source>J Infect Chemother</source><year>2013</year><volume>19</volume><fpage>732</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1007/s10156-013-0559-z</pub-id><pub-id pub-id-type="pmid">23361566</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galar</surname><given-names>A</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>P</given-names></name><name name-style="western"><surname>Valerio</surname><given-names>M</given-names></name><name name-style="western"><surname>Cercenado</surname><given-names>E</given-names></name><name name-style="western"><surname>Garcia-Gonzalez</surname><given-names>X</given-names></name><name name-style="western"><surname>Burillo</surname><given-names>A</given-names></name><name name-style="western"><surname>Sanchez-Somolinos</surname><given-names>M</given-names></name><name name-style="western"><surname>Juarez</surname><given-names>M</given-names></name><name name-style="western"><surname>Verde</surname><given-names>E</given-names></name><name name-style="western"><surname>Bouza</surname><given-names>E</given-names></name></person-group><article-title>Current use of daptomycin and systematic therapeutic drug monitoring: clinical experience in a tertiary care institution</article-title><source>Int J Antimicrob Agents</source><year>2019</year><volume>53</volume><fpage>40</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2018.09.015</pub-id><pub-id pub-id-type="pmid">30243587</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhavnani</surname><given-names>SM</given-names></name><name name-style="western"><surname>Rubino</surname><given-names>CM</given-names></name><name name-style="western"><surname>Ambrose</surname><given-names>PG</given-names></name><name name-style="western"><surname>Drusano</surname><given-names>GL</given-names></name></person-group><article-title>Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis</article-title><source>Clin Infect Dis</source><year>2010</year><volume>50</volume><fpage>1568</fpage><lpage>1574</lpage><pub-id pub-id-type="doi">10.1086/652767</pub-id><pub-id pub-id-type="pmid">20462352</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soraluce</surname><given-names>A</given-names></name><name name-style="western"><surname>Asin-Prieto</surname><given-names>E</given-names></name><name name-style="western"><surname>Rodriguez-Gascon</surname><given-names>A</given-names></name><name name-style="western"><surname>Barrasa</surname><given-names>H</given-names></name><name name-style="western"><surname>Maynar</surname><given-names>J</given-names></name><name name-style="western"><surname>Carcelero</surname><given-names>E</given-names></name><name name-style="western"><surname>Soy</surname><given-names>D</given-names></name><name name-style="western"><surname>Isla</surname><given-names>A</given-names></name></person-group><article-title>Population pharmacokinetics of daptomycin in critically ill patients</article-title><source>Int J Antimicrob Agents</source><year>2018</year><volume>52</volume><fpage>158</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2018.03.008</pub-id><pub-id pub-id-type="pmid">29572042</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Paolo</surname><given-names>A</given-names></name><name name-style="western"><surname>Tascini</surname><given-names>C</given-names></name><name name-style="western"><surname>Polillo</surname><given-names>M</given-names></name><name name-style="western"><surname>Gemignani</surname><given-names>G</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>EI</given-names></name><name name-style="western"><surname>Bocci</surname><given-names>G</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></name><name name-style="western"><surname>Menichetti</surname><given-names>F</given-names></name><name name-style="western"><surname>Danesi</surname><given-names>R</given-names></name></person-group><article-title>Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections</article-title><source>Int J Antimicrob Agents</source><year>2013</year><volume>42</volume><fpage>250</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2013.06.006</pub-id><pub-id pub-id-type="pmid">23891432</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barreau</surname><given-names>S</given-names></name><name name-style="western"><surname>Benaboud</surname><given-names>S</given-names></name><name name-style="western"><surname>Kerneis</surname><given-names>S</given-names></name><name name-style="western"><surname>Moachon</surname><given-names>L</given-names></name><name name-style="western"><surname>Blanche</surname><given-names>P</given-names></name><name name-style="western"><surname>Groh</surname><given-names>M</given-names></name><name name-style="western"><surname>Massias</surname><given-names>L</given-names></name><name name-style="western"><surname>Treluyer</surname><given-names>JM</given-names></name><name name-style="western"><surname>Poyart</surname><given-names>C</given-names></name><name name-style="western"><surname>Raymond</surname><given-names>J</given-names></name></person-group><article-title>Staphylococcus aureus osteo-articular infection: usefulness of the determination of daptomycin serum concentration to explain a treatment failure</article-title><source>Int J Clin Pharmacol Ther</source><year>2016</year><volume>54</volume><fpage>923</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.5414/CP202538</pub-id><pub-id pub-id-type="pmid">27509826</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reiber</surname><given-names>C</given-names></name><name name-style="western"><surname>Senn</surname><given-names>O</given-names></name><name name-style="western"><surname>Muller</surname><given-names>D</given-names></name><name name-style="western"><surname>Kullak-Ublick</surname><given-names>GA</given-names></name><name name-style="western"><surname>Corti</surname><given-names>N</given-names></name></person-group><article-title>Therapeutic drug monitoring of daptomycin: a retrospective monocentric analysis</article-title><source>Ther Drug Monit</source><year>2015</year><volume>37</volume><fpage>634</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1097/FTD.0000000000000196</pub-id><pub-id pub-id-type="pmid">26384039</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pai</surname><given-names>MP</given-names></name><name name-style="western"><surname>Russo</surname><given-names>A</given-names></name><name name-style="western"><surname>Novelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Venditti</surname><given-names>M</given-names></name><name name-style="western"><surname>Falcone</surname><given-names>M</given-names></name></person-group><article-title>Simplified equations using two concentrations to calculate area under the curve for antimicrobials with concentration-dependent pharmacodynamics: daptomycin as a motivating example</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><fpage>3162</fpage><lpage>3167</lpage><pub-id pub-id-type="doi">10.1128/AAC.02355-14</pub-id><pub-id pub-id-type="pmid">24663017</pub-id><pub-id pub-id-type="pmcid">PMC4068499</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drusano</surname><given-names>GL</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>DE</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>M</given-names></name><name name-style="western"><surname>Standiford</surname><given-names>HC</given-names></name></person-group><article-title>Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis</article-title><source>Antimicrob Agents Chemother</source><year>1993</year><volume>37</volume><fpage>483</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1128/AAC.37.3.483</pub-id><pub-id pub-id-type="pmid">8384815</pub-id><pub-id pub-id-type="pmcid">PMC187696</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blaser</surname><given-names>J</given-names></name><name name-style="western"><surname>Stone</surname><given-names>BB</given-names></name><name name-style="western"><surname>Groner</surname><given-names>MC</given-names></name><name name-style="western"><surname>Zinner</surname><given-names>SH</given-names></name></person-group><article-title>Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance</article-title><source>Antimicrob Agents Chemother</source><year>1987</year><volume>31</volume><fpage>1054</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1128/AAC.31.7.1054</pub-id><pub-id pub-id-type="pmid">3116917</pub-id><pub-id pub-id-type="pmcid">PMC174871</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zelenitsky</surname><given-names>SA</given-names></name><name name-style="western"><surname>Ariano</surname><given-names>RE</given-names></name></person-group><article-title>Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection</article-title><source>J Antimicrob Chemother</source><year>2010</year><volume>65</volume><fpage>1725</fpage><lpage>1732</lpage><pub-id pub-id-type="doi">10.1093/jac/dkq211</pub-id><pub-id pub-id-type="pmid">20558470</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forrest</surname><given-names>A</given-names></name><name name-style="western"><surname>Nix</surname><given-names>DE</given-names></name><name name-style="western"><surname>Ballow</surname><given-names>CH</given-names></name><name name-style="western"><surname>Goss</surname><given-names>TF</given-names></name><name name-style="western"><surname>Birmingham</surname><given-names>MC</given-names></name><name name-style="western"><surname>Schentag</surname><given-names>JJ</given-names></name></person-group><article-title>Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients</article-title><source>Antimicrob Agents Chemother</source><year>1993</year><volume>37</volume><fpage>1073</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1128/AAC.37.5.1073</pub-id><pub-id pub-id-type="pmid">8517694</pub-id><pub-id pub-id-type="pmcid">PMC187901</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cone</surname><given-names>C</given-names></name><name name-style="western"><surname>Horowitz</surname><given-names>B</given-names></name></person-group><article-title>Convulsions associated with moxifloxacin</article-title><source>Am J Health Syst Pharm</source><year>2015</year><volume>72</volume><issue>910</issue><fpage>912</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2146/ajhp130685</pub-id><pub-id pub-id-type="pmid">25987681</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazzei</surname><given-names>D</given-names></name><name name-style="western"><surname>Accardo</surname><given-names>J</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>A</given-names></name><name name-style="western"><surname>Primavera</surname><given-names>A</given-names></name></person-group><article-title>Levofloxacin neurotoxicity and non-convulsive status epilepticus (NCSE): a case report</article-title><source>Clin Neurol Neurosurg</source><year>2012</year><volume>114</volume><fpage>1371</fpage><lpage>1373</lpage><pub-id pub-id-type="doi">10.1016/j.clineuro.2012.03.029</pub-id><pub-id pub-id-type="pmid">22551579</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bellon</surname><given-names>A</given-names></name><name name-style="western"><surname>Perez-Garcia</surname><given-names>G</given-names></name><name name-style="western"><surname>Coverdale</surname><given-names>JH</given-names></name><name name-style="western"><surname>Chacko</surname><given-names>RC</given-names></name></person-group><article-title>Seizures associated with levofloxacin: case presentation and literature review</article-title><source>Eur J Clin Pharmacol</source><year>2009</year><volume>65</volume><fpage>959</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1007/s00228-009-0717-5</pub-id><pub-id pub-id-type="pmid">19707748</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chui</surname><given-names>CS</given-names></name><name name-style="western"><surname>Chan</surname><given-names>EW</given-names></name><name name-style="western"><surname>Wong</surname><given-names>AY</given-names></name><name name-style="western"><surname>Root</surname><given-names>A</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Wong</surname><given-names>IC</given-names></name></person-group><article-title>Association between oral fluoroquinolones and seizures: a self-controlled case series study</article-title><source>Neurology</source><year>2016</year><volume>86</volume><fpage>1708</fpage><lpage>1715</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000002633</pub-id><pub-id pub-id-type="pmid">27053716</pub-id><pub-id pub-id-type="pmcid">PMC4854590</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Byrne</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name><name name-style="western"><surname>McWhinney</surname><given-names>B</given-names></name><name name-style="western"><surname>Fennell</surname><given-names>JP</given-names></name><name name-style="western"><surname>O&#8217;Byrne</surname><given-names>P</given-names></name><name name-style="western"><surname>Deasy</surname><given-names>E</given-names></name><name name-style="western"><surname>Egan</surname><given-names>S</given-names></name><name name-style="western"><surname>Desmond</surname><given-names>R</given-names></name><name name-style="western"><surname>Enright</surname><given-names>H</given-names></name><name name-style="western"><surname>Ryder</surname><given-names>SA</given-names></name><name name-style="western"><surname>D&#8217;Arcy</surname><given-names>DM</given-names></name><name name-style="western"><surname>McHugh</surname><given-names>J</given-names></name></person-group><article-title>Variability in trough total and unbound teicoplanin concentrations and achievement of therapeutic drug monitoring targets in adult patients with hematological malignancy</article-title><source>Antimicrob Agents Chemother</source><year>2017</year><volume>61</volume><fpage>e02466-16</fpage><pub-id pub-id-type="doi">10.1128/AAC.02466-16</pub-id><pub-id pub-id-type="pmid">28320714</pub-id><pub-id pub-id-type="pmcid">PMC5444128</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brink</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Richards</surname><given-names>GA</given-names></name><name name-style="western"><surname>Lautenbach</surname><given-names>EE</given-names></name><name name-style="western"><surname>Rapeport</surname><given-names>N</given-names></name><name name-style="western"><surname>Schillack</surname><given-names>V</given-names></name><name name-style="western"><surname>van Niekerk</surname><given-names>L</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name></person-group><article-title>Albumin concentration significantly impacts on free teicoplanin plasma concentrations in non-critically ill patients with chronic bone sepsis</article-title><source>Int J Antimicrob Agents</source><year>2015</year><volume>45</volume><fpage>647</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2015.01.015</pub-id><pub-id pub-id-type="pmid">25819167</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name><name name-style="western"><surname>Stove</surname><given-names>V</given-names></name><name name-style="western"><surname>De Waele</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Sipinkoski</surname><given-names>B</given-names></name><name name-style="western"><surname>McWhinney</surname><given-names>B</given-names></name><name name-style="western"><surname>Ungerer</surname><given-names>JP</given-names></name><name name-style="western"><surname>Akova</surname><given-names>M</given-names></name><name name-style="western"><surname>Bassetti</surname><given-names>M</given-names></name><name name-style="western"><surname>Dimopoulos</surname><given-names>G</given-names></name><name name-style="western"><surname>Kaukonen</surname><given-names>KM</given-names></name><name name-style="western"><surname>Koulenti</surname><given-names>D</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C</given-names></name><name name-style="western"><surname>Montravers</surname><given-names>P</given-names></name><name name-style="western"><surname>Rello</surname><given-names>J</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>A</given-names></name><name name-style="western"><surname>Starr</surname><given-names>T</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>SC</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name><name name-style="western"><surname>Authors</surname><given-names>DS</given-names></name></person-group><article-title>Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study</article-title><source>Int J Antimicrob Agents</source><year>2014</year><volume>43</volume><fpage>423</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2014.01.023</pub-id><pub-id pub-id-type="pmid">24630304</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Guan</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lv</surname><given-names>W</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L</given-names></name></person-group><article-title>Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate-severe Gram-positive infections</article-title><source>Infect Drug Resist</source><year>2018</year><volume>11</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.2147/IDR.S146961</pub-id><pub-id pub-id-type="pmid">29379306</pub-id><pub-id pub-id-type="pmcid">PMC5759846</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Li</surname><given-names>N</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J</given-names></name><name name-style="western"><surname>Lei</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Xing</surname><given-names>J</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name></person-group><article-title>Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections</article-title><source>Int J Clin Pharmacol Ther</source><year>2015</year><volume>53</volume><fpage>356</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.5414/CP202247</pub-id><pub-id pub-id-type="pmid">25828639</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramos-Martin</surname><given-names>V</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>A</given-names></name><name name-style="western"><surname>McEntee</surname><given-names>L</given-names></name><name name-style="western"><surname>Farrington</surname><given-names>N</given-names></name><name name-style="western"><surname>Padmore</surname><given-names>K</given-names></name><name name-style="western"><surname>Cojutti</surname><given-names>P</given-names></name><name name-style="western"><surname>Pea</surname><given-names>F</given-names></name><name name-style="western"><surname>Neely</surname><given-names>MN</given-names></name><name name-style="western"><surname>Hope</surname><given-names>WW</given-names></name></person-group><article-title>Pharmacodynamics of teicoplanin against MRSA</article-title><source>J Antimicrob Chemother</source><year>2017</year><volume>72</volume><fpage>3382</fpage><lpage>3389</lpage><pub-id pub-id-type="doi">10.1093/jac/dkx289</pub-id><pub-id pub-id-type="pmid">28962026</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsumoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>E</given-names></name><name name-style="western"><surname>Kanazawa</surname><given-names>N</given-names></name><name name-style="western"><surname>Fukamizu</surname><given-names>T</given-names></name><name name-style="western"><surname>Shigemi</surname><given-names>A</given-names></name><name name-style="western"><surname>Yokoyama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ikawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Morikawa</surname><given-names>N</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>Y</given-names></name></person-group><article-title>Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections</article-title><source>Clin Pharmacol</source><year>2016</year><volume>8</volume><fpage>15</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">27099534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/CPAA.S96143</pub-id><pub-id pub-id-type="pmcid">PMC4822798</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martirosov</surname><given-names>DM</given-names></name><name name-style="western"><surname>Bidell</surname><given-names>MR</given-names></name><name name-style="western"><surname>Pai</surname><given-names>MP</given-names></name><name name-style="western"><surname>Scheetz</surname><given-names>MH</given-names></name><name name-style="western"><surname>Rosenkranz</surname><given-names>SL</given-names></name><name name-style="western"><surname>Lodise</surname><given-names>TP</given-names></name></person-group><article-title>Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest(R) MIC values of 1.5&#160;mg/L: a pilot study</article-title><source>Diagn Microbiol Infect Dis</source><year>2017</year><volume>88</volume><fpage>259</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2017.03.008</pub-id><pub-id pub-id-type="pmid">28449844</pub-id><pub-id pub-id-type="pmcid">PMC5512425</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghosh</surname><given-names>N</given-names></name><name name-style="western"><surname>Chavada</surname><given-names>R</given-names></name><name name-style="western"><surname>Maley</surname><given-names>M</given-names></name><name name-style="western"><surname>van Hal</surname><given-names>SJ</given-names></name></person-group><article-title>Impact of source of infection and vancomycin AUC0-24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia</article-title><source>Clin Microbiol Infect</source><year>2014</year><volume>20</volume><fpage>O1098</fpage><lpage>01105</lpage><pub-id pub-id-type="doi">10.1111/1469-0691.12695</pub-id><pub-id pub-id-type="pmid">24890030</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zelenitsky</surname><given-names>S</given-names></name><name name-style="western"><surname>Rubinstein</surname><given-names>E</given-names></name><name name-style="western"><surname>Ariano</surname><given-names>R</given-names></name><name name-style="western"><surname>Iacovides</surname><given-names>H</given-names></name><name name-style="western"><surname>Dodek</surname><given-names>P</given-names></name><name name-style="western"><surname>Mirzanejad</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><collab>Cooperative Antimicrobial Therapy of Septic Shock-CATSS Database Research Group</collab></person-group><article-title>Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock</article-title><source>Int J Antimicrob Agents</source><year>2013</year><volume>41</volume><fpage>255</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2012.10.015</pub-id><pub-id pub-id-type="pmid">23312606</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>EY</given-names></name><name name-style="western"><surname>Huh</surname><given-names>JW</given-names></name><name name-style="western"><surname>Lim</surname><given-names>CM</given-names></name><name name-style="western"><surname>Koh</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SH</given-names></name><name name-style="western"><surname>Choi</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MN</given-names></name><name name-style="western"><surname>Hong</surname><given-names>SB</given-names></name></person-group><article-title>Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia</article-title><source>Intensive Care Med</source><year>2011</year><volume>37</volume><fpage>639</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1007/s00134-011-2130-7</pub-id><pub-id pub-id-type="pmid">21253703</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hao</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>JX</given-names></name></person-group><article-title>Continuous versus intermittent infusion of vancomycin in adult patients: a systematic review and meta-analysis</article-title><source>Int J Antimicrob Agents</source><year>2016</year><volume>47</volume><fpage>28</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2015.10.019</pub-id><pub-id pub-id-type="pmid">26655032</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cataldo</surname><given-names>MA</given-names></name><name name-style="western"><surname>Tacconelli</surname><given-names>E</given-names></name><name name-style="western"><surname>Grilli</surname><given-names>E</given-names></name><name name-style="western"><surname>Pea</surname><given-names>F</given-names></name><name name-style="western"><surname>Petrosillo</surname><given-names>N</given-names></name></person-group><article-title>Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis</article-title><source>J Antimicrob Chemother</source><year>2012</year><volume>67</volume><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1093/jac/dkr442</pub-id><pub-id pub-id-type="pmid">22028203</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>RB</given-names></name><name name-style="western"><surname>Kojiro</surname><given-names>K</given-names></name><name name-style="western"><surname>Won</surname><given-names>R</given-names></name><name name-style="western"><surname>Chang</surname><given-names>E</given-names></name><name name-style="western"><surname>Chan</surname><given-names>D</given-names></name><name name-style="western"><surname>Elbarbry</surname><given-names>F</given-names></name></person-group><article-title>Prospective evaluation of vancomycin pharmacokinetics in a heterogeneous critically ill population</article-title><source>Diagn Microbiol Infect Dis</source><year>2018</year><volume>92</volume><fpage>346</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2018.06.022</pub-id><pub-id pub-id-type="pmid">30025969</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finch</surname><given-names>NA</given-names></name><name name-style="western"><surname>Zasowski</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Murray</surname><given-names>KP</given-names></name><name name-style="western"><surname>Mynatt</surname><given-names>RP</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Yost</surname><given-names>R</given-names></name><name name-style="western"><surname>Pogue</surname><given-names>JM</given-names></name><name name-style="western"><surname>Rybak</surname><given-names>MJ</given-names></name></person-group><article-title>A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity</article-title><source>Antimicrob Agents Chemother</source><year>2017</year><volume>61</volume><fpage>e01293-17</fpage><pub-id pub-id-type="doi">10.1128/AAC.01293-17</pub-id><pub-id pub-id-type="pmid">28923869</pub-id><pub-id pub-id-type="pmcid">PMC5700348</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hale</surname><given-names>CM</given-names></name><name name-style="western"><surname>Seabury</surname><given-names>RW</given-names></name><name name-style="western"><surname>Steele</surname><given-names>JM</given-names></name><name name-style="western"><surname>Darko</surname><given-names>W</given-names></name><name name-style="western"><surname>Miller</surname><given-names>CD</given-names></name></person-group><article-title>Are vancomycin trough concentrations of 15 to 20&#160;mg/L associated with increased attainment of an AUC/MIC&#8201;&gt;/=&#8201;400 in patients with presumed MRSA infection?</article-title><source>J Pharm Pract</source><year>2017</year><volume>30</volume><fpage>329</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1177/0897190016642692</pub-id><pub-id pub-id-type="pmid">27074786</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neely</surname><given-names>MN</given-names></name><name name-style="western"><surname>Youn</surname><given-names>G</given-names></name><name name-style="western"><surname>Jones</surname><given-names>B</given-names></name><name name-style="western"><surname>Jelliffe</surname><given-names>RW</given-names></name><name name-style="western"><surname>Drusano</surname><given-names>GL</given-names></name><name name-style="western"><surname>Rodvold</surname><given-names>KA</given-names></name><name name-style="western"><surname>Lodise</surname><given-names>TP</given-names></name></person-group><article-title>Are vancomycin trough concentrations adequate for optimal dosing?</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><fpage>309</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1128/AAC.01653-13</pub-id><pub-id pub-id-type="pmid">24165176</pub-id><pub-id pub-id-type="pmcid">PMC3910745</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holmes</surname><given-names>NE</given-names></name><name name-style="western"><surname>Turnidge</surname><given-names>JD</given-names></name><name name-style="western"><surname>Munckhof</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>JO</given-names></name><name name-style="western"><surname>Korman</surname><given-names>TM</given-names></name><name name-style="western"><surname>O&#8217;Sullivan</surname><given-names>MV</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>TL</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>SA</given-names></name><name name-style="western"><surname>Warren</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W</given-names></name><name name-style="western"><surname>Howden</surname><given-names>BP</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>PD</given-names></name></person-group><article-title>Vancomycin AUC/MIC ratio and 30-day mortality in patients with <italic toggle="yes">Staphylococcus aureus</italic> bacteremia</article-title><source>Antimicrob Agents Chemother</source><year>2013</year><volume>57</volume><fpage>1654</fpage><lpage>1663</lpage><pub-id pub-id-type="doi">10.1128/AAC.01485-12</pub-id><pub-id pub-id-type="pmid">23335735</pub-id><pub-id pub-id-type="pmcid">PMC3623342</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rayner</surname><given-names>CR</given-names></name><name name-style="western"><surname>Forrest</surname><given-names>A</given-names></name><name name-style="western"><surname>Meagher</surname><given-names>AK</given-names></name><name name-style="western"><surname>Birmingham</surname><given-names>MC</given-names></name><name name-style="western"><surname>Schentag</surname><given-names>JJ</given-names></name></person-group><article-title>Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme</article-title><source>Clin Pharmacokinet</source><year>2003</year><volume>42</volume><fpage>1411</fpage><lpage>1423</lpage><pub-id pub-id-type="doi">10.2165/00003088-200342150-00007</pub-id><pub-id pub-id-type="pmid">14674791</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taubert</surname><given-names>M</given-names></name><name name-style="western"><surname>Zoller</surname><given-names>M</given-names></name><name name-style="western"><surname>Maier</surname><given-names>B</given-names></name><name name-style="western"><surname>Frechen</surname><given-names>S</given-names></name><name name-style="western"><surname>Scharf</surname><given-names>C</given-names></name><name name-style="western"><surname>Holdt</surname><given-names>LM</given-names></name><name name-style="western"><surname>Frey</surname><given-names>L</given-names></name><name name-style="western"><surname>Vogeser</surname><given-names>M</given-names></name><name name-style="western"><surname>Fuhr</surname><given-names>U</given-names></name><name name-style="western"><surname>Zander</surname><given-names>J</given-names></name></person-group><article-title>Predictors of inadequate linezolid concentrations after standard dosing in critically ill patients</article-title><source>Antimicrob Agents Chemother</source><year>2016</year><volume>60</volume><fpage>5254</fpage><lpage>5261</lpage><pub-id pub-id-type="doi">10.1128/AAC.00356-16</pub-id><pub-id pub-id-type="pmid">27324768</pub-id><pub-id pub-id-type="pmcid">PMC4997846</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pea</surname><given-names>F</given-names></name><name name-style="western"><surname>Furlanut</surname><given-names>M</given-names></name><name name-style="western"><surname>Cojutti</surname><given-names>P</given-names></name><name name-style="western"><surname>Cristini</surname><given-names>F</given-names></name><name name-style="western"><surname>Zamparini</surname><given-names>E</given-names></name><name name-style="western"><surname>Franceschi</surname><given-names>L</given-names></name><name name-style="western"><surname>Viale</surname><given-names>P</given-names></name></person-group><article-title>Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis</article-title><source>Antimicrob Agents Chemother</source><year>2010</year><volume>54</volume><fpage>4605</fpage><lpage>4610</lpage><pub-id pub-id-type="doi">10.1128/AAC.00177-10</pub-id><pub-id pub-id-type="pmid">20733043</pub-id><pub-id pub-id-type="pmcid">PMC2976143</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pea</surname><given-names>F</given-names></name><name name-style="western"><surname>Viale</surname><given-names>P</given-names></name><name name-style="western"><surname>Cojutti</surname><given-names>P</given-names></name><name name-style="western"><surname>Del Pin</surname><given-names>B</given-names></name><name name-style="western"><surname>Zamparini</surname><given-names>E</given-names></name><name name-style="western"><surname>Furlanut</surname><given-names>M</given-names></name></person-group><article-title>Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients</article-title><source>J Antimicrob Chemother</source><year>2012</year><volume>67</volume><fpage>2034</fpage><lpage>2042</lpage><pub-id pub-id-type="doi">10.1093/jac/dks153</pub-id><pub-id pub-id-type="pmid">22553142</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamp</surname><given-names>J</given-names></name><name name-style="western"><surname>Bolhuis</surname><given-names>MS</given-names></name><name name-style="western"><surname>Tiberi</surname><given-names>S</given-names></name><name name-style="western"><surname>Akkerman</surname><given-names>OW</given-names></name><name name-style="western"><surname>Centis</surname><given-names>R</given-names></name><name name-style="western"><surname>de Lange</surname><given-names>WC</given-names></name><name name-style="western"><surname>Kosterink</surname><given-names>JG</given-names></name><name name-style="western"><surname>van der Werf</surname><given-names>TS</given-names></name><name name-style="western"><surname>Migliori</surname><given-names>GB</given-names></name><name name-style="western"><surname>Alffenaar</surname><given-names>JC</given-names></name></person-group><article-title>Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis</article-title><source>Int J Antimicrob Agents</source><year>2017</year><volume>49</volume><fpage>688</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2017.01.017</pub-id><pub-id pub-id-type="pmid">28389352</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohamed</surname><given-names>AF</given-names></name><name name-style="western"><surname>Karaiskos</surname><given-names>I</given-names></name><name name-style="western"><surname>Plachouras</surname><given-names>D</given-names></name><name name-style="western"><surname>Karvanen</surname><given-names>M</given-names></name><name name-style="western"><surname>Pontikis</surname><given-names>K</given-names></name><name name-style="western"><surname>Jansson</surname><given-names>B</given-names></name><name name-style="western"><surname>Papadomichelakis</surname><given-names>E</given-names></name><name name-style="western"><surname>Antoniadou</surname><given-names>A</given-names></name><name name-style="western"><surname>Giamarellou</surname><given-names>H</given-names></name><name name-style="western"><surname>Armaganidis</surname><given-names>A</given-names></name><name name-style="western"><surname>Cars</surname><given-names>O</given-names></name><name name-style="western"><surname>Friberg</surname><given-names>LE</given-names></name></person-group><article-title>Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill</article-title><source>Antimicrob Agents Chemother</source><year>2012</year><volume>56</volume><fpage>4241</fpage><lpage>4249</lpage><pub-id pub-id-type="doi">10.1128/AAC.06426-11</pub-id><pub-id pub-id-type="pmid">22615285</pub-id><pub-id pub-id-type="pmcid">PMC3421626</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheah</surname><given-names>SE</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>VT</given-names></name><name name-style="western"><surname>Turnidge</surname><given-names>JD</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Nation</surname><given-names>RL</given-names></name></person-group><article-title>New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against <italic toggle="yes">Pseudomonas aeruginosa</italic> and <italic toggle="yes">Acinetobacter baumanni</italic>i in mouse thigh and lung infection models: smaller response in lung infection</article-title><source>J Antimicrob Chemother</source><year>2015</year><volume>70</volume><fpage>3291</fpage><lpage>3297</lpage><pub-id pub-id-type="pmid">26318190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dkv267</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forrest</surname><given-names>A</given-names></name><name name-style="western"><surname>Garonzik</surname><given-names>SM</given-names></name><name name-style="western"><surname>Thamlikitkul</surname><given-names>V</given-names></name><name name-style="western"><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>DL</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Silveira</surname><given-names>FP</given-names></name><name name-style="western"><surname>Nation</surname><given-names>RL</given-names></name></person-group><article-title>Pharmacokinetic/toxicodynamic analysis of colistin-associated acute kidney injury in critically ill patients</article-title><source>Antimicrob Agents Chemother</source><year>2017</year><volume>61</volume><fpage>e01367-17</fpage><pub-id pub-id-type="doi">10.1128/AAC.01367-17</pub-id><pub-id pub-id-type="pmid">28893780</pub-id><pub-id pub-id-type="pmcid">PMC5655114</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phe</surname><given-names>K</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>ML</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>HR</given-names></name><name name-style="western"><surname>Tam</surname><given-names>VH</given-names></name></person-group><article-title>Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><fpage>6946</fpage><lpage>6948</lpage><pub-id pub-id-type="doi">10.1128/AAC.03776-14</pub-id><pub-id pub-id-type="pmid">25136012</pub-id><pub-id pub-id-type="pmcid">PMC4249357</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pogue</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Marchaim</surname><given-names>D</given-names></name><name name-style="western"><surname>Yee</surname><given-names>V</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Chopra</surname><given-names>T</given-names></name><name name-style="western"><surname>Lephart</surname><given-names>P</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>KS</given-names></name></person-group><article-title>Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system</article-title><source>Clin Infect Dis</source><year>2011</year><volume>53</volume><fpage>879</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1093/cid/cir611</pub-id><pub-id pub-id-type="pmid">21900484</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rattanaumpawan</surname><given-names>P</given-names></name><name name-style="western"><surname>Ungprasert</surname><given-names>P</given-names></name><name name-style="western"><surname>Thamlikitkul</surname><given-names>V</given-names></name></person-group><article-title>Risk factors for colistin-associated nephrotoxicity</article-title><source>J Infect</source><year>2011</year><volume>62</volume><fpage>187</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2010.11.013</pub-id><pub-id pub-id-type="pmid">21129401</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horcajada</surname><given-names>JP</given-names></name><name name-style="western"><surname>Sorli</surname><given-names>L</given-names></name><name name-style="western"><surname>Luque</surname><given-names>S</given-names></name><name name-style="western"><surname>Benito</surname><given-names>N</given-names></name><name name-style="western"><surname>Segura</surname><given-names>C</given-names></name><name name-style="western"><surname>Campillo</surname><given-names>N</given-names></name><name name-style="western"><surname>Montero</surname><given-names>M</given-names></name><name name-style="western"><surname>Esteve</surname><given-names>E</given-names></name><name name-style="western"><surname>Mirelis</surname><given-names>B</given-names></name><name name-style="western"><surname>Pomar</surname><given-names>V</given-names></name><name name-style="western"><surname>Cuquet</surname><given-names>J</given-names></name><name name-style="western"><surname>Marti</surname><given-names>C</given-names></name><name name-style="western"><surname>Garro</surname><given-names>P</given-names></name><name name-style="western"><surname>Grau</surname><given-names>S</given-names></name></person-group><article-title>Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate</article-title><source>Int J Antimicrob Agents</source><year>2016</year><volume>48</volume><fpage>725</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2016.08.020</pub-id><pub-id pub-id-type="pmid">28128096</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorli</surname><given-names>L</given-names></name><name name-style="western"><surname>Luque</surname><given-names>S</given-names></name><name name-style="western"><surname>Grau</surname><given-names>S</given-names></name><name name-style="western"><surname>Berenguer</surname><given-names>N</given-names></name><name name-style="western"><surname>Segura</surname><given-names>C</given-names></name><name name-style="western"><surname>Montero</surname><given-names>MM</given-names></name><name name-style="western"><surname>Alvarez-Lerma</surname><given-names>F</given-names></name><name name-style="western"><surname>Knobel</surname><given-names>H</given-names></name><name name-style="western"><surname>Benito</surname><given-names>N</given-names></name><name name-style="western"><surname>Horcajada</surname><given-names>JP</given-names></name></person-group><article-title>Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study</article-title><source>BMC Infect Dis</source><year>2013</year><volume>13</volume><fpage>380</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-13-380</pub-id><pub-id pub-id-type="pmid">23957376</pub-id><pub-id pub-id-type="pmcid">PMC3765824</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nation</surname><given-names>RL</given-names></name><name name-style="western"><surname>Garonzik</surname><given-names>SM</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Thamlikitkul</surname><given-names>V</given-names></name><name name-style="western"><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>DL</given-names></name><name name-style="western"><surname>Turnidge</surname><given-names>JD</given-names></name><name name-style="western"><surname>Forrest</surname><given-names>A</given-names></name><name name-style="western"><surname>Silveira</surname><given-names>FP</given-names></name></person-group><article-title>Updated US and European dose recommendations for intravenous colistin: how do they perform?</article-title><source>Clin Infect Dis</source><year>2016</year><volume>62</volume><fpage>552</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1093/cid/civ964</pub-id><pub-id pub-id-type="pmid">26607424</pub-id><pub-id pub-id-type="pmcid">PMC4741361</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nation</surname><given-names>RL</given-names></name><name name-style="western"><surname>Garonzik</surname><given-names>SM</given-names></name><name name-style="western"><surname>Thamlikitkul</surname><given-names>V</given-names></name><name name-style="western"><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Forrest</surname><given-names>A</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>DL</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Silveira</surname><given-names>FP</given-names></name></person-group><article-title>Dosing guidance for intravenous colistin in critically-ill patients</article-title><source>Clin Infect Dis</source><year>2017</year><volume>64</volume><fpage>565</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">28011614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciw839</pub-id><pub-id pub-id-type="pmcid">PMC5850520</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Landersdorfer</surname><given-names>CB</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wirth</surname><given-names>V</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>KS</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>BT</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Nation</surname><given-names>RL</given-names></name></person-group><article-title>Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against <italic toggle="yes">Klebsiella pneumoniae</italic> in mouse thigh and lung infection models</article-title><source>J Antimicrob Chemother</source><year>2018</year><volume>73</volume><fpage>462</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1093/jac/dkx409</pub-id><pub-id pub-id-type="pmid">29149294</pub-id><pub-id pub-id-type="pmcid">PMC5890666</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lakota</surname><given-names>EA</given-names></name><name name-style="western"><surname>Landersdorfer</surname><given-names>CB</given-names></name><name name-style="western"><surname>Nation</surname><given-names>RL</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>KS</given-names></name><name name-style="western"><surname>Rao</surname><given-names>GG</given-names></name><name name-style="western"><surname>Forrest</surname><given-names>A</given-names></name></person-group><article-title>Personalizing polymyxin B dosing using an adaptive feedback control algorithm</article-title><source>Antimicrob Agents Chemother</source><year>2018</year><volume>62</volume><fpage>e00483-18</fpage><pub-id pub-id-type="doi">10.1128/AAC.00483-18</pub-id><pub-id pub-id-type="pmid">29760144</pub-id><pub-id pub-id-type="pmcid">PMC6021635</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miglis</surname><given-names>C</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Avedissian</surname><given-names>SN</given-names></name><name name-style="western"><surname>Kubin</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Yin</surname><given-names>MT</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>BC</given-names></name><name name-style="western"><surname>Pai</surname><given-names>MP</given-names></name><name name-style="western"><surname>Scheetz</surname><given-names>MH</given-names></name></person-group><article-title>Population pharmacokinetics of polymyxin B in acutely ill adult patients</article-title><source>Antimicrob Agents Chemother</source><year>2018</year><volume>62</volume><fpage>e01475-17</fpage><pub-id pub-id-type="doi">10.1128/AAC.01475-17</pub-id><pub-id pub-id-type="pmid">29311071</pub-id><pub-id pub-id-type="pmcid">PMC5826159</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sandri</surname><given-names>AM</given-names></name><name name-style="western"><surname>Landersdorfer</surname><given-names>CB</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>J</given-names></name><name name-style="western"><surname>Boniatti</surname><given-names>MM</given-names></name><name name-style="western"><surname>Dalarosa</surname><given-names>MG</given-names></name><name name-style="western"><surname>Falci</surname><given-names>DR</given-names></name><name name-style="western"><surname>Behle</surname><given-names>TF</given-names></name><name name-style="western"><surname>Bordinhao</surname><given-names>RC</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Forrest</surname><given-names>A</given-names></name><name name-style="western"><surname>Nation</surname><given-names>RL</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Zavascki</surname><given-names>AP</given-names></name></person-group><article-title>Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens</article-title><source>Clin Infect Dis</source><year>2013</year><volume>57</volume><fpage>524</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1093/cid/cit334</pub-id><pub-id pub-id-type="pmid">23697744</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kubin</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>BC</given-names></name><name name-style="western"><surname>Miglis</surname><given-names>C</given-names></name><name name-style="western"><surname>Scheetz</surname><given-names>MH</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Avedissian</surname><given-names>SN</given-names></name><name name-style="western"><surname>Cremers</surname><given-names>S</given-names></name><name name-style="western"><surname>Yin</surname><given-names>MT</given-names></name></person-group><article-title>Population pharmacokinetics of intravenous polymyxin B from clinical Samples</article-title><source>Antimicrob Agents Chemother</source><year>2018</year><volume>62</volume><fpage>e01493-17</fpage><pub-id pub-id-type="doi">10.1128/AAC.01493-17</pub-id><pub-id pub-id-type="pmid">29311066</pub-id><pub-id pub-id-type="pmcid">PMC5826116</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andes</surname><given-names>D</given-names></name><name name-style="western"><surname>Ambrose</surname><given-names>PG</given-names></name><name name-style="western"><surname>Hammel</surname><given-names>JP</given-names></name><name name-style="western"><surname>Van Wart</surname><given-names>SA</given-names></name><name name-style="western"><surname>Iyer</surname><given-names>V</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>DK</given-names></name><name name-style="western"><surname>Buell</surname><given-names>DN</given-names></name><name name-style="western"><surname>Kovanda</surname><given-names>LL</given-names></name><name name-style="western"><surname>Bhavnani</surname><given-names>SM</given-names></name></person-group><article-title>Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia</article-title><source>Antimicrob Agents Chemother</source><year>2011</year><volume>55</volume><fpage>2113</fpage><lpage>2121</lpage><pub-id pub-id-type="doi">10.1128/AAC.01430-10</pub-id><pub-id pub-id-type="pmid">21300835</pub-id><pub-id pub-id-type="pmcid">PMC3088268</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maseda</surname><given-names>E</given-names></name><name name-style="western"><surname>Grau</surname><given-names>S</given-names></name><name name-style="western"><surname>Luque</surname><given-names>S</given-names></name><name name-style="western"><surname>Castillo-Mafla</surname><given-names>MP</given-names></name><name name-style="western"><surname>Suarez-de-la-Rica</surname><given-names>A</given-names></name><name name-style="western"><surname>Montero-Feijoo</surname><given-names>A</given-names></name><name name-style="western"><surname>Salgado</surname><given-names>P</given-names></name><name name-style="western"><surname>Gimenez</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Garcia-Bernedo</surname><given-names>CA</given-names></name><name name-style="western"><surname>Gilsanz</surname><given-names>F</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name></person-group><article-title>Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients</article-title><source>Crit Care</source><year>2018</year><volume>22</volume><fpage>94</fpage><pub-id pub-id-type="doi">10.1186/s13054-018-2019-8</pub-id><pub-id pub-id-type="pmid">29655372</pub-id><pub-id pub-id-type="pmcid">PMC5899833</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Elst</surname><given-names>KC</given-names></name><name name-style="western"><surname>Veringa</surname><given-names>A</given-names></name><name name-style="western"><surname>Zijlstra</surname><given-names>JG</given-names></name><name name-style="western"><surname>Beishuizen</surname><given-names>A</given-names></name><name name-style="western"><surname>Klont</surname><given-names>R</given-names></name><name name-style="western"><surname>Brummelhuis-Visser</surname><given-names>P</given-names></name><name name-style="western"><surname>Uges</surname><given-names>DR</given-names></name><name name-style="western"><surname>Touw</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Kosterink</surname><given-names>JG</given-names></name><name name-style="western"><surname>van der Werf</surname><given-names>TS</given-names></name><name name-style="western"><surname>Alffenaar</surname><given-names>JC</given-names></name></person-group><article-title>Low caspofungin exposure in patients in intensive care units</article-title><source>Antimicrob Agents Chemother</source><year>2017</year><volume>61</volume><fpage>e01582-16</fpage><pub-id pub-id-type="doi">10.1128/AAC.01582-16</pub-id><pub-id pub-id-type="pmid">27855112</pub-id><pub-id pub-id-type="pmcid">PMC5278683</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lempers</surname><given-names>VJ</given-names></name><name name-style="western"><surname>van Rongen</surname><given-names>A</given-names></name><name name-style="western"><surname>van Dongen</surname><given-names>EP</given-names></name><name name-style="western"><surname>van Ramshorst</surname><given-names>B</given-names></name><name name-style="western"><surname>Burger</surname><given-names>DM</given-names></name><name name-style="western"><surname>Aarnoutse</surname><given-names>RE</given-names></name><name name-style="western"><surname>Knibbe</surname><given-names>CA</given-names></name><name name-style="western"><surname>Bruggemann</surname><given-names>RJ</given-names></name></person-group><article-title>Does weight impact anidulafungin pharmacokinetics?</article-title><source>Clin Pharmacokinet</source><year>2016</year><volume>55</volume><fpage>1289</fpage><lpage>1294</lpage><pub-id pub-id-type="doi">10.1007/s40262-016-0401-8</pub-id><pub-id pub-id-type="pmid">27142114</pub-id><pub-id pub-id-type="pmcid">PMC5021753</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martial</surname><given-names>LC</given-names></name><name name-style="western"><surname>Bruggemann</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Schouten</surname><given-names>JA</given-names></name><name name-style="western"><surname>van Leeuwen</surname><given-names>HJ</given-names></name><name name-style="western"><surname>van Zanten</surname><given-names>AR</given-names></name><name name-style="western"><surname>de Lange</surname><given-names>DW</given-names></name><name name-style="western"><surname>Muilwijk</surname><given-names>EW</given-names></name><name name-style="western"><surname>Verweij</surname><given-names>PE</given-names></name><name name-style="western"><surname>Burger</surname><given-names>DM</given-names></name><name name-style="western"><surname>Aarnoutse</surname><given-names>RE</given-names></name><name name-style="western"><surname>Pickkers</surname><given-names>P</given-names></name><name name-style="western"><surname>Dorlo</surname><given-names>TP</given-names></name></person-group><article-title>Dose reduction of caspofungin in intensive care unit patients with Child Pugh B will result in suboptimal exposure</article-title><source>Clin Pharmacokinet</source><year>2016</year><volume>55</volume><fpage>723</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1007/s40262-015-0347-2</pub-id><pub-id pub-id-type="pmid">26649870</pub-id><pub-id pub-id-type="pmcid">PMC4875935</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Undre</surname><given-names>N</given-names></name><name name-style="western"><surname>Pretorius</surname><given-names>B</given-names></name><name name-style="western"><surname>Stevenson</surname><given-names>P</given-names></name></person-group><article-title>Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction</article-title><source>Eur J Drug Metab Pharmacokinet</source><year>2015</year><volume>40</volume><fpage>285</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1007/s13318-014-0204-y</pub-id><pub-id pub-id-type="pmid">24888485</pub-id><pub-id pub-id-type="pmcid">PMC4552778</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mistry</surname><given-names>GC</given-names></name><name name-style="western"><surname>Migoya</surname><given-names>E</given-names></name><name name-style="western"><surname>Deutsch</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Winchell</surname><given-names>G</given-names></name><name name-style="western"><surname>Hesney</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Bi</surname><given-names>S</given-names></name><name name-style="western"><surname>Dilzer</surname><given-names>S</given-names></name><name name-style="western"><surname>Lasseter</surname><given-names>KC</given-names></name><name name-style="western"><surname>Stone</surname><given-names>JA</given-names></name></person-group><article-title>Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations</article-title><source>J Clin Pharmacol</source><year>2007</year><volume>47</volume><fpage>951</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1177/0091270007303764</pub-id><pub-id pub-id-type="pmid">17660480</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pai</surname><given-names>MP</given-names></name><name name-style="western"><surname>Turpin</surname><given-names>RS</given-names></name><name name-style="western"><surname>Garey</surname><given-names>KW</given-names></name></person-group><article-title>Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia</article-title><source>Antimicrob Agents Chemother</source><year>2007</year><volume>51</volume><fpage>35</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1128/AAC.00474-06</pub-id><pub-id pub-id-type="pmid">17101684</pub-id><pub-id pub-id-type="pmcid">PMC1797664</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez-Tudela</surname><given-names>JL</given-names></name><name name-style="western"><surname>Almirante</surname><given-names>B</given-names></name><name name-style="western"><surname>Rodriguez-Pardo</surname><given-names>D</given-names></name><name name-style="western"><surname>Laguna</surname><given-names>F</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>JP</given-names></name><name name-style="western"><surname>Mouton</surname><given-names>JW</given-names></name><name name-style="western"><surname>Pahissa</surname><given-names>A</given-names></name><name name-style="western"><surname>Cuenca-Estrella</surname><given-names>M</given-names></name></person-group><article-title>Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia</article-title><source>Antimicrob Agents Chemother</source><year>2007</year><volume>51</volume><fpage>3599</fpage><lpage>3604</lpage><pub-id pub-id-type="doi">10.1128/AAC.00296-07</pub-id><pub-id pub-id-type="pmid">17646421</pub-id><pub-id pub-id-type="pmcid">PMC2043257</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Louie</surname><given-names>A</given-names></name><name name-style="western"><surname>Drusano</surname><given-names>GL</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>QF</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Kaw</surname><given-names>P</given-names></name><name name-style="western"><surname>Shayegani</surname><given-names>M</given-names></name><name name-style="western"><surname>Taber</surname><given-names>H</given-names></name><name name-style="western"><surname>Miller</surname><given-names>MH</given-names></name></person-group><article-title>Pharmacodynamics of fluconazole in a murine model of systemic candidiasis</article-title><source>Antimicrob Agents Chemother</source><year>1998</year><volume>42</volume><fpage>1105</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1128/AAC.42.5.1105</pub-id><pub-id pub-id-type="pmid">9593135</pub-id><pub-id pub-id-type="pmcid">PMC105753</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clancy</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Yu</surname><given-names>VL</given-names></name><name name-style="western"><surname>Morris</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Snydman</surname><given-names>DR</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>MH</given-names></name></person-group><article-title>Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia</article-title><source>Antimicrob Agents Chemother</source><year>2005</year><volume>49</volume><fpage>3171</fpage><lpage>3177</lpage><pub-id pub-id-type="doi">10.1128/AAC.49.8.3171-3177.2005</pub-id><pub-id pub-id-type="pmid">16048920</pub-id><pub-id pub-id-type="pmcid">PMC1196236</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anaissie</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Kontoyiannis</surname><given-names>DP</given-names></name><name name-style="western"><surname>Huls</surname><given-names>C</given-names></name><name name-style="western"><surname>Vartivarian</surname><given-names>SE</given-names></name><name name-style="western"><surname>Karl</surname><given-names>C</given-names></name><name name-style="western"><surname>Prince</surname><given-names>RA</given-names></name><name name-style="western"><surname>Bosso</surname><given-names>J</given-names></name><name name-style="western"><surname>Bodey</surname><given-names>GP</given-names></name></person-group><article-title>Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections</article-title><source>J Infect Dis</source><year>1995</year><volume>172</volume><fpage>599</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1093/infdis/172.2.599</pub-id><pub-id pub-id-type="pmid">7622915</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alobaid</surname><given-names>AS</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>SC</given-names></name><name name-style="western"><surname>Jarrett</surname><given-names>P</given-names></name><name name-style="western"><surname>Starr</surname><given-names>T</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>J</given-names></name><name name-style="western"><surname>Lassig-Smith</surname><given-names>M</given-names></name><name name-style="western"><surname>Mejia</surname><given-names>JL</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>MS</given-names></name><name name-style="western"><surname>Sinnollareddy</surname><given-names>MG</given-names></name><name name-style="western"><surname>Roger</surname><given-names>C</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name></person-group><article-title>Effect of obesity on the population pharmacokinetics of fluconazole in critically ill patients</article-title><source>Antimicrob Agents Chemother</source><year>2016</year><volume>60</volume><fpage>6550</fpage><lpage>6557</lpage><pub-id pub-id-type="doi">10.1128/AAC.01088-16</pub-id><pub-id pub-id-type="pmid">27550344</pub-id><pub-id pub-id-type="pmcid">PMC5075058</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vermes</surname><given-names>A</given-names></name><name name-style="western"><surname>van Der Sijs</surname><given-names>H</given-names></name><name name-style="western"><surname>Guchelaar</surname><given-names>HJ</given-names></name></person-group><article-title>Flucytosine: correlation between toxicity and pharmacokinetic parameters</article-title><source>Chemotherapy</source><year>2000</year><volume>46</volume><fpage>86</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1159/000007260</pub-id><pub-id pub-id-type="pmid">10671757</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stamm</surname><given-names>AM</given-names></name><name name-style="western"><surname>Diasio</surname><given-names>RB</given-names></name><name name-style="western"><surname>Dismukes</surname><given-names>WE</given-names></name><name name-style="western"><surname>Shadomy</surname><given-names>S</given-names></name><name name-style="western"><surname>Cloud</surname><given-names>GA</given-names></name><name name-style="western"><surname>Bowles</surname><given-names>CA</given-names></name><name name-style="western"><surname>Karam</surname><given-names>GH</given-names></name><name name-style="western"><surname>Espinel-Ingroff</surname><given-names>A</given-names></name></person-group><article-title>Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis</article-title><source>Am J Med</source><year>1987</year><volume>83</volume><fpage>236</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/0002-9343(87)90691-7</pub-id><pub-id pub-id-type="pmid">3303926</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>JE</given-names></name><name name-style="western"><surname>Dismukes</surname><given-names>WE</given-names></name><name name-style="western"><surname>Duma</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Medoff</surname><given-names>G</given-names></name><name name-style="western"><surname>Sande</surname><given-names>MA</given-names></name><name name-style="western"><surname>Gallis</surname><given-names>H</given-names></name><name name-style="western"><surname>Leonard</surname><given-names>J</given-names></name><name name-style="western"><surname>Fields</surname><given-names>BT</given-names></name><name name-style="western"><surname>Bradshaw</surname><given-names>M</given-names></name><name name-style="western"><surname>Haywood</surname><given-names>H</given-names></name><name name-style="western"><surname>McGee</surname><given-names>ZA</given-names></name><name name-style="western"><surname>Cate</surname><given-names>TR</given-names></name><name name-style="western"><surname>Cobbs</surname><given-names>CG</given-names></name><name name-style="western"><surname>Warner</surname><given-names>JF</given-names></name><name name-style="western"><surname>Alling</surname><given-names>DW</given-names></name></person-group><article-title>A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis</article-title><source>N Engl J Med</source><year>1979</year><volume>301</volume><fpage>126</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1056/NEJM197907193010303</pub-id><pub-id pub-id-type="pmid">449951</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kauffman</surname><given-names>CA</given-names></name><name name-style="western"><surname>Frame</surname><given-names>PT</given-names></name></person-group><article-title>Bone marrow toxicity associated with 5-fluorocytosine therapy</article-title><source>Antimicrob Agents Chemother</source><year>1977</year><volume>11</volume><fpage>244</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1128/AAC.11.2.244</pub-id><pub-id pub-id-type="pmid">848928</pub-id><pub-id pub-id-type="pmcid">PMC351961</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Normark</surname><given-names>S</given-names></name><name name-style="western"><surname>Schonebeck</surname><given-names>J</given-names></name></person-group><article-title>In vitro studies of 5-fluorocytosine resistance in <italic toggle="yes">Candida albicans</italic> and <italic toggle="yes">Torulopsis glabrata</italic></article-title><source>Antimicrob Agents Chemother</source><year>1972</year><volume>2</volume><fpage>114</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1128/AAC.2.3.114</pub-id><pub-id pub-id-type="pmid">4597703</pub-id><pub-id pub-id-type="pmcid">PMC444277</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andes</surname><given-names>D</given-names></name><name name-style="western"><surname>Kovanda</surname><given-names>L</given-names></name><name name-style="western"><surname>Desai</surname><given-names>A</given-names></name><name name-style="western"><surname>Kitt</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>TJ</given-names></name></person-group><article-title>Isavuconazole concentration in real-world practice: consistency with results from clinical trials</article-title><source>Antimicrob Agents Chemother</source><year>2018</year><volume>62</volume><fpage>e00585-18</fpage><pub-id pub-id-type="doi">10.1128/AAC.00585-18</pub-id><pub-id pub-id-type="pmid">29735569</pub-id><pub-id pub-id-type="pmcid">PMC6021624</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desai</surname><given-names>A</given-names></name><name name-style="western"><surname>Kovanda</surname><given-names>L</given-names></name><name name-style="western"><surname>Kowalski</surname><given-names>D</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Townsend</surname><given-names>R</given-names></name><name name-style="western"><surname>Bonate</surname><given-names>PL</given-names></name></person-group><article-title>Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to aspergillus and other filamentous fungi</article-title><source>Antimicrob Agents Chemother</source><year>2016</year><volume>60</volume><fpage>5483</fpage><lpage>5491</lpage><pub-id pub-id-type="doi">10.1128/AAC.02819-15</pub-id><pub-id pub-id-type="pmid">27381396</pub-id><pub-id pub-id-type="pmcid">PMC4997882</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coronel</surname><given-names>B</given-names></name><name name-style="western"><surname>Persat</surname><given-names>F</given-names></name><name name-style="western"><surname>Dorez</surname><given-names>D</given-names></name><name name-style="western"><surname>Moskovtchenko</surname><given-names>JF</given-names></name><name name-style="western"><surname>Peins</surname><given-names>MA</given-names></name><name name-style="western"><surname>Mercatello</surname><given-names>A</given-names></name></person-group><article-title>Itraconazole concentrations during continuous haemodiafiltration</article-title><source>J Antimicrob Chemother</source><year>1994</year><volume>34</volume><fpage>448</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1093/jac/34.3.448</pub-id><pub-id pub-id-type="pmid">7829423</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denning</surname><given-names>DW</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>RM</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>LH</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>DA</given-names></name></person-group><article-title>Treatment of invasive aspergillosis with itraconazole</article-title><source>Am J Med</source><year>1989</year><volume>86</volume><fpage>791</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1016/0002-9343(89)90475-0</pub-id><pub-id pub-id-type="pmid">2543220</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharkey</surname><given-names>PK</given-names></name><name name-style="western"><surname>Rinaldi</surname><given-names>MG</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>JF</given-names></name><name name-style="western"><surname>Hardin</surname><given-names>TC</given-names></name><name name-style="western"><surname>Fetchick</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Graybill</surname><given-names>JR</given-names></name></person-group><article-title>High-dose itraconazole in the treatment of severe mycoses</article-title><source>Antimicrob Agents Chemother</source><year>1991</year><volume>35</volume><fpage>707</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1128/AAC.35.4.707</pub-id><pub-id pub-id-type="pmid">1648887</pub-id><pub-id pub-id-type="pmcid">PMC245083</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denning</surname><given-names>DW</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>RM</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>LH</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>JR</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>DA</given-names></name></person-group><article-title>Itraconazole therapy for cryptococcal meningitis and cryptococcosis</article-title><source>Arch Intern Med</source><year>1989</year><volume>149</volume><fpage>2301</fpage><lpage>2308</lpage><pub-id pub-id-type="doi">10.1001/archinte.1989.00390100107024</pub-id><pub-id pub-id-type="pmid">2552949</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wheat</surname><given-names>J</given-names></name><name name-style="western"><surname>Hafner</surname><given-names>R</given-names></name><name name-style="western"><surname>Korzun</surname><given-names>AH</given-names></name><name name-style="western"><surname>Limjoco</surname><given-names>MT</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>P</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>RA</given-names></name><name name-style="western"><surname>Hecht</surname><given-names>FM</given-names></name><name name-style="western"><surname>Powderly</surname><given-names>W</given-names></name></person-group><article-title>Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group</article-title><source>Am J Med</source><year>1995</year><volume>98</volume><fpage>336</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1016/S0002-9343(99)80311-8</pub-id><pub-id pub-id-type="pmid">7709945</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glasmacher</surname><given-names>A</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>C</given-names></name><name name-style="western"><surname>Leutner</surname><given-names>C</given-names></name><name name-style="western"><surname>Molitor</surname><given-names>E</given-names></name><name name-style="western"><surname>Wardelmann</surname><given-names>E</given-names></name><name name-style="western"><surname>Losem</surname><given-names>C</given-names></name><name name-style="western"><surname>Sauerbruch</surname><given-names>T</given-names></name><name name-style="western"><surname>Marklein</surname><given-names>G</given-names></name><name name-style="western"><surname>Schmidt-Wolf</surname><given-names>IG</given-names></name></person-group><article-title>Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole</article-title><source>Mycoses</source><year>1999</year><volume>42</volume><fpage>443</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1046/j.1439-0507.1999.00505.x</pub-id><pub-id pub-id-type="pmid">10546485</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boogaerts</surname><given-names>MA</given-names></name><name name-style="western"><surname>Verhoef</surname><given-names>GE</given-names></name><name name-style="western"><surname>Zachee</surname><given-names>P</given-names></name><name name-style="western"><surname>Demuynck</surname><given-names>H</given-names></name><name name-style="western"><surname>Verbist</surname><given-names>L</given-names></name><name name-style="western"><surname>De Beule</surname><given-names>K</given-names></name></person-group><article-title>Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels</article-title><source>Mycoses</source><year>1989</year><volume>32</volume><issue>Suppl 1</issue><fpage>103</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1111/j.1439-0507.1989.tb02299.x</pub-id><pub-id pub-id-type="pmid">2561181</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tricot</surname><given-names>G</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>E</given-names></name><name name-style="western"><surname>Boogaerts</surname><given-names>MA</given-names></name><name name-style="western"><surname>VandePitte</surname><given-names>J</given-names></name><name name-style="western"><surname>Cauwenbergh</surname><given-names>G</given-names></name></person-group><article-title>Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies</article-title><source>Rev Infect Dis</source><year>1987</year><volume>9</volume><issue>Suppl 1</issue><fpage>S94</fpage><lpage>S99</lpage><pub-id pub-id-type="pmid">3027853</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/clinids/9.supplement_1.s94</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cross</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Bagg</surname><given-names>J</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>D</given-names></name><name name-style="western"><surname>Warnock</surname><given-names>D</given-names></name></person-group><article-title>Serum itraconazole concentrations and clinical responses in Candida-associated denture stomatitis patients treated with itraconazole solution and itraconazole capsules</article-title><source>J Antimicrob Chemother</source><year>2000</year><volume>45</volume><fpage>95</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1093/jac/45.1.95</pub-id><pub-id pub-id-type="pmid">10629018</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cartledge</surname><given-names>JD</given-names></name><name name-style="western"><surname>Midgely</surname><given-names>J</given-names></name><name name-style="western"><surname>Gazzard</surname><given-names>BG</given-names></name></person-group><article-title>Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis</article-title><source>J Clin Pathol</source><year>1997</year><volume>50</volume><fpage>477</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1136/jcp.50.6.477</pub-id><pub-id pub-id-type="pmid">9378812</pub-id><pub-id pub-id-type="pmcid">PMC499974</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lestner</surname><given-names>JM</given-names></name><name name-style="western"><surname>Denning</surname><given-names>DW</given-names></name></person-group><article-title>Tremor: a newly described adverse event with long-term itraconazole therapy</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2010</year><volume>81</volume><fpage>327</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2009.174706</pub-id><pub-id pub-id-type="pmid">20185472</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lestner</surname><given-names>JM</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>SA</given-names></name><name name-style="western"><surname>Moore</surname><given-names>CB</given-names></name><name name-style="western"><surname>Howard</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Denning</surname><given-names>DW</given-names></name><name name-style="western"><surname>Hope</surname><given-names>WW</given-names></name></person-group><article-title>Toxicodynamics of itraconazole: implications for therapeutic drug monitoring</article-title><source>Clin Infect Dis</source><year>2009</year><volume>49</volume><fpage>928</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1086/605499</pub-id><pub-id pub-id-type="pmid">19681707</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hardin</surname><given-names>TC</given-names></name><name name-style="western"><surname>Graybill</surname><given-names>JR</given-names></name><name name-style="western"><surname>Fetchick</surname><given-names>R</given-names></name><name name-style="western"><surname>Woestenborghs</surname><given-names>R</given-names></name><name name-style="western"><surname>Rinaldi</surname><given-names>MG</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>JG</given-names></name></person-group><article-title>Pharmacokinetics of itraconazole following oral administration to normal volunteers</article-title><source>Antimicrob Agents Chemother</source><year>1988</year><volume>32</volume><fpage>1310</fpage><lpage>1313</lpage><pub-id pub-id-type="doi">10.1128/AAC.32.9.1310</pub-id><pub-id pub-id-type="pmid">2848442</pub-id><pub-id pub-id-type="pmcid">PMC175857</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>WM</given-names></name><name name-style="western"><surname>Schoeppler</surname><given-names>KE</given-names></name><name name-style="western"><surname>Jaeger</surname><given-names>J</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>SW</given-names></name><name name-style="western"><surname>MacLaren</surname><given-names>R</given-names></name><name name-style="western"><surname>Fish</surname><given-names>DN</given-names></name><name name-style="western"><surname>Kiser</surname><given-names>TH</given-names></name></person-group><article-title>Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study</article-title><source>Ann Clin Microbiol Antimicrob</source><year>2017</year><volume>16</volume><fpage>60</fpage><pub-id pub-id-type="doi">10.1186/s12941-017-0235-8</pub-id><pub-id pub-id-type="pmid">28893246</pub-id><pub-id pub-id-type="pmcid">PMC5594434</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Elst</surname><given-names>KC</given-names></name><name name-style="western"><surname>Brouwers</surname><given-names>CH</given-names></name><name name-style="western"><surname>van den Heuvel</surname><given-names>ER</given-names></name><name name-style="western"><surname>van Wanrooy</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Uges</surname><given-names>DR</given-names></name><name name-style="western"><surname>van der Werf</surname><given-names>TS</given-names></name><name name-style="western"><surname>Kosterink</surname><given-names>JG</given-names></name><name name-style="western"><surname>Span</surname><given-names>LF</given-names></name><name name-style="western"><surname>Alffenaar</surname><given-names>JW</given-names></name></person-group><article-title>Subtherapeutic posaconazole exposure and treatment outcome in patients with invasive fungal disease</article-title><source>Ther Drug Monit</source><year>2015</year><volume>37</volume><fpage>766</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1097/FTD.0000000000000235</pub-id><pub-id pub-id-type="pmid">26565789</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dolton</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Bruggemann</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Burger</surname><given-names>DM</given-names></name><name name-style="western"><surname>McLachlan</surname><given-names>AJ</given-names></name></person-group><article-title>Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><fpage>6879</fpage><lpage>6885</lpage><pub-id pub-id-type="doi">10.1128/AAC.03777-14</pub-id><pub-id pub-id-type="pmid">25199779</pub-id><pub-id pub-id-type="pmcid">PMC4249414</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ray</surname><given-names>J</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>L</given-names></name><name name-style="western"><surname>Rudham</surname><given-names>S</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Marriott</surname><given-names>D</given-names></name></person-group><article-title>Posaconazole plasma concentrations in critically ill patients</article-title><source>Ther Drug Monit</source><year>2011</year><volume>33</volume><fpage>387</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1097/FTD.0b013e31821fb197</pub-id><pub-id pub-id-type="pmid">21654350</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walravens</surname><given-names>J</given-names></name><name name-style="western"><surname>Brouwers</surname><given-names>J</given-names></name><name name-style="western"><surname>Spriet</surname><given-names>I</given-names></name><name name-style="western"><surname>Tack</surname><given-names>J</given-names></name><name name-style="western"><surname>Annaert</surname><given-names>P</given-names></name><name name-style="western"><surname>Augustijns</surname><given-names>P</given-names></name></person-group><article-title>Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations</article-title><source>Clin Pharmacokinet</source><year>2011</year><volume>50</volume><fpage>725</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.2165/11592630-000000000-00000</pub-id><pub-id pub-id-type="pmid">21973269</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Meng</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Hao</surname><given-names>R</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name></person-group><article-title>Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis</article-title><source>BMC Infect Dis</source><year>2018</year><volume>18</volume><fpage>155</fpage><pub-id pub-id-type="doi">10.1186/s12879-018-3055-3</pub-id><pub-id pub-id-type="pmid">29609553</pub-id><pub-id pub-id-type="pmcid">PMC5879730</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cattaneo</surname><given-names>C</given-names></name><name name-style="western"><surname>Panzali</surname><given-names>A</given-names></name><name name-style="western"><surname>Passi</surname><given-names>A</given-names></name><name name-style="western"><surname>Borlenghi</surname><given-names>E</given-names></name><name name-style="western"><surname>Lamorgese</surname><given-names>C</given-names></name><name name-style="western"><surname>Petulla</surname><given-names>M</given-names></name><name name-style="western"><surname>Re</surname><given-names>A</given-names></name><name name-style="western"><surname>Caimi</surname><given-names>L</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>G</given-names></name></person-group><article-title>Serum posaconazole levels during acute myeloid leukaemia induction therapy: correlations with breakthrough invasive fungal infections</article-title><source>Mycoses</source><year>2015</year><volume>58</volume><fpage>362</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1111/myc.12326</pub-id><pub-id pub-id-type="pmid">25907298</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eiden</surname><given-names>C</given-names></name><name name-style="western"><surname>Meniane</surname><given-names>JC</given-names></name><name name-style="western"><surname>Peyriere</surname><given-names>H</given-names></name><name name-style="western"><surname>Eymard-Duvernay</surname><given-names>S</given-names></name><name name-style="western"><surname>Le Falher</surname><given-names>G</given-names></name><name name-style="western"><surname>Ceballos</surname><given-names>P</given-names></name><name name-style="western"><surname>Fegueux</surname><given-names>N</given-names></name><name name-style="western"><surname>Cociglio</surname><given-names>M</given-names></name><name name-style="western"><surname>Reynes</surname><given-names>J</given-names></name><name name-style="western"><surname>Hillaire-Buys</surname><given-names>D</given-names></name></person-group><article-title>Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake</article-title><source>Eur J Clin Microbiol Infect Dis</source><year>2012</year><volume>31</volume><fpage>161</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1007/s10096-011-1288-9</pub-id><pub-id pub-id-type="pmid">21611869</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoenigl</surname><given-names>M</given-names></name><name name-style="western"><surname>Raggam</surname><given-names>RB</given-names></name><name name-style="western"><surname>Salzer</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Valentin</surname><given-names>T</given-names></name><name name-style="western"><surname>Valentin</surname><given-names>A</given-names></name><name name-style="western"><surname>Zollner-Schwetz</surname><given-names>I</given-names></name><name name-style="western"><surname>Strohmeier</surname><given-names>AT</given-names></name><name name-style="western"><surname>Seeber</surname><given-names>K</given-names></name><name name-style="western"><surname>Wolfler</surname><given-names>A</given-names></name><name name-style="western"><surname>Sill</surname><given-names>H</given-names></name><name name-style="western"><surname>Krause</surname><given-names>R</given-names></name></person-group><article-title>Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies</article-title><source>Int J Antimicrob Agents</source><year>2012</year><volume>39</volume><fpage>510</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2012.02.002</pub-id><pub-id pub-id-type="pmid">22481057</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tonini</surname><given-names>J</given-names></name><name name-style="western"><surname>Thiebaut</surname><given-names>A</given-names></name><name name-style="western"><surname>Jourdil</surname><given-names>JF</given-names></name><name name-style="western"><surname>Berruyer</surname><given-names>AS</given-names></name><name name-style="western"><surname>Bulabois</surname><given-names>CE</given-names></name><name name-style="western"><surname>Cahn</surname><given-names>JY</given-names></name><name name-style="western"><surname>Stanke-Labesque</surname><given-names>F</given-names></name></person-group><article-title>Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease</article-title><source>Antimicrob Agents Chemother</source><year>2012</year><volume>56</volume><fpage>5247</fpage><lpage>5252</lpage><pub-id pub-id-type="doi">10.1128/AAC.00815-12</pub-id><pub-id pub-id-type="pmid">22850515</pub-id><pub-id pub-id-type="pmcid">PMC3457412</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bryant</surname><given-names>AM</given-names></name><name name-style="western"><surname>Slain</surname><given-names>D</given-names></name><name name-style="western"><surname>Cumpston</surname><given-names>A</given-names></name><name name-style="western"><surname>Craig</surname><given-names>M</given-names></name></person-group><article-title>A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis</article-title><source>Int J Antimicrob Agents</source><year>2011</year><volume>37</volume><fpage>266</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2010.11.021</pub-id><pub-id pub-id-type="pmid">21236645</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shields</surname><given-names>RK</given-names></name><name name-style="western"><surname>Clancy</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Vadnerkar</surname><given-names>A</given-names></name><name name-style="western"><surname>Kwak</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Silveira</surname><given-names>FP</given-names></name><name name-style="western"><surname>Massih</surname><given-names>RC</given-names></name><name name-style="western"><surname>Pilewski</surname><given-names>JM</given-names></name><name name-style="western"><surname>Crespo</surname><given-names>M</given-names></name><name name-style="western"><surname>Toyoda</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bhama</surname><given-names>JK</given-names></name><name name-style="western"><surname>Bermudez</surname><given-names>C</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>MH</given-names></name></person-group><article-title>Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy</article-title><source>Antimicrob Agents Chemother</source><year>2011</year><volume>55</volume><fpage>1308</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1128/AAC.01325-10</pub-id><pub-id pub-id-type="pmid">21189337</pub-id><pub-id pub-id-type="pmcid">PMC3067082</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lebeaux</surname><given-names>D</given-names></name><name name-style="western"><surname>Lanternier</surname><given-names>F</given-names></name><name name-style="western"><surname>Elie</surname><given-names>C</given-names></name><name name-style="western"><surname>Suarez</surname><given-names>F</given-names></name><name name-style="western"><surname>Buzyn</surname><given-names>A</given-names></name><name name-style="western"><surname>Viard</surname><given-names>JP</given-names></name><name name-style="western"><surname>Bougnoux</surname><given-names>ME</given-names></name><name name-style="western"><surname>Lecuit</surname><given-names>M</given-names></name><name name-style="western"><surname>Jullien</surname><given-names>V</given-names></name><name name-style="western"><surname>Lortholary</surname><given-names>O</given-names></name></person-group><article-title>Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults</article-title><source>Antimicrob Agents Chemother</source><year>2009</year><volume>53</volume><fpage>5224</fpage><lpage>5229</lpage><pub-id pub-id-type="doi">10.1128/AAC.00939-09</pub-id><pub-id pub-id-type="pmid">19752284</pub-id><pub-id pub-id-type="pmcid">PMC2786318</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>SH</given-names></name><name name-style="western"><surname>Colangelo</surname><given-names>PM</given-names></name><name name-style="western"><surname>Gobburu</surname><given-names>JV</given-names></name></person-group><article-title>Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma</article-title><source>Clin Pharmacol Ther</source><year>2010</year><volume>88</volume><fpage>115</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1038/clpt.2010.64</pub-id><pub-id pub-id-type="pmid">20505665</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Raad</surname><given-names>I</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>TF</given-names></name><name name-style="western"><surname>Chandrasekar</surname><given-names>P</given-names></name><name name-style="western"><surname>Donowitz</surname><given-names>GR</given-names></name><name name-style="western"><surname>Graybill</surname><given-names>R</given-names></name><name name-style="western"><surname>Greene</surname><given-names>RE</given-names></name><name name-style="western"><surname>Hachem</surname><given-names>R</given-names></name><name name-style="western"><surname>Hadley</surname><given-names>S</given-names></name><name name-style="western"><surname>Herbrecht</surname><given-names>R</given-names></name><name name-style="western"><surname>Langston</surname><given-names>A</given-names></name><name name-style="western"><surname>Louie</surname><given-names>A</given-names></name><name name-style="western"><surname>Ribaud</surname><given-names>P</given-names></name><name name-style="western"><surname>Segal</surname><given-names>BH</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>DA</given-names></name><name name-style="western"><surname>van Burik</surname><given-names>JA</given-names></name><name name-style="western"><surname>White</surname><given-names>CS</given-names></name><name name-style="western"><surname>Corcoran</surname><given-names>G</given-names></name><name name-style="western"><surname>Gogate</surname><given-names>J</given-names></name><name name-style="western"><surname>Krishna</surname><given-names>G</given-names></name><name name-style="western"><surname>Pedicone</surname><given-names>L</given-names></name><name name-style="western"><surname>Hardalo</surname><given-names>C</given-names></name><name name-style="western"><surname>Perfect</surname><given-names>JR</given-names></name></person-group><article-title>Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial</article-title><source>Clin Infect Dis</source><year>2007</year><volume>44</volume><fpage>2</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1086/508774</pub-id><pub-id pub-id-type="pmid">17143808</pub-id></element-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boglione-Kerrien</surname><given-names>C</given-names></name><name name-style="western"><surname>Picard</surname><given-names>S</given-names></name><name name-style="western"><surname>Tron</surname><given-names>C</given-names></name><name name-style="western"><surname>Nimubona</surname><given-names>S</given-names></name><name name-style="western"><surname>Gangneux</surname><given-names>JP</given-names></name><name name-style="western"><surname>Lalanne</surname><given-names>S</given-names></name><name name-style="western"><surname>Lemaitre</surname><given-names>F</given-names></name><name name-style="western"><surname>Bellissant</surname><given-names>E</given-names></name><name name-style="western"><surname>Verdier</surname><given-names>MC</given-names></name><name name-style="western"><surname>Petitcollin</surname><given-names>A</given-names></name></person-group><article-title>Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies</article-title><source>J Cancer Res Clin Oncol</source><year>2018</year><volume>144</volume><fpage>127</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1007/s00432-017-2523-2</pub-id><pub-id pub-id-type="pmid">28932906</pub-id><pub-id pub-id-type="pmcid">PMC11813287</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cornely</surname><given-names>OA</given-names></name><name name-style="western"><surname>Duarte</surname><given-names>RF</given-names></name><name name-style="western"><surname>Haider</surname><given-names>S</given-names></name><name name-style="western"><surname>Chandrasekar</surname><given-names>P</given-names></name><name name-style="western"><surname>Helfgott</surname><given-names>D</given-names></name><name name-style="western"><surname>Jimenez</surname><given-names>JL</given-names></name><name name-style="western"><surname>Candoni</surname><given-names>A</given-names></name><name name-style="western"><surname>Raad</surname><given-names>I</given-names></name><name name-style="western"><surname>Laverdiere</surname><given-names>M</given-names></name><name name-style="western"><surname>Langston</surname><given-names>A</given-names></name><name name-style="western"><surname>Kartsonis</surname><given-names>N</given-names></name><name name-style="western"><surname>Van Iersel</surname><given-names>M</given-names></name><name name-style="western"><surname>Connelly</surname><given-names>N</given-names></name><name name-style="western"><surname>Waskin</surname><given-names>H</given-names></name></person-group><article-title>Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease</article-title><source>J Antimicrob Chemother</source><year>2016</year><volume>71</volume><fpage>1747</fpage><pub-id pub-id-type="doi">10.1093/jac/dkw079</pub-id><pub-id pub-id-type="pmid">26960721</pub-id><pub-id pub-id-type="pmcid">PMC7297299</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duarte</surname><given-names>RF</given-names></name><name name-style="western"><surname>Lopez-Jimenez</surname><given-names>J</given-names></name><name name-style="western"><surname>Cornely</surname><given-names>OA</given-names></name><name name-style="western"><surname>Laverdiere</surname><given-names>M</given-names></name><name name-style="western"><surname>Helfgott</surname><given-names>D</given-names></name><name name-style="western"><surname>Haider</surname><given-names>S</given-names></name><name name-style="western"><surname>Chandrasekar</surname><given-names>P</given-names></name><name name-style="western"><surname>Langston</surname><given-names>A</given-names></name><name name-style="western"><surname>Perfect</surname><given-names>J</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>van Iersel</surname><given-names>ML</given-names></name><name name-style="western"><surname>Connelly</surname><given-names>N</given-names></name><name name-style="western"><surname>Kartsonis</surname><given-names>N</given-names></name><name name-style="western"><surname>Waskin</surname><given-names>H</given-names></name></person-group><article-title>Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><fpage>5758</fpage><lpage>5765</lpage><pub-id pub-id-type="doi">10.1128/AAC.03050-14</pub-id><pub-id pub-id-type="pmid">25049247</pub-id><pub-id pub-id-type="pmcid">PMC4187965</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maertens</surname><given-names>J</given-names></name><name name-style="western"><surname>Cornely</surname><given-names>OA</given-names></name><name name-style="western"><surname>Ullmann</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Heinz</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Krishna</surname><given-names>G</given-names></name><name name-style="western"><surname>Patino</surname><given-names>H</given-names></name><name name-style="western"><surname>Caceres</surname><given-names>M</given-names></name><name name-style="western"><surname>Kartsonis</surname><given-names>N</given-names></name><name name-style="western"><surname>Waskin</surname><given-names>H</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>MN</given-names></name></person-group><article-title>Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><fpage>3610</fpage><lpage>3617</lpage><pub-id pub-id-type="doi">10.1128/AAC.02686-13</pub-id><pub-id pub-id-type="pmid">24733463</pub-id><pub-id pub-id-type="pmcid">PMC4068540</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sime</surname><given-names>FB</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>J</given-names></name><name name-style="western"><surname>Butler</surname><given-names>J</given-names></name><name name-style="western"><surname>Starr</surname><given-names>T</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>SC</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>S</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name></person-group><article-title>Pharmacokinetics of intravenous posaconazole in critically ill patients</article-title><source>Antimicrob Agents Chemother</source><year>2018</year><volume>62</volume><fpage>e00242-18</fpage><pub-id pub-id-type="doi">10.1128/AAC.00242-18</pub-id><pub-id pub-id-type="pmid">29581122</pub-id><pub-id pub-id-type="pmcid">PMC5971586</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagappan</surname><given-names>V</given-names></name><name name-style="western"><surname>Deresinski</surname><given-names>S</given-names></name></person-group><article-title>Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent</article-title><source>Clin Infect Dis</source><year>2007</year><volume>45</volume><fpage>1610</fpage><lpage>1617</lpage><pub-id pub-id-type="doi">10.1086/523576</pub-id><pub-id pub-id-type="pmid">18190324</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hashemizadeh</surname><given-names>Z</given-names></name><name name-style="western"><surname>Badiee</surname><given-names>P</given-names></name><name name-style="western"><surname>Malekhoseini</surname><given-names>SA</given-names></name><name name-style="western"><surname>Raeisi Shahraki</surname><given-names>H</given-names></name><name name-style="western"><surname>Geramizadeh</surname><given-names>B</given-names></name><name name-style="western"><surname>Montaseri</surname><given-names>H</given-names></name></person-group><article-title>Observational study of associations between voriconazole therapeutic drug monitoring, toxicity, and outcome in liver transplant patients</article-title><source>Antimicrob Agents Chemother</source><year>2017</year><volume>61</volume><fpage>e01211-17</fpage><pub-id pub-id-type="doi">10.1128/AAC.01211-17</pub-id><pub-id pub-id-type="pmid">28923870</pub-id><pub-id pub-id-type="pmcid">PMC5700347</pub-id></element-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoenigl</surname><given-names>M</given-names></name><name name-style="western"><surname>Duettmann</surname><given-names>W</given-names></name><name name-style="western"><surname>Raggam</surname><given-names>RB</given-names></name><name name-style="western"><surname>Seeber</surname><given-names>K</given-names></name><name name-style="western"><surname>Troppan</surname><given-names>K</given-names></name><name name-style="western"><surname>Fruhwald</surname><given-names>S</given-names></name><name name-style="western"><surname>Prueller</surname><given-names>F</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>J</given-names></name><name name-style="western"><surname>Valentin</surname><given-names>T</given-names></name><name name-style="western"><surname>Zollner-Schwetz</surname><given-names>I</given-names></name><name name-style="western"><surname>Wolfler</surname><given-names>A</given-names></name><name name-style="western"><surname>Krause</surname><given-names>R</given-names></name></person-group><article-title>Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies</article-title><source>Antimicrob Agents Chemother</source><year>2013</year><volume>57</volume><fpage>3262</fpage><lpage>3267</lpage><pub-id pub-id-type="doi">10.1128/AAC.00251-13</pub-id><pub-id pub-id-type="pmid">23629724</pub-id><pub-id pub-id-type="pmcid">PMC3697337</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dolton</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Ray</surname><given-names>JE</given-names></name><name name-style="western"><surname>Chen</surname><given-names>SC</given-names></name><name name-style="western"><surname>Ng</surname><given-names>K</given-names></name><name name-style="western"><surname>Pont</surname><given-names>LG</given-names></name><name name-style="western"><surname>McLachlan</surname><given-names>AJ</given-names></name></person-group><article-title>Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring</article-title><source>Antimicrob Agents Chemother</source><year>2012</year><volume>56</volume><fpage>4793</fpage><lpage>4799</lpage><pub-id pub-id-type="doi">10.1128/AAC.00626-12</pub-id><pub-id pub-id-type="pmid">22751544</pub-id><pub-id pub-id-type="pmcid">PMC3421881</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomez-Lopez</surname><given-names>A</given-names></name><name name-style="western"><surname>Cendejas-Bueno</surname><given-names>E</given-names></name><name name-style="western"><surname>Cuesta</surname><given-names>I</given-names></name><name name-style="western"><surname>Garcia Rodriguez</surname><given-names>J</given-names></name><name name-style="western"><surname>Rodriguez-Tudela</surname><given-names>JL</given-names></name><name name-style="western"><surname>Gutierrez-Altes</surname><given-names>A</given-names></name><name name-style="western"><surname>Cuenca-Estrella</surname><given-names>M</given-names></name></person-group><article-title>Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients</article-title><source>Med Mycol</source><year>2012</year><volume>50</volume><fpage>439</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.3109/13693786.2011.630039</pub-id><pub-id pub-id-type="pmid">22070341</pub-id></element-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>WB</given-names></name><name name-style="western"><surname>Kim</surname><given-names>NH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name><name name-style="western"><surname>Nam</surname><given-names>WS</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>SH</given-names></name><name name-style="western"><surname>Song</surname><given-names>KH</given-names></name><name name-style="western"><surname>Choe</surname><given-names>PG</given-names></name><name name-style="western"><surname>Kim</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Jang</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Oh</surname><given-names>MD</given-names></name><name name-style="western"><surname>Yu</surname><given-names>KS</given-names></name></person-group><article-title>The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial</article-title><source>Clin Infect Dis</source><year>2012</year><volume>55</volume><fpage>1080</fpage><lpage>1087</lpage><pub-id pub-id-type="doi">10.1093/cid/cis599</pub-id><pub-id pub-id-type="pmid">22761409</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pascual</surname><given-names>A</given-names></name><name name-style="western"><surname>Csajka</surname><given-names>C</given-names></name><name name-style="western"><surname>Buclin</surname><given-names>T</given-names></name><name name-style="western"><surname>Bolay</surname><given-names>S</given-names></name><name name-style="western"><surname>Bille</surname><given-names>J</given-names></name><name name-style="western"><surname>Calandra</surname><given-names>T</given-names></name><name name-style="western"><surname>Marchetti</surname><given-names>O</given-names></name></person-group><article-title>Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections</article-title><source>Clin Infect Dis</source><year>2012</year><volume>55</volume><fpage>381</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1093/cid/cis437</pub-id><pub-id pub-id-type="pmid">22610925</pub-id></element-citation></ref><ref id="CR165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pascual</surname><given-names>A</given-names></name><name name-style="western"><surname>Calandra</surname><given-names>T</given-names></name><name name-style="western"><surname>Bolay</surname><given-names>S</given-names></name><name name-style="western"><surname>Buclin</surname><given-names>T</given-names></name><name name-style="western"><surname>Bille</surname><given-names>J</given-names></name><name name-style="western"><surname>Marchetti</surname><given-names>O</given-names></name></person-group><article-title>Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes</article-title><source>Clin Infect Dis</source><year>2008</year><volume>46</volume><fpage>201</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1086/524669</pub-id><pub-id pub-id-type="pmid">18171251</pub-id></element-citation></ref><ref id="CR166"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyakis</surname><given-names>S</given-names></name><name name-style="western"><surname>van Hal</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Ray</surname><given-names>J</given-names></name><name name-style="western"><surname>Marriott</surname><given-names>D</given-names></name></person-group><article-title>Voriconazole concentrations and outcome of invasive fungal infections</article-title><source>Clin Microbiol Infect</source><year>2010</year><volume>16</volume><fpage>927</fpage><lpage>933</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2009.02990.x</pub-id><pub-id pub-id-type="pmid">19845698</pub-id></element-citation></ref><ref id="CR167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueda</surname><given-names>K</given-names></name><name name-style="western"><surname>Nannya</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kumano</surname><given-names>K</given-names></name><name name-style="western"><surname>Hangaishi</surname><given-names>A</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Imai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kurokawa</surname><given-names>M</given-names></name></person-group><article-title>Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders</article-title><source>Int J Hematol</source><year>2009</year><volume>89</volume><fpage>592</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1007/s12185-009-0296-3</pub-id><pub-id pub-id-type="pmid">19340528</pub-id></element-citation></ref><ref id="CR168"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>J</given-names></name><name name-style="western"><surname>Safdar</surname><given-names>N</given-names></name><name name-style="western"><surname>Knasinski</surname><given-names>V</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>W</given-names></name><name name-style="western"><surname>Bhavnani</surname><given-names>SM</given-names></name><name name-style="western"><surname>Ambrose</surname><given-names>PG</given-names></name><name name-style="western"><surname>Andes</surname><given-names>D</given-names></name></person-group><article-title>Voriconazole therapeutic drug monitoring</article-title><source>Antimicrob Agents Chemother</source><year>2006</year><volume>50</volume><fpage>1570</fpage><lpage>1572</lpage><pub-id pub-id-type="doi">10.1128/AAC.50.4.1570-1572.2006</pub-id><pub-id pub-id-type="pmid">16569888</pub-id><pub-id pub-id-type="pmcid">PMC1426935</pub-id></element-citation></ref><ref id="CR169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Troke</surname><given-names>PF</given-names></name><name name-style="western"><surname>Hockey</surname><given-names>HP</given-names></name><name name-style="western"><surname>Hope</surname><given-names>WW</given-names></name></person-group><article-title>Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients</article-title><source>Antimicrob Agents Chemother</source><year>2011</year><volume>55</volume><fpage>4782</fpage><lpage>4788</lpage><pub-id pub-id-type="doi">10.1128/AAC.01083-10</pub-id><pub-id pub-id-type="pmid">21768513</pub-id><pub-id pub-id-type="pmcid">PMC3186950</pub-id></element-citation></ref><ref id="CR170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitsani</surname><given-names>D</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>MH</given-names></name><name name-style="western"><surname>Shields</surname><given-names>RK</given-names></name><name name-style="western"><surname>Toyoda</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kwak</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Silveira</surname><given-names>FP</given-names></name><name name-style="western"><surname>Pilewski</surname><given-names>JM</given-names></name><name name-style="western"><surname>Crespo</surname><given-names>MM</given-names></name><name name-style="western"><surname>Bermudez</surname><given-names>C</given-names></name><name name-style="western"><surname>Bhama</surname><given-names>JK</given-names></name><name name-style="western"><surname>Clancy</surname><given-names>CJ</given-names></name></person-group><article-title>Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity</article-title><source>Antimicrob Agents Chemother</source><year>2012</year><volume>56</volume><fpage>2371</fpage><lpage>2377</lpage><pub-id pub-id-type="doi">10.1128/AAC.05219-11</pub-id><pub-id pub-id-type="pmid">22330924</pub-id><pub-id pub-id-type="pmcid">PMC3346665</pub-id></element-citation></ref><ref id="CR171"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trifilio</surname><given-names>S</given-names></name><name name-style="western"><surname>Singhal</surname><given-names>S</given-names></name><name name-style="western"><surname>Williams</surname><given-names>S</given-names></name><name name-style="western"><surname>Frankfurt</surname><given-names>O</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>L</given-names></name><name name-style="western"><surname>Evens</surname><given-names>A</given-names></name><name name-style="western"><surname>Winter</surname><given-names>J</given-names></name><name name-style="western"><surname>Tallman</surname><given-names>M</given-names></name><name name-style="western"><surname>Pi</surname><given-names>J</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>J</given-names></name></person-group><article-title>Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole</article-title><source>Bone Marrow Transplant</source><year>2007</year><volume>40</volume><fpage>451</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1038/sj.bmt.1705754</pub-id><pub-id pub-id-type="pmid">17589527</pub-id></element-citation></ref><ref id="CR172"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tokimatsu</surname><given-names>I</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kawasaki</surname><given-names>K</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Goto</surname><given-names>T</given-names></name><name name-style="western"><surname>Hashinaga</surname><given-names>K</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>H</given-names></name><name name-style="western"><surname>Hiramatsu</surname><given-names>K</given-names></name><name name-style="western"><surname>Kadota</surname><given-names>J</given-names></name></person-group><article-title>Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity</article-title><source>Clin Chim Acta</source><year>2013</year><volume>424</volume><fpage>119</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2013.05.025</pub-id><pub-id pub-id-type="pmid">23747486</pub-id></element-citation></ref><ref id="CR173"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>SH</given-names></name><name name-style="western"><surname>Yim</surname><given-names>DS</given-names></name><name name-style="western"><surname>Choi</surname><given-names>SM</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>JC</given-names></name><name name-style="western"><surname>Han</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>DG</given-names></name><name name-style="western"><surname>Park</surname><given-names>C</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>EY</given-names></name><name name-style="western"><surname>Park</surname><given-names>SH</given-names></name><name name-style="western"><surname>Choi</surname><given-names>JH</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>JH</given-names></name></person-group><article-title>Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients</article-title><source>Int J Infect Dis</source><year>2011</year><volume>15</volume><fpage>e753</fpage><lpage>e758</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2011.06.004</pub-id><pub-id pub-id-type="pmid">21831685</pub-id></element-citation></ref><ref id="CR174"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsumoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Ikawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Abematsu</surname><given-names>K</given-names></name><name name-style="western"><surname>Fukunaga</surname><given-names>N</given-names></name><name name-style="western"><surname>Nishida</surname><given-names>K</given-names></name><name name-style="western"><surname>Fukamizu</surname><given-names>T</given-names></name><name name-style="western"><surname>Shimodozono</surname><given-names>Y</given-names></name><name name-style="western"><surname>Morikawa</surname><given-names>N</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>K</given-names></name></person-group><article-title>Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes</article-title><source>Int J Antimicrob Agents</source><year>2009</year><volume>34</volume><fpage>91</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2009.01.008</pub-id><pub-id pub-id-type="pmid">19261446</pub-id></element-citation></ref><ref id="CR175"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imhof</surname><given-names>A</given-names></name><name name-style="western"><surname>Schaer</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Schanz</surname><given-names>U</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>U</given-names></name></person-group><article-title>Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring</article-title><source>Swiss Med Wkly</source><year>2006</year><volume>136</volume><fpage>739</fpage><lpage>742</lpage><pub-id pub-id-type="pmid">17183438</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4414/smw.2006.11547</pub-id></element-citation></ref><ref id="CR176"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veringa</surname><given-names>A</given-names></name><name name-style="western"><surname>Ter Avest</surname><given-names>M</given-names></name><name name-style="western"><surname>Span</surname><given-names>LF</given-names></name><name name-style="western"><surname>van den Heuvel</surname><given-names>ER</given-names></name><name name-style="western"><surname>Touw</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Zijlstra</surname><given-names>JG</given-names></name><name name-style="western"><surname>Kosterink</surname><given-names>JG</given-names></name><name name-style="western"><surname>van der Werf</surname><given-names>TS</given-names></name><name name-style="western"><surname>Alffenaar</surname><given-names>JC</given-names></name></person-group><article-title>Voriconazole metabolism is influenced by severe inflammation: a prospective study</article-title><source>J Antimicrob Chemother</source><year>2017</year><volume>72</volume><fpage>261</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1093/jac/dkw349</pub-id><pub-id pub-id-type="pmid">27601292</pub-id></element-citation></ref><ref id="CR177"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Encalada Ventura</surname><given-names>MA</given-names></name><name name-style="western"><surname>van Wanrooy</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Span</surname><given-names>LF</given-names></name><name name-style="western"><surname>Rodgers</surname><given-names>MG</given-names></name><name name-style="western"><surname>van den Heuvel</surname><given-names>ER</given-names></name><name name-style="western"><surname>Uges</surname><given-names>DR</given-names></name><name name-style="western"><surname>van der Werf</surname><given-names>TS</given-names></name><name name-style="western"><surname>Kosterink</surname><given-names>JG</given-names></name><name name-style="western"><surname>Alffenaar</surname><given-names>JW</given-names></name></person-group><article-title>Longitudinal analysis of the effect of inflammation on voriconazole trough concentrations</article-title><source>Antimicrob Agents Chemother</source><year>2016</year><volume>60</volume><fpage>2727</fpage><lpage>2731</lpage><pub-id pub-id-type="doi">10.1128/AAC.02830-15</pub-id><pub-id pub-id-type="pmid">26883707</pub-id><pub-id pub-id-type="pmcid">PMC4862487</pub-id></element-citation></ref><ref id="CR178"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Wanrooy</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Span</surname><given-names>LF</given-names></name><name name-style="western"><surname>Rodgers</surname><given-names>MG</given-names></name><name name-style="western"><surname>van den Heuvel</surname><given-names>ER</given-names></name><name name-style="western"><surname>Uges</surname><given-names>DR</given-names></name><name name-style="western"><surname>van der Werf</surname><given-names>TS</given-names></name><name name-style="western"><surname>Kosterink</surname><given-names>JG</given-names></name><name name-style="western"><surname>Alffenaar</surname><given-names>JW</given-names></name></person-group><article-title>Inflammation is associated with voriconazole trough concentrations</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><fpage>7098</fpage><lpage>7101</lpage><pub-id pub-id-type="doi">10.1128/AAC.03820-14</pub-id><pub-id pub-id-type="pmid">25223994</pub-id><pub-id pub-id-type="pmcid">PMC4249508</pub-id></element-citation></ref><ref id="CR179"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tod</surname><given-names>M</given-names></name><name name-style="western"><surname>Lokiec</surname><given-names>F</given-names></name><name name-style="western"><surname>Bidault</surname><given-names>R</given-names></name><name name-style="western"><surname>De Bony</surname><given-names>F</given-names></name><name name-style="western"><surname>Petitjean</surname><given-names>O</given-names></name><name name-style="western"><surname>Aujard</surname><given-names>Y</given-names></name></person-group><article-title>Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis</article-title><source>Antimicrob Agents Chemother</source><year>2001</year><volume>45</volume><fpage>150</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1128/AAC.45.1.150-157.2001</pub-id><pub-id pub-id-type="pmid">11120958</pub-id><pub-id pub-id-type="pmcid">PMC90253</pub-id></element-citation></ref><ref id="CR180"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saiag</surname><given-names>P</given-names></name><name name-style="western"><surname>Praindhui</surname><given-names>D</given-names></name><name name-style="western"><surname>Chastang</surname><given-names>C</given-names></name></person-group><article-title>A double-blind, randomized study assessing the equivalence of valacyclovir 1000&#160;mg once daily versus 500&#160;mg twice daily in the episodic treatment of recurrent genital herpes</article-title><source>Genival Study Group. J Antimicrob Chemother</source><year>1999</year><volume>44</volume><fpage>525</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1093/jac/44.4.525</pub-id><pub-id pub-id-type="pmid">10588314</pub-id></element-citation></ref><ref id="CR181"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reitano</surname><given-names>M</given-names></name><name name-style="western"><surname>Tyring</surname><given-names>S</given-names></name><name name-style="western"><surname>Lang</surname><given-names>W</given-names></name><name name-style="western"><surname>Thoming</surname><given-names>C</given-names></name><name name-style="western"><surname>Worm</surname><given-names>AM</given-names></name><name name-style="western"><surname>Borelli</surname><given-names>S</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>LO</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>JM</given-names></name><name name-style="western"><surname>Corey</surname><given-names>L</given-names></name></person-group><article-title>Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group</article-title><source>J Infect Dis</source><year>1998</year><volume>178</volume><fpage>603</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1086/515385</pub-id><pub-id pub-id-type="pmid">9728526</pub-id></element-citation></ref><ref id="CR182"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spruance</surname><given-names>SL</given-names></name><name name-style="western"><surname>Tyring</surname><given-names>SK</given-names></name><name name-style="western"><surname>DeGregorio</surname><given-names>B</given-names></name><name name-style="western"><surname>Miller</surname><given-names>C</given-names></name><name name-style="western"><surname>Beutner</surname><given-names>K</given-names></name></person-group><article-title>A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group</article-title><source>Arch Intern Med</source><year>1996</year><volume>156</volume><fpage>1729</fpage><lpage>1735</lpage><pub-id pub-id-type="doi">10.1001/archinte.1996.00440140169018</pub-id><pub-id pub-id-type="pmid">8694673</pub-id></element-citation></ref><ref id="CR183"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weller</surname><given-names>S</given-names></name><name name-style="western"><surname>Blum</surname><given-names>MR</given-names></name><name name-style="western"><surname>Doucette</surname><given-names>M</given-names></name><name name-style="western"><surname>Burnette</surname><given-names>T</given-names></name><name name-style="western"><surname>Cederberg</surname><given-names>DM</given-names></name><name name-style="western"><surname>de Miranda</surname><given-names>P</given-names></name><name name-style="western"><surname>Smiley</surname><given-names>ML</given-names></name></person-group><article-title>Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers</article-title><source>Clin Pharmacol Ther</source><year>1993</year><volume>54</volume><fpage>595</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1038/clpt.1993.196</pub-id><pub-id pub-id-type="pmid">8275615</pub-id></element-citation></ref><ref id="CR184"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chowdhury</surname><given-names>MA</given-names></name><name name-style="western"><surname>Derar</surname><given-names>N</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>S</given-names></name><name name-style="western"><surname>Hinch</surname><given-names>B</given-names></name><name name-style="western"><surname>Ratnam</surname><given-names>S</given-names></name><name name-style="western"><surname>Assaly</surname><given-names>R</given-names></name></person-group><article-title>Acyclovir-induced neurotoxicity: a case report and review of literature</article-title><source>Am J Ther</source><year>2016</year><volume>23</volume><fpage>e941</fpage><lpage>e943</lpage><pub-id pub-id-type="doi">10.1097/MJT.0000000000000093</pub-id><pub-id pub-id-type="pmid">24942005</pub-id></element-citation></ref><ref id="CR185"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bradley</surname><given-names>J</given-names></name><name name-style="western"><surname>Forero</surname><given-names>N</given-names></name><name name-style="western"><surname>Pho</surname><given-names>H</given-names></name><name name-style="western"><surname>Escobar</surname><given-names>B</given-names></name><name name-style="western"><surname>Kasinath</surname><given-names>BS</given-names></name><name name-style="western"><surname>Anzueto</surname><given-names>A</given-names></name></person-group><article-title>Progressive somnolence leading to coma in a 68-year-old man</article-title><source>Chest</source><year>1997</year><volume>112</volume><fpage>538</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1378/chest.112.2.538</pub-id><pub-id pub-id-type="pmid">9266897</pub-id></element-citation></ref><ref id="CR186"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haefeli</surname><given-names>WE</given-names></name><name name-style="western"><surname>Schoenenberger</surname><given-names>RA</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>P</given-names></name><name name-style="western"><surname>Ritz</surname><given-names>RF</given-names></name></person-group><article-title>Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose</article-title><source>Am J Med</source><year>1993</year><volume>94</volume><fpage>212</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1016/0002-9343(93)90186-S</pub-id><pub-id pub-id-type="pmid">8430717</pub-id></element-citation></ref><ref id="CR187"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bean</surname><given-names>B</given-names></name><name name-style="western"><surname>Aeppli</surname><given-names>D</given-names></name></person-group><article-title>Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster</article-title><source>J Infect Dis</source><year>1985</year><volume>151</volume><fpage>362</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1093/infdis/151.2.362</pub-id><pub-id pub-id-type="pmid">3881542</pub-id></element-citation></ref><ref id="CR188"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pouplin</surname><given-names>T</given-names></name><name name-style="western"><surname>Pouplin</surname><given-names>JN</given-names></name><name name-style="western"><surname>Van Toi</surname><given-names>P</given-names></name><name name-style="western"><surname>Lindegardh</surname><given-names>N</given-names></name><name name-style="western"><surname>Rogier van Doorn</surname><given-names>H</given-names></name><name name-style="western"><surname>Hien</surname><given-names>TT</given-names></name><name name-style="western"><surname>Farrar</surname><given-names>J</given-names></name><name name-style="western"><surname>Torok</surname><given-names>ME</given-names></name><name name-style="western"><surname>Chau</surname><given-names>TT</given-names></name></person-group><article-title>Valacyclovir for herpes simplex encephalitis</article-title><source>Antimicrob Agents Chemother</source><year>2011</year><volume>55</volume><fpage>3624</fpage><lpage>3626</lpage><pub-id pub-id-type="doi">10.1128/AAC.01023-10</pub-id><pub-id pub-id-type="pmid">21576427</pub-id><pub-id pub-id-type="pmcid">PMC3122427</pub-id></element-citation></ref><ref id="CR189"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>M</given-names></name><name name-style="western"><surname>Menson</surname><given-names>E</given-names></name><name name-style="western"><surname>Tong</surname><given-names>CY</given-names></name><name name-style="western"><surname>Lin</surname><given-names>JP</given-names></name></person-group><article-title>Use of therapeutic drug monitoring in the long-term valaciclovir therapy of relapsing herpes simplex virus encephalitis in children</article-title><source>J Antimicrob Chemother</source><year>2009</year><volume>64</volume><fpage>1340</fpage><lpage>1341</lpage><pub-id pub-id-type="doi">10.1093/jac/dkp373</pub-id><pub-id pub-id-type="pmid">19828489</pub-id></element-citation></ref><ref id="CR190"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balfour</surname><given-names>HH</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Fletcher</surname><given-names>CV</given-names></name><name name-style="western"><surname>Erice</surname><given-names>A</given-names></name><name name-style="western"><surname>Henry</surname><given-names>WK</given-names></name><name name-style="western"><surname>Acosta</surname><given-names>EP</given-names></name><name name-style="western"><surname>Smith</surname><given-names>SA</given-names></name><name name-style="western"><surname>Holm</surname><given-names>MA</given-names></name><name name-style="western"><surname>Boivin</surname><given-names>G</given-names></name><name name-style="western"><surname>Shepp</surname><given-names>DH</given-names></name><name name-style="western"><surname>Crumpacker</surname><given-names>CS</given-names></name><name name-style="western"><surname>Eaton</surname><given-names>CA</given-names></name><name name-style="western"><surname>Martin-Munley</surname><given-names>SS</given-names></name></person-group><article-title>Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS</article-title><source>Antimicrob Agents Chemother</source><year>1996</year><volume>40</volume><fpage>2721</fpage><lpage>2726</lpage><pub-id pub-id-type="doi">10.1128/AAC.40.12.2721</pub-id><pub-id pub-id-type="pmid">9124829</pub-id><pub-id pub-id-type="pmcid">PMC163610</pub-id></element-citation></ref><ref id="CR191"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drusano</surname><given-names>GL</given-names></name><name name-style="western"><surname>Aweeka</surname><given-names>F</given-names></name><name name-style="western"><surname>Gambertoglio</surname><given-names>J</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>M</given-names></name><name name-style="western"><surname>Polis</surname><given-names>M</given-names></name><name name-style="western"><surname>Lane</surname><given-names>HC</given-names></name><name name-style="western"><surname>Eaton</surname><given-names>C</given-names></name><name name-style="western"><surname>Martin-Munley</surname><given-names>S</given-names></name></person-group><article-title>Relationship between foscarnet exposure, baseline cytomegalovirus (CMV) blood culture and the time to progression of CMV retinitis in HIV-positive patients</article-title><source>AIDS</source><year>1996</year><volume>10</volume><fpage>1113</fpage><lpage>1119</lpage><pub-id pub-id-type="pmid">8874628</pub-id></element-citation></ref><ref id="CR192"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fletcher</surname><given-names>CV</given-names></name><name name-style="western"><surname>Collier</surname><given-names>AC</given-names></name><name name-style="western"><surname>Rhame</surname><given-names>FS</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D</given-names></name><name name-style="western"><surname>Para</surname><given-names>MF</given-names></name><name name-style="western"><surname>Beatty</surname><given-names>CC</given-names></name><name name-style="western"><surname>Jones</surname><given-names>CE</given-names></name><name name-style="western"><surname>Balfour</surname><given-names>HH</given-names><suffix>Jr</suffix></name></person-group><article-title>Foscarnet for suppression of human immunodeficiency virus replication</article-title><source>Antimicrob Agents Chemother</source><year>1994</year><volume>38</volume><fpage>604</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1128/AAC.38.3.604</pub-id><pub-id pub-id-type="pmid">7911290</pub-id><pub-id pub-id-type="pmcid">PMC284505</pub-id></element-citation></ref><ref id="CR193"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobson</surname><given-names>MA</given-names></name><name name-style="western"><surname>Polsky</surname><given-names>B</given-names></name><name name-style="western"><surname>Causey</surname><given-names>D</given-names></name><name name-style="western"><surname>Davis</surname><given-names>R</given-names></name><name name-style="western"><surname>Tong</surname><given-names>W</given-names></name><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Kuppermann</surname><given-names>BD</given-names></name><name name-style="western"><surname>Heinemann</surname><given-names>MH</given-names></name><name name-style="western"><surname>Feinberg</surname><given-names>J</given-names></name><name name-style="western"><surname>Lizak</surname><given-names>P</given-names></name><etal/></person-group><article-title>Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis</article-title><source>Antimicrob Agents Chemother</source><year>1994</year><volume>38</volume><fpage>1190</fpage><lpage>1193</lpage><pub-id pub-id-type="doi">10.1128/AAC.38.5.1190</pub-id><pub-id pub-id-type="pmid">8067763</pub-id><pub-id pub-id-type="pmcid">PMC188177</pub-id></element-citation></ref><ref id="CR194"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobson</surname><given-names>MA</given-names></name><name name-style="western"><surname>Crowe</surname><given-names>S</given-names></name><name name-style="western"><surname>Levy</surname><given-names>J</given-names></name><name name-style="western"><surname>Aweeka</surname><given-names>F</given-names></name><name name-style="western"><surname>Gambertoglio</surname><given-names>J</given-names></name><name name-style="western"><surname>McManus</surname><given-names>N</given-names></name><name name-style="western"><surname>Mills</surname><given-names>J</given-names></name></person-group><article-title>Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS</article-title><source>J Infect Dis</source><year>1988</year><volume>158</volume><fpage>862</fpage><lpage>865</lpage><pub-id pub-id-type="pmid">2844921</pub-id></element-citation></ref><ref id="CR195"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Billat</surname><given-names>PA</given-names></name><name name-style="western"><surname>Woillard</surname><given-names>JB</given-names></name><name name-style="western"><surname>Essig</surname><given-names>M</given-names></name><name name-style="western"><surname>Sauvage</surname><given-names>FL</given-names></name><name name-style="western"><surname>Picard</surname><given-names>N</given-names></name><name name-style="western"><surname>Alain</surname><given-names>S</given-names></name><name name-style="western"><surname>Neely</surname><given-names>M</given-names></name><name name-style="western"><surname>Marquet</surname><given-names>P</given-names></name><name name-style="western"><surname>Saint-Marcoux</surname><given-names>F</given-names></name></person-group><article-title>Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?</article-title><source>J Antimicrob Chemother</source><year>2016</year><volume>71</volume><fpage>484</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1093/jac/dkv342</pub-id><pub-id pub-id-type="pmid">26538506</pub-id></element-citation></ref><ref id="CR196"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perrottet</surname><given-names>N</given-names></name><name name-style="western"><surname>Manuel</surname><given-names>O</given-names></name><name name-style="western"><surname>Lamoth</surname><given-names>F</given-names></name><name name-style="western"><surname>Venetz</surname><given-names>JP</given-names></name><name name-style="western"><surname>Sahli</surname><given-names>R</given-names></name><name name-style="western"><surname>Decosterd</surname><given-names>LA</given-names></name><name name-style="western"><surname>Buclin</surname><given-names>T</given-names></name><name name-style="western"><surname>Pascual</surname><given-names>M</given-names></name><name name-style="western"><surname>Meylan</surname><given-names>P</given-names></name></person-group><article-title>Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D&#8201;+/R&#8201;&#8722;&#8201;transplant recipients</article-title><source>BMC Infect Dis</source><year>2010</year><volume>10</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-10-2</pub-id><pub-id pub-id-type="pmid">20053269</pub-id><pub-id pub-id-type="pmcid">PMC2820479</pub-id></element-citation></ref><ref id="CR197"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vezina</surname><given-names>HE</given-names></name><name name-style="western"><surname>Brundage</surname><given-names>RC</given-names></name><name name-style="western"><surname>Balfour</surname><given-names>HH</given-names><suffix>Jr</suffix></name></person-group><article-title>Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients</article-title><source>Br J Clin Pharmacol</source><year>2014</year><volume>78</volume><fpage>343</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1111/bcp.12343</pub-id><pub-id pub-id-type="pmid">24528138</pub-id><pub-id pub-id-type="pmcid">PMC4137826</pub-id></element-citation></ref><ref id="CR198"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boivin</surname><given-names>G</given-names></name><name name-style="western"><surname>Goyette</surname><given-names>N</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>C</given-names></name><name name-style="western"><surname>Covington</surname><given-names>E</given-names></name></person-group><article-title>Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis</article-title><source>J Med Virol</source><year>2005</year><volume>77</volume><fpage>425</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1002/jmv.20471</pub-id><pub-id pub-id-type="pmid">16173018</pub-id></element-citation></ref><ref id="CR199"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiltshire</surname><given-names>H</given-names></name><name name-style="western"><surname>Paya</surname><given-names>CV</given-names></name><name name-style="western"><surname>Pescovitz</surname><given-names>MD</given-names></name><name name-style="western"><surname>Humar</surname><given-names>A</given-names></name><name name-style="western"><surname>Dominguez</surname><given-names>E</given-names></name><name name-style="western"><surname>Washburn</surname><given-names>K</given-names></name><name name-style="western"><surname>Blumberg</surname><given-names>E</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>B</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>R</given-names></name><name name-style="western"><surname>Heaton</surname><given-names>N</given-names></name><name name-style="western"><surname>Zuideveld</surname><given-names>KP</given-names></name><collab>Valganciclovir Solid Organ Transplant Study Group</collab></person-group><article-title>Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients</article-title><source>Transplantation</source><year>2005</year><volume>79</volume><fpage>1477</fpage><lpage>1483</lpage><pub-id pub-id-type="doi">10.1097/01.TP.0000164512.99703.AD</pub-id><pub-id pub-id-type="pmid">15940035</pub-id></element-citation></ref><ref id="CR200"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boivin</surname><given-names>G</given-names></name><name name-style="western"><surname>Goyette</surname><given-names>N</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>C</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>N</given-names></name><name name-style="western"><surname>Macey</surname><given-names>K</given-names></name><name name-style="western"><surname>Paya</surname><given-names>C</given-names></name><name name-style="western"><surname>Pescovitz</surname><given-names>MD</given-names></name><name name-style="western"><surname>Humar</surname><given-names>A</given-names></name><name name-style="western"><surname>Dominguez</surname><given-names>E</given-names></name><name name-style="western"><surname>Washburn</surname><given-names>K</given-names></name><name name-style="western"><surname>Blumberg</surname><given-names>E</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>B</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>R</given-names></name><name name-style="western"><surname>Heaton</surname><given-names>N</given-names></name><name name-style="western"><surname>Covington</surname><given-names>E</given-names></name></person-group><article-title>Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients</article-title><source>J Infect Dis</source><year>2004</year><volume>189</volume><fpage>1615</fpage><lpage>1618</lpage><pub-id pub-id-type="doi">10.1086/382753</pub-id><pub-id pub-id-type="pmid">15116297</pub-id></element-citation></ref><ref id="CR201"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lalezari</surname><given-names>JP</given-names></name><name name-style="western"><surname>Friedberg</surname><given-names>DN</given-names></name><name name-style="western"><surname>Bissett</surname><given-names>J</given-names></name><name name-style="western"><surname>Giordano</surname><given-names>MF</given-names></name><name name-style="western"><surname>Hardy</surname><given-names>WD</given-names></name><name name-style="western"><surname>Drew</surname><given-names>WL</given-names></name><name name-style="western"><surname>Hubbard</surname><given-names>LD</given-names></name><name name-style="western"><surname>Buhles</surname><given-names>WC</given-names></name><name name-style="western"><surname>Stempien</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Georgiou</surname><given-names>P</given-names></name><name name-style="western"><surname>Jung</surname><given-names>DT</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>CA</given-names></name><collab>Roche Cooperative Oral Ganciclovir Study Group</collab></person-group><article-title>High dose oral ganciclovir treatment for cytomegalovirus retinitis</article-title><source>J Clin Virol</source><year>2002</year><volume>24</volume><fpage>67</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/S1386-6532(01)00229-3</pub-id><pub-id pub-id-type="pmid">11744430</pub-id></element-citation></ref><ref id="CR202"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fishman</surname><given-names>JA</given-names></name><name name-style="western"><surname>Doran</surname><given-names>MT</given-names></name><name name-style="western"><surname>Volpicelli</surname><given-names>SA</given-names></name><name name-style="western"><surname>Cosimi</surname><given-names>AB</given-names></name><name name-style="western"><surname>Flood</surname><given-names>JG</given-names></name><name name-style="western"><surname>Rubin</surname><given-names>RH</given-names></name></person-group><article-title>Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients</article-title><source>Transplantation</source><year>2000</year><volume>69</volume><fpage>389</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1097/00007890-200002150-00014</pub-id><pub-id pub-id-type="pmid">10706048</pub-id></element-citation></ref><ref id="CR203"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piketty</surname><given-names>C</given-names></name><name name-style="western"><surname>Bardin</surname><given-names>C</given-names></name><name name-style="western"><surname>Gilquin</surname><given-names>J</given-names></name><name name-style="western"><surname>Gairard</surname><given-names>A</given-names></name><name name-style="western"><surname>Kazatchkine</surname><given-names>MD</given-names></name><name name-style="western"><surname>Chast</surname><given-names>F</given-names></name></person-group><article-title>Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis</article-title><source>Clin Microbiol Infect</source><year>2000</year><volume>6</volume><fpage>117</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1046/j.1469-0691.2000.00014.x</pub-id><pub-id pub-id-type="pmid">11168085</pub-id></element-citation></ref><ref id="CR204"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spector</surname><given-names>SA</given-names></name><name name-style="western"><surname>Busch</surname><given-names>DF</given-names></name><name name-style="western"><surname>Follansbee</surname><given-names>S</given-names></name><name name-style="western"><surname>Squires</surname><given-names>K</given-names></name><name name-style="western"><surname>Lalezari</surname><given-names>JP</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>MA</given-names></name><name name-style="western"><surname>Connor</surname><given-names>JD</given-names></name><name name-style="western"><surname>Jung</surname><given-names>D</given-names></name><name name-style="western"><surname>Shadman</surname><given-names>A</given-names></name><name name-style="western"><surname>Mastre</surname><given-names>B</given-names></name><etal/></person-group><article-title>Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group</article-title><source>J Infect Dis</source><year>1995</year><volume>171</volume><fpage>1431</fpage><lpage>1437</lpage><pub-id pub-id-type="doi">10.1093/infdis/171.6.1431</pub-id><pub-id pub-id-type="pmid">7769276</pub-id></element-citation></ref><ref id="CR205"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sommadossi</surname><given-names>JP</given-names></name><name name-style="western"><surname>Bevan</surname><given-names>R</given-names></name><name name-style="western"><surname>Ling</surname><given-names>T</given-names></name><name name-style="western"><surname>Lee</surname><given-names>F</given-names></name><name name-style="western"><surname>Mastre</surname><given-names>B</given-names></name><name name-style="western"><surname>Chaplin</surname><given-names>MD</given-names></name><name name-style="western"><surname>Nerenberg</surname><given-names>C</given-names></name><name name-style="western"><surname>Koretz</surname><given-names>S</given-names></name><name name-style="western"><surname>Buhles</surname><given-names>WC</given-names><suffix>Jr</suffix></name></person-group><article-title>Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function</article-title><source>Rev Infect Dis</source><year>1988</year><volume>10</volume><issue>Suppl 3</issue><fpage>S507</fpage><lpage>S514</lpage><pub-id pub-id-type="doi">10.1093/clinids/10.Supplement_3.S507</pub-id><pub-id pub-id-type="pmid">2847287</pub-id></element-citation></ref><ref id="CR206"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winston</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Ho</surname><given-names>WG</given-names></name><name name-style="western"><surname>Bartoni</surname><given-names>K</given-names></name><name name-style="western"><surname>Holland</surname><given-names>GN</given-names></name><name name-style="western"><surname>Mitsuyasu</surname><given-names>RT</given-names></name><name name-style="western"><surname>Gale</surname><given-names>RP</given-names></name><name name-style="western"><surname>Busuttil</surname><given-names>RW</given-names></name><name name-style="western"><surname>Champlin</surname><given-names>RE</given-names></name></person-group><article-title>Ganciclovir therapy for cytomegalovirus infections in recipients of bone marrow transplants and other immunosuppressed patients</article-title><source>Rev Infect Dis</source><year>1988</year><volume>10</volume><issue>Suppl 3</issue><fpage>S547</fpage><lpage>S553</lpage><pub-id pub-id-type="doi">10.1093/clinids/10.Supplement_3.S547</pub-id><pub-id pub-id-type="pmid">2847292</pub-id></element-citation></ref><ref id="CR207"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fletcher</surname><given-names>C</given-names></name><name name-style="western"><surname>Sawchuk</surname><given-names>R</given-names></name><name name-style="western"><surname>Chinnock</surname><given-names>B</given-names></name><name name-style="western"><surname>de Miranda</surname><given-names>P</given-names></name><name name-style="western"><surname>Balfour</surname><given-names>HH</given-names><suffix>Jr</suffix></name></person-group><article-title>Human pharmacokinetics of the antiviral drug DHPG</article-title><source>Clin Pharmacol Ther</source><year>1986</year><volume>40</volume><fpage>281</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1038/clpt.1986.177</pub-id><pub-id pub-id-type="pmid">3017630</pub-id></element-citation></ref><ref id="CR208"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Padulles</surname><given-names>A</given-names></name><name name-style="western"><surname>Colom</surname><given-names>H</given-names></name><name name-style="western"><surname>Bestard</surname><given-names>O</given-names></name><name name-style="western"><surname>Melilli</surname><given-names>E</given-names></name><name name-style="western"><surname>Sabe</surname><given-names>N</given-names></name><name name-style="western"><surname>Rigo</surname><given-names>R</given-names></name><name name-style="western"><surname>Niubo</surname><given-names>J</given-names></name><name name-style="western"><surname>Torras</surname><given-names>J</given-names></name><name name-style="western"><surname>Llado</surname><given-names>L</given-names></name><name name-style="western"><surname>Manito</surname><given-names>N</given-names></name><name name-style="western"><surname>Caldes</surname><given-names>A</given-names></name><name name-style="western"><surname>Cruzado</surname><given-names>JM</given-names></name><name name-style="western"><surname>Grinyo</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lloberas</surname><given-names>N</given-names></name></person-group><article-title>Contribution of population pharmacokinetics to dose optimization of ganciclovir-valganciclovir in solid-organ transplant patients</article-title><source>Antimicrob Agents Chemother</source><year>2016</year><volume>60</volume><fpage>1992</fpage><lpage>2002</lpage><pub-id pub-id-type="doi">10.1128/AAC.02130-15</pub-id><pub-id pub-id-type="pmid">26824942</pub-id><pub-id pub-id-type="pmcid">PMC4808182</pub-id></element-citation></ref><ref id="CR209"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tangden</surname><given-names>T</given-names></name><name name-style="western"><surname>Cojutti</surname><given-names>PG</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name><name name-style="western"><surname>Pea</surname><given-names>F</given-names></name></person-group><article-title>Valganciclovir pharmacokinetics in patients receiving oral prophylaxis following kidney transplantation and model-based predictions of optimal dosing regimens</article-title><source>Clin Pharmacokinet</source><year>2018</year><volume>57</volume><fpage>1399</fpage><lpage>1405</lpage><pub-id pub-id-type="doi">10.1007/s40262-018-0638-5</pub-id><pub-id pub-id-type="pmid">29546589</pub-id></element-citation></ref><ref id="CR210"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gimenez</surname><given-names>E</given-names></name><name name-style="western"><surname>Solano</surname><given-names>C</given-names></name><name name-style="western"><surname>Azanza</surname><given-names>JR</given-names></name><name name-style="western"><surname>Amat</surname><given-names>P</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>D</given-names></name></person-group><article-title>Monitoring of trough plasma ganciclovir levels and peripheral blood cytomegalovirus (CMV)-specific CD8&#8201;+&#8201;T cells to predict CMV DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><fpage>5602</fpage><lpage>5605</lpage><pub-id pub-id-type="doi">10.1128/AAC.02953-14</pub-id><pub-id pub-id-type="pmid">24982073</pub-id><pub-id pub-id-type="pmcid">PMC4135831</pub-id></element-citation></ref><ref id="CR211"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lilleri</surname><given-names>D</given-names></name><name name-style="western"><surname>Gerna</surname><given-names>G</given-names></name><name name-style="western"><surname>Zelini</surname><given-names>P</given-names></name><name name-style="western"><surname>Chiesa</surname><given-names>A</given-names></name><name name-style="western"><surname>Rognoni</surname><given-names>V</given-names></name><name name-style="western"><surname>Mastronuzzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Giorgiani</surname><given-names>G</given-names></name><name name-style="western"><surname>Zecca</surname><given-names>M</given-names></name><name name-style="western"><surname>Locatelli</surname><given-names>F</given-names></name></person-group><article-title>Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><fpage>e41648</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0041648</pub-id><pub-id pub-id-type="pmid">22848556</pub-id><pub-id pub-id-type="pmcid">PMC3405005</pub-id></element-citation></ref><ref id="CR212"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>MB</given-names></name><name name-style="western"><surname>Yang</surname><given-names>KH</given-names></name><name name-style="western"><surname>Rao</surname><given-names>G</given-names></name><name name-style="western"><surname>Rayner</surname><given-names>CR</given-names></name><name name-style="western"><surname>Nie</surname><given-names>J</given-names></name><name name-style="western"><surname>Pamulapati</surname><given-names>C</given-names></name><name name-style="western"><surname>Marathe</surname><given-names>BM</given-names></name><name name-style="western"><surname>Forrest</surname><given-names>A</given-names></name><name name-style="western"><surname>Govorkova</surname><given-names>EA</given-names></name></person-group><article-title>Oseltamivir population pharmacokinetics in the ferret: model application for pharmacokinetic/pharmacodynamic study design</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><fpage>e0138069</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0138069</pub-id><pub-id pub-id-type="pmid">26460484</pub-id><pub-id pub-id-type="pmcid">PMC4603953</pub-id></element-citation></ref><ref id="CR213"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>DY</given-names></name><name name-style="western"><surname>Lowther</surname><given-names>S</given-names></name><name name-style="western"><surname>McCaw</surname><given-names>JM</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>SG</given-names></name><name name-style="western"><surname>Leang</surname><given-names>SK</given-names></name><name name-style="western"><surname>Haining</surname><given-names>J</given-names></name><name name-style="western"><surname>Arkinstall</surname><given-names>R</given-names></name><name name-style="western"><surname>Kelso</surname><given-names>A</given-names></name><name name-style="western"><surname>McVernon</surname><given-names>J</given-names></name><name name-style="western"><surname>Barr</surname><given-names>IG</given-names></name><name name-style="western"><surname>Middleton</surname><given-names>D</given-names></name><name name-style="western"><surname>Hurt</surname><given-names>AC</given-names></name></person-group><article-title>Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact</article-title><source>J Antimicrob Chemother</source><year>2014</year><volume>69</volume><fpage>2458</fpage><lpage>2469</lpage><pub-id pub-id-type="doi">10.1093/jac/dku146</pub-id><pub-id pub-id-type="pmid">24840623</pub-id><pub-id pub-id-type="pmcid">PMC4130381</pub-id></element-citation></ref><ref id="CR214"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendel</surname><given-names>DB</given-names></name><name name-style="western"><surname>Tai</surname><given-names>CY</given-names></name><name name-style="western"><surname>Escarpe</surname><given-names>PA</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Sidwell</surname><given-names>RW</given-names></name><name name-style="western"><surname>Huffman</surname><given-names>JH</given-names></name><name name-style="western"><surname>Sweet</surname><given-names>C</given-names></name><name name-style="western"><surname>Jakeman</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Merson</surname><given-names>J</given-names></name><name name-style="western"><surname>Lacy</surname><given-names>SA</given-names></name><name name-style="western"><surname>Lew</surname><given-names>W</given-names></name><name name-style="western"><surname>Williams</surname><given-names>MA</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>MS</given-names></name><name name-style="western"><surname>Bischofberger</surname><given-names>N</given-names></name><name name-style="western"><surname>Kim</surname><given-names>CU</given-names></name></person-group><article-title>Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection</article-title><source>Antimicrob Agents Chemother</source><year>1998</year><volume>42</volume><fpage>640</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1128/AAC.42.3.640</pub-id><pub-id pub-id-type="pmid">9517945</pub-id><pub-id pub-id-type="pmcid">PMC105511</pub-id></element-citation></ref><ref id="CR215"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rayner</surname><given-names>CR</given-names></name><name name-style="western"><surname>Bulik</surname><given-names>CC</given-names></name><name name-style="western"><surname>Kamal</surname><given-names>MA</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>DK</given-names></name><name name-style="western"><surname>Toovey</surname><given-names>S</given-names></name><name name-style="western"><surname>Hammel</surname><given-names>JP</given-names></name><name name-style="western"><surname>Smith</surname><given-names>PF</given-names></name><name name-style="western"><surname>Bhavnani</surname><given-names>SM</given-names></name><name name-style="western"><surname>Van Wart</surname><given-names>SA</given-names></name><name name-style="western"><surname>Ambrose</surname><given-names>PG</given-names></name><name name-style="western"><surname>Forrest</surname><given-names>A</given-names></name></person-group><article-title>Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies</article-title><source>Antimicrob Agents Chemother</source><year>2013</year><volume>57</volume><fpage>3478</fpage><lpage>3487</lpage><pub-id pub-id-type="doi">10.1128/AAC.02440-12</pub-id><pub-id pub-id-type="pmid">23669386</pub-id><pub-id pub-id-type="pmcid">PMC3719781</pub-id></element-citation></ref><ref id="CR216"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McSharry</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Weng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Brown</surname><given-names>A</given-names></name><name name-style="western"><surname>Kulawy</surname><given-names>R</given-names></name><name name-style="western"><surname>Drusano</surname><given-names>GL</given-names></name></person-group><article-title>Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system</article-title><source>Antimicrob Agents Chemother</source><year>2009</year><volume>53</volume><fpage>2375</fpage><lpage>2381</lpage><pub-id pub-id-type="doi">10.1128/AAC.00167-09</pub-id><pub-id pub-id-type="pmid">19364864</pub-id><pub-id pub-id-type="pmcid">PMC2687202</pub-id></element-citation></ref><ref id="CR217"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wattanagoon</surname><given-names>Y</given-names></name><name name-style="western"><surname>Stepniewska</surname><given-names>K</given-names></name><name name-style="western"><surname>Lindegardh</surname><given-names>N</given-names></name><name name-style="western"><surname>Pukrittayakamee</surname><given-names>S</given-names></name><name name-style="western"><surname>Silachamroon</surname><given-names>U</given-names></name><name name-style="western"><surname>Piyaphanee</surname><given-names>W</given-names></name><name name-style="western"><surname>Singtoroj</surname><given-names>T</given-names></name><name name-style="western"><surname>Hanpithakpong</surname><given-names>W</given-names></name><name name-style="western"><surname>Davies</surname><given-names>G</given-names></name><name name-style="western"><surname>Tarning</surname><given-names>J</given-names></name><name name-style="western"><surname>Pongtavornpinyo</surname><given-names>W</given-names></name><name name-style="western"><surname>Fukuda</surname><given-names>C</given-names></name><name name-style="western"><surname>Singhasivanon</surname><given-names>P</given-names></name><name name-style="western"><surname>Day</surname><given-names>NP</given-names></name><name name-style="western"><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>Pharmacokinetics of high-dose oseltamivir in healthy volunteers</article-title><source>Antimicrob Agents Chemother</source><year>2009</year><volume>53</volume><fpage>945</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1128/AAC.00588-08</pub-id><pub-id pub-id-type="pmid">19104028</pub-id><pub-id pub-id-type="pmcid">PMC2650521</pub-id></element-citation></ref><ref id="CR218"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rayner</surname><given-names>CR</given-names></name><name name-style="western"><surname>Chanu</surname><given-names>P</given-names></name><name name-style="western"><surname>Gieschke</surname><given-names>R</given-names></name><name name-style="western"><surname>Boak</surname><given-names>LM</given-names></name><name name-style="western"><surname>Jonsson</surname><given-names>EN</given-names></name></person-group><article-title>Population pharmacokinetics of oseltamivir when coadministered with probenecid</article-title><source>J Clin Pharmacol</source><year>2008</year><volume>48</volume><fpage>935</fpage><lpage>947</lpage><pub-id pub-id-type="doi">10.1177/0091270008320317</pub-id><pub-id pub-id-type="pmid">18524996</pub-id></element-citation></ref><ref id="CR219"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>May</surname><given-names>F</given-names></name><name name-style="western"><surname>Peytavin</surname><given-names>G</given-names></name><name name-style="western"><surname>Fourati</surname><given-names>S</given-names></name><name name-style="western"><surname>Pressiat</surname><given-names>C</given-names></name><name name-style="western"><surname>Carteaux</surname><given-names>G</given-names></name><name name-style="western"><surname>Razazi</surname><given-names>K</given-names></name><name name-style="western"><surname>Mekontso Dessap</surname><given-names>A</given-names></name><name name-style="western"><surname>de Prost</surname><given-names>N</given-names></name></person-group><article-title>Paracetamol absorption test to detect poor enteric absorption of oseltamivir in intensive care unit patients with severe influenza: a pilot study</article-title><source>Intensive Care Med</source><year>2019</year><volume>45</volume><fpage>1484</fpage><lpage>1486</lpage><pub-id pub-id-type="doi">10.1007/s00134-019-05693-z</pub-id><pub-id pub-id-type="pmid">31332462</pub-id><pub-id pub-id-type="pmcid">PMC7094964</pub-id></element-citation></ref><ref id="CR220"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dominguez</surname><given-names>S</given-names></name><name name-style="western"><surname>Ghosn</surname><given-names>J</given-names></name><name name-style="western"><surname>Cassard</surname><given-names>B</given-names></name><name name-style="western"><surname>Melica</surname><given-names>G</given-names></name><name name-style="western"><surname>Poizot-Martin</surname><given-names>I</given-names></name><name name-style="western"><surname>Solas</surname><given-names>C</given-names></name><name name-style="western"><surname>Lascaux</surname><given-names>AS</given-names></name><name name-style="western"><surname>Bouvier-Alias</surname><given-names>M</given-names></name><name name-style="western"><surname>Katlama</surname><given-names>C</given-names></name><name name-style="western"><surname>Levy</surname><given-names>Y</given-names></name><name name-style="western"><surname>Peytavin</surname><given-names>G</given-names></name></person-group><article-title>Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV</article-title><source>J Antimicrob Chemother</source><year>2012</year><volume>67</volume><fpage>1449</fpage><lpage>1452</lpage><pub-id pub-id-type="doi">10.1093/jac/dks045</pub-id><pub-id pub-id-type="pmid">22396433</pub-id></element-citation></ref><ref id="CR221"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedersen</surname><given-names>C</given-names></name><name name-style="western"><surname>Alsio</surname><given-names>A</given-names></name><name name-style="western"><surname>Lagging</surname><given-names>M</given-names></name><name name-style="western"><surname>Langeland</surname><given-names>N</given-names></name><name name-style="western"><surname>Farkkila</surname><given-names>M</given-names></name><name name-style="western"><surname>Buhl</surname><given-names>MR</given-names></name><name name-style="western"><surname>Morch</surname><given-names>K</given-names></name><name name-style="western"><surname>Westin</surname><given-names>J</given-names></name><name name-style="western"><surname>Sangfelt</surname><given-names>P</given-names></name><name name-style="western"><surname>Norkrans</surname><given-names>G</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>PB</given-names></name><collab>NORDynamicIC Study Group</collab></person-group><article-title>Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection</article-title><source>J Viral Hepat</source><year>2011</year><volume>18</volume><fpage>245</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2893.2010.01303.x</pub-id><pub-id pub-id-type="pmid">20384961</pub-id></element-citation></ref><ref id="CR222"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguilar Marucco</surname><given-names>D</given-names></name><name name-style="western"><surname>Gonzalez de Requena</surname><given-names>D</given-names></name><name name-style="western"><surname>Bonora</surname><given-names>S</given-names></name><name name-style="western"><surname>Tettoni</surname><given-names>C</given-names></name><name name-style="western"><surname>Bonasso</surname><given-names>M</given-names></name><name name-style="western"><surname>De Blasi</surname><given-names>T</given-names></name><name name-style="western"><surname>D&#8217;Avolio</surname><given-names>A</given-names></name><name name-style="western"><surname>Sciandra</surname><given-names>M</given-names></name><name name-style="western"><surname>Siccardi</surname><given-names>M</given-names></name><name name-style="western"><surname>Baietto</surname><given-names>L</given-names></name><name name-style="western"><surname>Trentini</surname><given-names>L</given-names></name><name name-style="western"><surname>Sinicco</surname><given-names>A</given-names></name><name name-style="western"><surname>Cariti</surname><given-names>G</given-names></name><name name-style="western"><surname>Di Perri</surname><given-names>G</given-names></name></person-group><article-title>The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon</article-title><source>J Antimicrob Chemother</source><year>2008</year><volume>61</volume><fpage>919</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.1093/jac/dkn013</pub-id><pub-id pub-id-type="pmid">18238889</pub-id></element-citation></ref><ref id="CR223"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maynard</surname><given-names>M</given-names></name><name name-style="western"><surname>Pradat</surname><given-names>P</given-names></name><name name-style="western"><surname>Gagnieu</surname><given-names>MC</given-names></name><name name-style="western"><surname>Souvignet</surname><given-names>C</given-names></name><name name-style="western"><surname>Trepo</surname><given-names>C</given-names></name></person-group><article-title>Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients</article-title><source>Antivir Ther</source><year>2008</year><volume>13</volume><fpage>607</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">18672540</pub-id></element-citation></ref><ref id="CR224"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arase</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>K</given-names></name><name name-style="western"><surname>Tsubota</surname><given-names>A</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>F</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Saitoh</surname><given-names>S</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>M</given-names></name><name name-style="western"><surname>Akuta</surname><given-names>N</given-names></name><name name-style="western"><surname>Someya</surname><given-names>T</given-names></name><name name-style="western"><surname>Hosaka</surname><given-names>T</given-names></name><name name-style="western"><surname>Sezaki</surname><given-names>H</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>M</given-names></name><name name-style="western"><surname>Kumada</surname><given-names>H</given-names></name></person-group><article-title>Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C</article-title><source>Intervirology</source><year>2005</year><volume>48</volume><fpage>138</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1159/000081741</pub-id><pub-id pub-id-type="pmid">15812187</pub-id></element-citation></ref><ref id="CR225"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsubota</surname><given-names>A</given-names></name><name name-style="western"><surname>Hirose</surname><given-names>Y</given-names></name><name name-style="western"><surname>Izumi</surname><given-names>N</given-names></name><name name-style="western"><surname>Kumada</surname><given-names>H</given-names></name></person-group><article-title>Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection</article-title><source>Br J Clin Pharmacol</source><year>2003</year><volume>55</volume><fpage>360</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2125.2003.01780.x</pub-id><pub-id pub-id-type="pmid">12680884</pub-id><pub-id pub-id-type="pmcid">PMC1884236</pub-id></element-citation></ref><ref id="CR226"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jen</surname><given-names>JF</given-names></name><name name-style="western"><surname>Glue</surname><given-names>P</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Zambas</surname><given-names>D</given-names></name><name name-style="western"><surname>Hajian</surname><given-names>G</given-names></name></person-group><article-title>Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C</article-title><source>Ther Drug Monit</source><year>2000</year><volume>22</volume><fpage>555</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1097/00007691-200010000-00010</pub-id><pub-id pub-id-type="pmid">11034261</pub-id></element-citation></ref><ref id="CR227"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stickel</surname><given-names>F</given-names></name><name name-style="western"><surname>Worni</surname><given-names>M</given-names></name><name name-style="western"><surname>Pache</surname><given-names>I</given-names></name><name name-style="western"><surname>Moradpour</surname><given-names>D</given-names></name><name name-style="western"><surname>Helbling</surname><given-names>B</given-names></name><name name-style="western"><surname>Borovicka</surname><given-names>J</given-names></name><name name-style="western"><surname>Gerlach</surname><given-names>TJ</given-names></name></person-group><article-title>Optimizing ribavirin exposure by therapeutic drug monitoring improves treatment response in patients with chronic hepatitis C genotype 1</article-title><source>Am J Gastroenterol</source><year>2013</year><volume>108</volume><fpage>1176</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1038/ajg.2013.140</pub-id><pub-id pub-id-type="pmid">23821001</pub-id></element-citation></ref><ref id="CR228"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loustaud-Ratti</surname><given-names>V</given-names></name><name name-style="western"><surname>Alain</surname><given-names>S</given-names></name><name name-style="western"><surname>Rousseau</surname><given-names>A</given-names></name><name name-style="western"><surname>Hubert</surname><given-names>IF</given-names></name><name name-style="western"><surname>Sauvage</surname><given-names>FL</given-names></name><name name-style="western"><surname>Marquet</surname><given-names>P</given-names></name><name name-style="western"><surname>Denis</surname><given-names>F</given-names></name><name name-style="western"><surname>Lunel</surname><given-names>F</given-names></name><name name-style="western"><surname>Cales</surname><given-names>P</given-names></name><name name-style="western"><surname>Lefebvre</surname><given-names>A</given-names></name><name name-style="western"><surname>Fauchais</surname><given-names>AL</given-names></name><name name-style="western"><surname>Liozon</surname><given-names>E</given-names></name><name name-style="western"><surname>Vidal</surname><given-names>E</given-names></name></person-group><article-title>Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C</article-title><source>Hepatology</source><year>2008</year><volume>47</volume><fpage>1453</fpage><lpage>1461</lpage><pub-id pub-id-type="doi">10.1002/hep.22217</pub-id><pub-id pub-id-type="pmid">18435468</pub-id></element-citation></ref><ref id="CR229"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rendon</surname><given-names>AL</given-names></name><name name-style="western"><surname>Nunez</surname><given-names>M</given-names></name><name name-style="western"><surname>Romero</surname><given-names>M</given-names></name><name name-style="western"><surname>Barreiro</surname><given-names>P</given-names></name><name name-style="western"><surname>Martin-Carbonero</surname><given-names>L</given-names></name><name name-style="western"><surname>Garcia-Samaniego</surname><given-names>J</given-names></name><name name-style="western"><surname>Jimenez-Nacher</surname><given-names>I</given-names></name><name name-style="western"><surname>Gonzalez-Lahoz</surname><given-names>J</given-names></name><name name-style="western"><surname>Soriano</surname><given-names>V</given-names></name></person-group><article-title>Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients</article-title><source>J Acquir Immune Defic Syndr</source><year>2005</year><volume>39</volume><fpage>401</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1097/01.qai.0000170034.90438.68</pub-id><pub-id pub-id-type="pmid">16010160</pub-id></element-citation></ref><ref id="CR230"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maeda</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kiribayashi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Moriya</surname><given-names>T</given-names></name><name name-style="western"><surname>Maruhashi</surname><given-names>A</given-names></name><name name-style="western"><surname>Omoda</surname><given-names>K</given-names></name><name name-style="western"><surname>Funakoshi</surname><given-names>S</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>T</given-names></name><name name-style="western"><surname>Takano</surname><given-names>M</given-names></name></person-group><article-title>Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C</article-title><source>Ther Drug Monit</source><year>2004</year><volume>26</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1097/00007691-200402000-00004</pub-id><pub-id pub-id-type="pmid">14749543</pub-id></element-citation></ref><ref id="CR231"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez-Cortes</surname><given-names>LF</given-names></name><name name-style="western"><surname>Valera-Bestard</surname><given-names>B</given-names></name><name name-style="western"><surname>Gutierrez-Valencia</surname><given-names>A</given-names></name><name name-style="western"><surname>Ruiz-Valderas</surname><given-names>R</given-names></name><name name-style="western"><surname>Jimenez</surname><given-names>L</given-names></name><name name-style="western"><surname>Arizcorreta</surname><given-names>A</given-names></name><name name-style="western"><surname>Terron</surname><given-names>A</given-names></name><name name-style="western"><surname>Viciana</surname><given-names>P</given-names></name></person-group><article-title>Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients</article-title><source>Clin Pharmacol Ther</source><year>2008</year><volume>84</volume><fpage>573</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1038/clpt.2008.110</pub-id><pub-id pub-id-type="pmid">18596682</pub-id></element-citation></ref><ref id="CR232"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milliken</surname><given-names>E</given-names></name><name name-style="western"><surname>de Zwart</surname><given-names>AES</given-names></name><name name-style="western"><surname>Alffenaar</surname><given-names>JC</given-names></name><name name-style="western"><surname>Marriott</surname><given-names>DJE</given-names></name><name name-style="western"><surname>Riezebos-Brilman</surname><given-names>A</given-names></name><name name-style="western"><surname>Schteinman</surname><given-names>A</given-names></name><name name-style="western"><surname>Evans</surname><given-names>AM</given-names></name><name name-style="western"><surname>Glanville</surname><given-names>AR</given-names></name><name name-style="western"><surname>Verschuuren</surname><given-names>EAM</given-names></name><name name-style="western"><surname>Reuter</surname><given-names>SE</given-names></name></person-group><article-title>Population pharmacokinetics of ribavirin in lung transplant recipients and examination of current and alternative dosing regimens</article-title><source>J Antimicrob Chemother</source><year>2019</year><volume>74</volume><fpage>691</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1093/jac/dky466</pub-id><pub-id pub-id-type="pmid">30452661</pub-id></element-citation></ref><ref id="CR233"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rhodes</surname><given-names>A</given-names></name><name name-style="western"><surname>Evans</surname><given-names>LE</given-names></name><name name-style="western"><surname>Alhazzani</surname><given-names>W</given-names></name><name name-style="western"><surname>Levy</surname><given-names>MM</given-names></name><name name-style="western"><surname>Antonelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Ferrer</surname><given-names>R</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Sevransky</surname><given-names>JE</given-names></name><name name-style="western"><surname>Sprung</surname><given-names>CL</given-names></name><name name-style="western"><surname>Nunnally</surname><given-names>ME</given-names></name><name name-style="western"><surname>Rochwerg</surname><given-names>B</given-names></name><name name-style="western"><surname>Rubenfeld</surname><given-names>GD</given-names></name><name name-style="western"><surname>Angus</surname><given-names>DC</given-names></name><name name-style="western"><surname>Annane</surname><given-names>D</given-names></name><name name-style="western"><surname>Beale</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Bellinghan</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Bernard</surname><given-names>GR</given-names></name><name name-style="western"><surname>Chiche</surname><given-names>JD</given-names></name><name name-style="western"><surname>Coopersmith</surname><given-names>C</given-names></name><name name-style="western"><surname>De Backer</surname><given-names>DP</given-names></name><name name-style="western"><surname>French</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Fujishima</surname><given-names>S</given-names></name><name name-style="western"><surname>Gerlach</surname><given-names>H</given-names></name><name name-style="western"><surname>Hidalgo</surname><given-names>JL</given-names></name><name name-style="western"><surname>Hollenberg</surname><given-names>SM</given-names></name><name name-style="western"><surname>Jones</surname><given-names>AE</given-names></name><name name-style="western"><surname>Karnad</surname><given-names>DR</given-names></name><name name-style="western"><surname>Kleinpell</surname><given-names>RM</given-names></name><name name-style="western"><surname>Koh</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lisboa</surname><given-names>TC</given-names></name><name name-style="western"><surname>Machado</surname><given-names>FR</given-names></name><name name-style="western"><surname>Marini</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>JC</given-names></name><name name-style="western"><surname>Mazuski</surname><given-names>JE</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>LA</given-names></name><name name-style="western"><surname>McLean</surname><given-names>AS</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>S</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>RP</given-names></name><name name-style="western"><surname>Myburgh</surname><given-names>J</given-names></name><name name-style="western"><surname>Navalesi</surname><given-names>P</given-names></name><name name-style="western"><surname>Nishida</surname><given-names>O</given-names></name><name name-style="western"><surname>Osborn</surname><given-names>TM</given-names></name><name name-style="western"><surname>Perner</surname><given-names>A</given-names></name><name name-style="western"><surname>Plunkett</surname><given-names>CM</given-names></name><name name-style="western"><surname>Ranieri</surname><given-names>M</given-names></name><name name-style="western"><surname>Schorr</surname><given-names>CA</given-names></name><name name-style="western"><surname>Seckel</surname><given-names>MA</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>CW</given-names></name><name name-style="western"><surname>Shieh</surname><given-names>L</given-names></name><name name-style="western"><surname>Shukri</surname><given-names>KA</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>SQ</given-names></name><name name-style="western"><surname>Singer</surname><given-names>M</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>BT</given-names></name><name name-style="western"><surname>Townsend</surname><given-names>SR</given-names></name><name name-style="western"><surname>Van der Poll</surname><given-names>T</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>JL</given-names></name><name name-style="western"><surname>Wiersinga</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>JL</given-names></name><name name-style="western"><surname>Dellinger</surname><given-names>RP</given-names></name></person-group><article-title>Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016</article-title><source>Intensive Care Med</source><year>2017</year><volume>43</volume><fpage>304</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1007/s00134-017-4683-6</pub-id><pub-id pub-id-type="pmid">28101605</pub-id></element-citation></ref><ref id="CR234"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kovanda</surname><given-names>LL</given-names></name><name name-style="western"><surname>Kolamunnage-Dona</surname><given-names>R</given-names></name><name name-style="western"><surname>Neely</surname><given-names>M</given-names></name><name name-style="western"><surname>Maertens</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M</given-names></name><name name-style="western"><surname>Hope</surname><given-names>WW</given-names></name></person-group><article-title>Pharmacodynamics of isavuconazole for invasive mold disease: role of galactomannan for real-time monitoring of therapeutic response</article-title><source>Clin Infect Dis</source><year>2017</year><volume>64</volume><fpage>1557</fpage><lpage>1563</lpage><pub-id pub-id-type="doi">10.1093/cid/cix198</pub-id><pub-id pub-id-type="pmid">28472247</pub-id><pub-id pub-id-type="pmcid">PMC5434340</pub-id></element-citation></ref><ref id="CR235"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huurneman</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Neely</surname><given-names>M</given-names></name><name name-style="western"><surname>Veringa</surname><given-names>A</given-names></name><name name-style="western"><surname>Docobo Perez</surname><given-names>F</given-names></name><name name-style="western"><surname>Ramos-Martin</surname><given-names>V</given-names></name><name name-style="western"><surname>Tissing</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Alffenaar</surname><given-names>JW</given-names></name><name name-style="western"><surname>Hope</surname><given-names>W</given-names></name></person-group><article-title>Pharmacodynamics of voriconazole in children: further steps along the path to true individualized therapy</article-title><source>Antimicrob Agents Chemother</source><year>2016</year><volume>60</volume><fpage>2336</fpage><lpage>2342</lpage><pub-id pub-id-type="doi">10.1128/AAC.03023-15</pub-id><pub-id pub-id-type="pmid">26833158</pub-id><pub-id pub-id-type="pmcid">PMC4808208</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>